integrated report 2017 h um healt h care content company introduction editorial policy integrated report 2017 3 materiality third issue eisais integrated report aim 4 human capital driving force eisai human health care hhc provide wide range stakeholder including longterm 6 intellectual capital eisais strength dementia area investor better understanding corporate value enhancement midtolong term perspective order 8 history eisai think important continuously improve 10 eisais value creation process flow quality based valuable opinion received 12 major product engagement stakeholder following area focused issue management strategy enriched description corporate philosophy human health care hhc eisais driving force 14 ceo message enriched description eisais strength dementia 18 mediumterm business plan eway 2025 area 20 human capital cto message revision eisais value creation process flow 24 human capital hhc special feature enhancement executive message solution patient program enriched description initiative esg human capital development strategy initiative improving access global hhc best practice medicine corporate governance others 26 financial capital cfo message continuously try best improve quality report next fiscal year beyond provide value creating activity reader better understanding corporate value neurology area enhancement 32 intellectual capital message corporate officer 34 intellectual capital 6 ricchi ongoing project note icon page 36 intellectual capital development new potential dementia treatment page strongly related 6 capital consist 40 intellectual capital social relationship capital eisais corporate value intellectual capital human capital initiative dementia area manufactured capital social relationship capital offering solution go beyond providing pharmaceutical natural capital financial capital stamped 42 global brand fycompa belviq corresponding icon page strongly related 17 sustainable oncology area development goal sdgs stamped sdgs icon 44 intellectual capital message corporate officer 47 intellectual capital 2 ricchi ongoing project 48 global brand lenvima halaven period covered integrated report cover business performance 50 intellectual capital global drug creation activity april 1 2016 march 31 2017 section may 52 intellectual capital major rd pipeline include information activity recent fiscal 2017 55 intellectual capital intellectual property strategy reporting organization 56 human capital global marketing organization eisai co ltd domestic overseas consolidated 58 manufactured capital global production system subsidiary 60 social relationship capital improving access medicine atm forwardlooking statement risk factor business base related esg material information provided integrated report may contain forwardlooking statement based current 64 initiative sustainable development goalssdgs expectation forecast estimate business goal assumption subject risk uncertainty 66 corporate governance system could cause actual outcome result differ 69 interview outside director materially statement moreover target 70 board director executive officer value contained report merely express 74 compliance risk management mediumterm strategy intended direction vision 78 human capital initiative human right development working official earnings forecast official earnings forecast please refer annual financial report environment occupational safety health consolidated financial statement accordance 80 social contribution activity social relationship capital rule set tokyo stock exchange factor could 81 social relationship capital initiative pharmaceutical product material impact future outlook include safety side effect limited change economic environment 82 social relationship capital eisais partnership initiative competitive pressure surrounding eisais business environment revision law regulation fluctuation 84 natural capital business consideration global currency exchange rate uncertainty associated environment new drug development infringement intellectual appendix property right third party although report contains information pharmaceutical including 86 financial capital consolidated financial highlight development content intended advertising medical advice purpose addition result fiscal 2016 detail business risk stated described 88 esg index annual security report 90 fundamental knowledge terminology english report translated original japanese pharmaceutical industry version event inconsistency 96 status share statement two version statement japanese version shall prevail 97 corporate information note description generic name drug given omitting base hydrate 2 materiality eisais corporate philosophy give first thought patient family increase benefit health care provides likewise eisai provides employee bearer patient contribution opportunity develop career talent eisais mission increase benefit patient revenue profit brought consequently put emphasis order mission result hand order sustain corporate value maximization fulfil every stakeholder satisfaction corporate philosophy concept mission result consideration regarded efficient focus longterm investor beneficiary residual income important stakeholder1 longterm interest stakeholder including patient employee taken account believed identifying concern relate interest longterm investor taking initiative priority basis fast track maximization corporate value process establishing materiality eisais materiality matrix shown review update undertaken needed 1 concept derived enlightened value maximization theory michael c jensen 2001 process establishing materiality process 1 identification issue process 2 prioritization issue creation select issue giving consideration materiality matrix various type guideline eg priority order identified issue considered sustainability accounting standard priority given issue particularly pharmaceutical sasb2 gri high degree importance matrix created guideline sustainable development perspective impact eisais business goal sdgs3 communication considering corporate philosophy impact stakeholder socially responsible finance interest longterm investor investment sri index eg dow jones includes financial reporting opportunity sustainability index create innovation impact legal restriction industry norm process 3 review update review update undertaken needed taking consideration progress initiative toward issue change business environment 2 sasb sustainability accounting standard board usbased nonprofit organization identifies materiality reasonable investor industry develops sustainability disclosure standard 3 sustainable development goal sdgs set international goal 2030 agenda sustainable development adopted united nation sustainable development summit september 2015 detail please refer page 64 eisais materiality matrix figure parenthesis indicate corresponding page report initiative improving access creating innovative product high medicine p6063 p3239425462 offering solution go beyond initiative pharmaceutical providing pharmaceutical p4041 product safety side effect provision opportunity develop p81 interest longterm investor career talent employee ethical transparent drug p2023 creation activity p51 appropriate pricing p56 compliance risk management p7477 corporate governance p6669 financial strategy p2631 intellectual property strategy p55 reduction co2 emission prevention bribery corruption promotion based compliance formation lowcarbon society p75 p75 p84 information disclosure4 quality assurance stable supply waste reduction establishment employee health safety p5859 recyclingoriented society p85 management p7879 efficient use water resource p85 promoting diversity p2023 initiative counterfeit drug high p81 high high impact eisais business 4 please refer article 11 eisais corporate governance guideline httpwwweisaicomcompanycgguidelinehtml 3 eisai integrated report 2017 driving force eisai human health care hhc established corporate philosophy 1992 understood internalized core value employee within group japan overseas encourages employee use 1 total business hour interact patient incorporated corporate philosophy company article incorporation june 2005 carry 300 hhc activity globally every year based clear understanding patient well family customer key player health care eisai seek sense pride providing benefit stakeholder corporate philosophy summarized term human health care hhc believe order truly consider perspective patient family important employee first get close patient see situation perspective order learn empathize thought feeling might necessarily always expressed word accordingly recommend employee spend 1 business hour patient commemorate value goal incorporated corporate philosophy company article incorporation upon receiving approval annual general shareholder meeting june 2005 corporate philosophy give first thought patient family increase benefit health care provides article incorporation article 2 1 company corporate philosophy give first thought patient family increase benefit health care provides philosophy company endeavor become human health care hhc company 2 company mission enhancement patient satisfaction company belief revenue earnings generated fulfilling mission company place importance sequence placing mission ensuing result 3 company strives fulfill social responsibility positioning compliance ie observance legal ethical standard basis business activity 4 company principal stakeholder patient customer shareholder employee company endeavor develop maintain good relationship stakeholder enhance value stake 1 satisfying unmet medical need ensuring stable supply highquality product providing useful information subject including drug safety efficacy 2 timely disclosure corporate management information enhancement corporate value positive return shareholder 3 ensuring stable employment offering challenging fulfilling duty providing full opportunity development employee capability 4 living hhc philosophy everyday work eisai plan promotes various activity order employee recognize eisais corporate philosophy shared value express philosophy employee daily work duty providing opportunity share experience patient eisai provides employee variety opportunity spend time patient disease dementia cancer epilepsy part business operation one opportunity field experience training program employee visit hospital nursing care facility gain firsthand knowledge medical nursing care practice new employee host workshop collaboration advocacy group discus idea solving various issue patient person disability face society sharing knowledge hhc initiative eisai promotes specific action plan called hhc activity aim realize hhc organizational level project basis every year eisai hold annual hhc initiative acknowledge outstanding activity made significant contribution patient among 300 hhc activity carried globally award winner top management eisai group company around world gather together event present best practice sharing collective knowledge strive contribute patient detail please refer page 25 business model based hhc csr csv hhc corporate social responsibility creating shared value human health care value economic societal value good value common good benefit relative cost citizenship philanthropy joint company community company together create value sustainability value creation tune community need discretionary response integral competing fixation competition external pressure profit gained result separate profit maximization integral profit maximization common good strived agenda determined external agenda company specific internally generated agenda shared company reporting personal preference impact limited corporate realigns entire corporate included company regular footprint csr budget budget operating budget example transforming procurement example inputting customer example fair trade purchasing increase quality yield need value chain compiled deloitte tohmatsu consulting based michael e porter creating shared value harvard business review resource revised eisai supervised ikujiro nonaka professor emeritus hitotsubashi university eisais hhc different corporate social responsibility csr mainly involves social contribution activity including act charity directly contribute business corporate value relatively close creating shared value csv business model aim pursue social value economic value eisais mission create social value enhancing patient satisfaction economic value form revenue profit generated result eisai place importance sequence placing mission ensuring result 5 eisai integrated report 2017 take challenge develop next generation alzheimers disease treatment leveraging strength dementia area 6 strength dementia area 1 industryleading rd pipeline 11 project development 6 project targeting accumulation aggressive factor bace inhibitor elenbecestat1 2 antibeta amyloid aβ protofibrils antibody ban24011 3 antiaβ antibody aducanumab4 inhouse antitau antibody antitau antibody biib0764 antifractalkine antibody e6011 5 project targeting transformation symptom time dual orexin receptor antagonist lemborexant5 novel mechanism action e2730 next generation ampa receptor antagonist e2082 pde9 inhibitor e2027 epha4 synaptic functional modulator 1 codevelopment biogen inc 2 generic name e2609 generic name yet fixed time 3 licensedin bioarctic ab 4 development biogen inc eisai option jointly develop commercialize 5 codevelopment purdue pharma lp 2 abundant experience knowledge drug creation disease awareness activity dementia area drug creation activity 30 year dementia area disease awareness event carried globally estimated 10000 time 3 global collaboration collaboration enables increase probability success accelerate development financial efficiency 7 eisai integrated report 2017 1960s 1970s 1980s aiming contribute patient around world history eisai establishment global marketing structure late 1960s early 1970s 2017 eisai celebrated 76th anniversary local subsidiary established southeast asia founding commenced fullfledged overseas expansion since establishment predecessor nihon eisai co ltd eisai overcome 1969 singapore thailand taiwan numerous trial difficulty effectively 1970 indonesia nurture business environment corporate 1974 malaysia philippine culture employee make every effort see health care perspective eisai recognized corporate activity aimed overseas expansion fiscal 1969 received award patient based founding philosophy corporate contribution japan export industry presented contributing health wellbeing minister international trade industry many people region world eisai continue take exciting new challenge delivery novel innovative drug creation global brand 1941 established nihon eisai co ltd 1955 c hanged corporate name nihon eisai co 1980s early 1990s ltd eisai co ltd threehub rd network established 1982 tsukuba research laboratory japan 1989 eisai research institute boston inc u 1992 eisai london research laboratory ltd uk founder toyoji naito 18891978 tsukuba research laboratory eisai research institute eisai london research boston laboratory time typical strategy japanese pharmaceutical company expand business overseas license product pharmaceutical company abroad eisai determined handle process regarding product research serf fountainhead product phase flow manufacturing driven determination eisai one first industry establish rd base japan u europe strived creation global brand 1980s advertisement chocola first chocola brand product launched 1951 fullfledged entry oncology neurology area 1983 commenced drug discovery research dementia advertisement sampoon contraceptive launched 1948 tsukuba research laboratory 1987 launched rd group develop proprietary evolution logomarks anticancer agent tsukuba research laboratory 1941 time establishment logo nihon eisai co ltd predecessor eisai co ltd cuttingedge initiative global company 1955 time corporate name change displaying company name katakana instead chinese character quite rare japan early 1990s time logo also redesigned include elaborately designed redandblue motif birth hhc philosophy 1988 haruo naito appointed president eisai 1990 announced concept eisai innovation challenge employee present change way looked job meaning behind color life world message red blue color eisai logomark represent world changing let u change along red oxygenated blood flowing artery itpictured right blue deoxygenated blood flowing vein 1992 adopted corporate philosophy type blood flow incessantly heart human health care hhc task prevent stagnation blood flow promoting good health improving quality life time eisai beginning expand overseas market succinct corporate hhc philosophy also served common core value universally understood shared employee throughout eisai 8 1990s 2000s 2010s acceleration overseas expansion growth aricept pariet commencement mediumterm business plan eway 2025 mid 1990s early 2010s april 2016 establishment pharmaceutical sale subsidiary major country overseas mediumterm business plan eway 2025 1995 u uk germany 2006 australia portugal eisai aim leverage position 1996 france china 2007 belgium neurology oncology area create 1997 south korea 2009 austria flagship drug 2001 spain 2010 canada 2004 india 2011 brazil mexico 2005 italy switzerland sweden 2013 russia late 1990s 2000s 2010s growth aricept pariet toward era new global brand aricept pariet u name aciphex detail please refer page 4243 4849 1997 launched u europe uk 1997 launched japan 2010 launched anticancer agent 1998 launched asia thailand 1998 launched europe uk halaven u 1999 launched japan 1999 launched u asia thailand 2012 launched antiepileptic agent fycompa europe transition consolidated revenue revenue peak sale 2013 launched antiobesity agent major product billion yen aricept 3228 billion fy2009 belviq u pariet 1759 billion fy2007 others total 4708 billion fy2009 2015 launched anticancer agent global brand halaven lenvima fycompa belviq lenvima u parietaciphex 7817 8032 7689 japan europe 7343 aricept 6741 6480 loe aricept 6013 5737 6004 5485 5330 5479 5391 2010 u 5002 4666 2011 japan 4317 3617 2012 eu 3025 loe parietaciphex 2010 japan 2012 eu fy1999 fy2000 fy2001 fy2002 fy2003 fy2004 fy2005 fy2006 fy2007 fy2008 fy2009 fy2010 fy2011 fy2012 fy2013 fy2014 fy2015 fy2016 2013 u result fy2013 calculated pursuant jgaap result fy2014 beyond calculated pursuant ifrs loe loss exclusivity late 2000s 2010s strengthened foundation oncology area accelerated development next generation dementia treatment 2007 concluded agreement acquire 2013 commenced ban240112 phase ⅱ study morphotek inc u 2014 entered collaboration agreement biogen inc development 2008 completed procedure acquire mgi commercialization alzheimers disease treatment pharma inc u 2015 entered collaboration agreement purdue pharma lp 2010 established h3 biomedicine inc u development commercialization lemborexant 2016 commenced elenbecestat13 phase ⅲ study 1 codevelopment biogen inc 2 licensed bioarctic ab 3 generic name e2609 generic name yet fixed time late 1990s 2000s 2010s strengthening compliance promotion system enhancement corporate governance strengthening measure improve access medicine 1999 appointed director responsible 2000 introduced corporate officer system detail please refer page 6063 corporate ethic appointed outside director established compliance committee established corporate governance committee consisting mainly outside attorney 2003 separated two position chair board director 2000 formulated eisai network company president representative corporate officer ceo enw charter business conduct 2004 adopted company nomination committee etc system enw code conduct appointed 6 currently 7 11 director outside director issued compliance handbook 2005 outside director assumed chair board director set compliance counter added corporate philosophy hhc eisai article detail please refer page 7477 incorporation approval annual general shareholder ceremony agreement signing meeting world health organization november 2010 detail please refer page 6668 9 eisai integrated report 2017 eisais value creation process flow eisai seek increase corporate value putting corporate philosophy practice accordingly eisai considers top priority work build relationship trust wide range stakeholder including customer shareholder local community maximize value patient shareholder employee strive socially responsible company value generated corporate activity built capital increased decreased converted business model report based framework1 released international integrated reporting council iirc process investing capital engage business create added value wherein increase capital exceeds input considered value creation process meanwhile value creation flow value generated business activity ultimately assessment focused financial perspective based balanced scorecards2 four perspectives3 4 also consistent thinking sequence goal outcome based eisais corporate philosophy creating social value enhancing patient satisfaction sole objective thereby generating economic value form sale profit report express eisais continuous value generation value creation process flow model based new model incorporates iirc framework balanced scorecard eisais value creation process strategy map six capital based four perspective basis eisais strategy map iirc framework balanced scorecard financial capital expanding longterm shareholder value p3 2631 financial perspective pool fund use corporate activity organization respond shareholder order succeed financially increasing revenue p8687 manufactured capital facility manufacture product provision service customer perspective cultivating new customer intellectual capital done achieve patient knowledgebased intangible asset satisfaction pipeline intellectual property enhancing customer satisfaction human capital internal business process perspective creating innovative providing solution beyond capability experience eisais human product provision pharmaceutical asset well motivation innovation business model excel p3239 4254 62 product p4041 transformed social relationship capital building relationship trust society stakeholder common good learning development global leader support growth perspective take active role professional p2023 employee natural capital organization capacity improved maintained environmental resource process order realize corporate penetrating concept associated corporate activity philosophy human health care hhc p45 2425 10 chain target result based hhc corporate philosophy 1 iirc international ir framework international integrated reporting council 2013 2 kaplan robert norton david p using balanced scorecard strategic management system boston harvard business review januaryfebruary 1996 target 3 jensen michael c value maximization stakeholder theory corporate objective function business ethic quarterly 122 2002 4 porter michael e kramer mark r creating shared value harvard customer satisfaction business review june 2011 page 831 create keep customer business activity result sale profit etc source created basis theory mitsuaki shimaguchi figure parenthesis indicate corresponding page report financial capital increasing profit p8687 manufactured capital expanding customer base improving social value intellectual capital strengthening compliance human capital strengthening initiative risk management p7477 improving access pharmaceutical product medicine p6063 safety side effect p81 strengthening corporate governance p6669 social relationship capital natural capital encouraging ethic transparency ource created eisai based kazunori ito toshiaki nishihara disclosure usability information integrated report eisai kaikeigaku kenkyu annual bulletin accounting study no43 2017 advice professor kazunori ito 11 eisai integrated report 2017 major product product lineup mainly consisting two major focus area neurology oncology prescription drug business revenue fiscal 2016 5111 billion composition consolidated revenue 948 neurology area revenue fiscal 2016 1619 billion composition consolidated revenue 300 aricept generic name donepezil methycobal generic name mecobalamin treatment alzheimers diseasedementia lewy body peripheral neuropathy treatment revenue fiscal 2016 492 billion revenue fiscal 2016 400 billion dementia mecobalamin vitamin b12 coenzyme product originally discovered treatment developed eisai restores damaged peripheral nerve discovered widely used treatment peripheral neuropathy japan developed asian country house eisai believed slow overall progression symptom associated alzheimers disease inhibiting acetylcholinesterase enzyme break neurotransmitter acetylcholine currently approved 100 country worldwide agent received additional approval new indication treatment dementia lewy body japan philippine fycompa generic name perampanel lyrica generic name pregabalin antiepileptic agent pain treatment revenue fiscal 2016 103 billion revenue fiscal 2016 copromotion income 243 billion ampa receptor antagonist pain treatment discovered developed originally developed house eisai fycompa pfizer inc u approved japan currently approved u europe asia 130 adjunctive treatment country worldwide partialonset seizure copromoted primary generalized tonicclonic seizure japan pfizer japan inc eisai co ltd company detail please refer page 42 working provide information proper use belviq generic name lorcaserin lunesta generic name eszopiclone treatment chronic weight management insomnia treatment revenue fiscal 2016 37 billion revenue fiscal 2016 80 billion new chemical entity discovered nonbenzodiazepine developed arena pharmaceutical inc type gabaa receptor believed encourage decreased agonist food consumption promote satiety originally developed selectively activating serotonin 2c receptor sunovion brain belviq first prescription pharmaceutical inc treatment obesity approved u eisai pursued food drug administration 13 year development launched june 2013 additionally product since acquiring exclusive right sunovion oncedaily formulation launched u october 2016 pharmaceutical inc develop market agent japan detail please refer page 43 product launched japan april 2012 12 oncology area gastrointestinal area ea pharma co ltd revenue fiscal 2016 1183 billion composition consolidated revenue 219 april 2016 eisai integrated gastrointestinal disease treatment business built 60 year halaven generic name eribulin operation ajinomoto pharmaceutical co ltd form new company ea pharma co ltd full value chain ranging anticancer agentmicrotubule dynamic inhibitor revenue fiscal 2016 373 billion research development production logistics sale marketing new company commenced anticancer agent discovered developed inhouse eisai operation aiming become japan largest gastrointestinal synthetic analog halichondrin b derived marine sponge specialty pharma halichondria okadai show antitumor effect arresting pariet generic name rabeprazole cell cycle inhibition protonpump inhibitor growth microtubule approved revenue fiscal 2016 japan 212 billion 60 country treatment breast cancer protonpump inhibitor additionally approved 2016 originally discovered use treatment soft tissue developed inhouse sarcoma japan u eisai indicated europe treatment gastric detail please refer page 49 duodenal ulcer reflux esophagitis eradication helicobacter pylorus infection lenvima generic name lenvatinib etc approved 100 anticancer agentmolecular targeted drug country worldwide addition revenue fiscal 2016 215 billion japan eisai sell rabecure selective tyrosine kinase pack 400 rabecure pack 800 primary h pylorus eradication inhibitor tki novel rabefine pack secondary h pylorus eradication triple binding mode originally formulation combination pack contain pariet tablet 10 mg discovered developed use h pylorus eradication inhouse eisai approved treatment refractory generic business elmed eisai co ltd thyroid cancer 50 revenue fiscal 2016 280 billion country worldwide may 2016 lenvima also approved combination everolimus treatment renal cell carcinoma generic business japan carried elmed eisai u co ltd wholly owned subsidiary eisai mainly detail please refer page 48 developing valueadded generic drug accessibly priced easy patient administer close cooperation aloxi generic name palonosetron medical representative mr eisai strive provide medical professional detailed product information antiemetic agent revenue fiscal 2016 481 billion serotonin3 5ht3 receptor antagonist indicated prevention consumer healthcare business others chemotherapyinduced nausea vomiting revenue fiscal 2016 190 billion cinv postoperative nausea composition consolidated revenue 35 vomiting ponv marketed u eisai inc chocola bb product revenue fiscal 2016 124 billion ranging signature product chocola bb plus vitamin b2 preparation rough skin stomatitis variety product others thirdclass otc drug designated quasidrugs food nutrient function claim available humira generic name adalimumab chocolacom fully human antitnfα monoclonal antibody httpwwwchocolacomindexhtml japanese revenue fiscal 2016 473 billion treatment autoimmune disease rheumatoid arthritis japan agent manufactured marketed abbvie gk marketed bb plus bb royal 2 eisai abbvie gk eisai co thirdclass otc drug designated quasidrug promoting agent indication area gastrointestinal disease abbvie gk ea pharma co ltd copromoting agent indication gastrointestinal disease area 13 eisai integrated report 2017 ceo message stakeholder started midterm business plan eway agent lenvima treatment hepatocellular 2025 fiscal 2016 set goal 10 carcinoma completed successfully global year time medico societal innovator phase ⅲ study firstline treatment patient word company change society unresectable hepatocellular carcinoma lenvima creating medicine providing solution fiscal met statistical criterion noninferiority 2016 secured increase revenue region primary endpoint overall survival o compared local currency basis achieved double digit comparator drug additionally lenvima showed growth consolidated operating profit additionally highly statistically significant clinically meaningful product development progressing two improvement secondary endpoint therapeutic area focus neurology oncology progression free survival pfs time progression neurology area initiated phase ⅲ study ttp objective response rate orr doubling bace inhibitor elenbecestat12 patient median value ratio submitted early alzheimers disease japan u application treatment hepatocellular europe likewise development antiaβ beta carcinoma japan june 2017 u amyloid protofibrils antibody ban240113 steadily europe july also planning submit china ongoing enrollment largescale phase ⅱ second half fiscal 2017 study patient early ad patient accomplished 1 c odevelopment biogen inc 2 g eneric name e2609 generic name yet fixed time oncology area development anticancer 3 l icensedin bioarctic ab 14 increase corporate value enhancing nonfinancial capital 5 ntds neglected tropical disease include 20 disease world health organization recent year important theme improving identifies tropical disease human race must overcome prominent among corporate value lot attention paid lymphatic filariasis chaga disease mycetoma dengue fever initiative enhancing nonfinancial capital centered governance adopted company esg environment social governance esg committee system june 2004 clearly divide investment expanding globally based function supervision management evaluation esg initiative company execution business well ensuring fairness enhancing esg initiative transparency management eisai seven developing business based hhc philosophy eleven director outside director high environment category making degree independence chairman board effort reduce impact global environment well chair nomination audit many year result awarded compensation committee outside director rating cdp4 climate change report 2016 ceo member management side highest evaluation japanese healthcare sector always active discussion concerning business supervision various perspective 4 cdp formerly known carbon disclosure project nonprofit organization based london run collaboration institutional investor request information relating climate change outside director board meeting jefferies water forest company top ranking market capitalization principal country discloses information government investor security fiscal 2016 governance review report eisai awarded first place among topix500 society representative example include company initiative improving access medicine additionally eisai selected member provision dec diethylcarbamazine tablet ftse4good index series 16th consecutive treatment lymphatic filariasis one neglected year since 2002 well membership tropical disease ntds5 price zero activity dow jones sustainability asia pacific index create community patient dementia 5th consecutive year since 2013 july 2017 eisai live safely collaboration medical care also selected membership msci japan professional local government municipality esg select leader index ftse blossom japan citizen access medicine index eisai index adopted esg index gpif ranked first among japanese pharmaceutical government pension investment fund company eleventh among global pharmaceutical initiative enhance nonfinancial company consecutively 2014 2016 capital focus esg continue make effort increase corporate value initiative eliminate gap exist worldwide midterm business plan eway 2025 set gap five core approach innovation goal eisai medico societal innovator access strategy partnership flexible pricing word company change society policy solution intend creating medicine providing solution order expand approach realize corporate aspiration believe believe initiative eliminate gap need work eliminating various medical lead enhancing nonfinancial capital care gap exist throughout world also achieving united nation 17 sustainability ideal world everyone would access development goal sdgs line treatmentcare need thing different aspiration changing society making reality result difference region income medicine providing solution lack medical system huge discrepancy level treatment care available regional 1 creation innovative medicine gap income gap institutional gap exist globally regardless difference region income stand way everyone receiving equal access medicine universal value patient high quality medicine care creation innovative medicine fulfill enhance initiative eliminate need patient important mission 15 eisai integrated report 2017 pharmaceutical company particularly eisais priority g uinness world record awarded pharmaceutical company donation medicine create new medicine fulfill high unmet need dementia area despite estimate dementia patient increasing globally new dementia drug approved u fda since 2003 however convinced capable succeeding challenge industryleading pipeline possesses vast experience knowledge drug creation activity dementia area strive deliver new treatment patient family early possible eisai company conduct rd activity dementia based three new paradigm january 30 anniversary day london declaration 10 donor company including eisai set guinness world record medication aiming create new medicine taking donated 24 hour total 270 million tablet advantage knowhow accumulated year 2 access strategy human biology approach elenbecestat mission pharmaceutical company ban2401 two treatment target aggressive solely create innovative new medicine factor beta amyloid aβ late stage clinical overcome regional income institutional gap development also developing new medicine product must reach people need therefore focusing transformation symptom securing access also important time namely sleep disorder behavioral ntds lymphatic filariasis lf serious disorder finally cognitive disorder dual orexin medical social issue patient receptor antagonist lemborexant target sleep developing emerging country moreover disorder iswrd irregular sleepwake rhythm due poverty lack infrastructure many disorder also stage clinical development people cannot receive treatment moreover looking possibility new necessary order eliminate lf eisai began medicine target brain maintenance system manufacturing lf treatment dec tablet play important role preserving brain vizag plant india providing world homeostasis collaboration keio university health organization price zero free possesses worldclass ip cell technology charge supply commenced october 2013 basicclinical medical science aiming delivered approximately 11 billion tablet create next generation dementia treatment 27 country end june 2017 april 18 new approach based genetic background 2017 event marking fifth anniversary environmental factor protective mechanism london declaration largest international public additionally rich pipeline potential private partnership field global health took opportunity combination therapy place geneva switzerland event eisai aiming realize preemptive medicine announced commitment continue providing dec c odevelopment purdue pharma lp tablet beyond 2020 lfendemic country additionally ceo global health roundtable held three pillar new paradigm dementia area day eisai participated cochairperson progress aggressive factor accumulation alongside mr bill gate bill melinda reactive gate foundation together ceo aβ tau glial cell major pharmaceutical company discussed result past activity elimination ntds brain maintenance system genetic background potential future project elimination ntds protective environmental mechanism longterm investment aim expanding factor productive population middle income group transformation symptom time developing emerging country sleep behavioral cognitive continue proactively engage initiative disorder disorder disorder hand access medicine also become serious issue developed country pursuing various strategy overcome problem representative example initiative geriatric health service facility japan 16 pointed medical treatment decreased 5 provision solution facility payment medicine difficulty issue faced patient family injection limited longterm care cannot solved medicine alone eisais hhc insurance japan mean dementia solution business aim create foundation patient particular often blank period society coexists dementia identifying treatment order eliminate institutional clinical question based true need patient gap entered direct agreement dementia family providing solution organization facility joining verification real world data additionally provide aricept treatment alzheimers disease also providing tool used solution dementia lewy body along information interprofessional collaboration service disease facility since fiscal 2016 hikari one team sp medication administration business scheme first introduced tokyo support device eokusurisan smell identification sequentially expanded region test upsit series tracking tool support elderly people going memamorio 3 partnership solution potential eliminate regard partnership highly effective way various gap one actual case dementia patient improve efficiency productivity business living alone remote island goal improving speed success necessary family spend time rate development new medicine realizing carefully monitor medicine administration however cost efficiency development commercialization thanks introduction eokusurisan concluded partnership agreement able take correct amount medication numerous company academia neurology time day lessened burden oncology area family example eliminating regional gap rd activity treatment ntds create case providing partnered several international solution research organization acquire specific research technology experience run clinical study networking clinical facility endemic region specific example currently running phase ⅱ study inhouse antifungal agent fosravuconazole e1224 treatment chaga disease mycetoma collaboration npo drug neglected disease initiative dndi eliminating gap exist worldwide goal accomplish partnership company international research organization nonprofit organization accelerate initiative medication administration support device eokusurisan 4 flexible pricing policy developing emerging country would like undertake stakeholder vast number patient cannot obtain mandate increasing corporate value continuously medicine need due low income concept human health care hhc order improve access medicine people compliance ask stakeholder essential pursue affordable pricing policy continued support india indonesia eisai set price medicine aricept match living standard september 2017 country additionally several country haruo naito including philippine india thailand representative corporate officer ceo introduced tiered pricing scheme price medicine varies based patient income health insurance system provided many patient anticancer agent halaven scheme order eliminate income gap pursue pricing policy 17 eisai integrated report 2017 mediumterm business plan eway 2025 hhc ricchi core concept eway 2025 started april 2016 eisai started eway 2025 mediumterm business plan fiscal year 2025 april 2016 pharmaceutical company conducted development medicine course many year decade certainly long period time eisai endeavor make steady contribution patient looking ahead goal must reached 10 year later eway 2025 aim achieve following three strategic intent 1 aim support patient thought want get sick want know get sick want cured 2 aim support patient thought want control disease neighborhood safely spend rest life peace mind 3 f ocus business domain eisai find ricchi based hhc need fulfill eisai innovation foundation strategic intent hhc main concept plan eway 2025 human health care corporate philosophy hhc socialization reflects desire contribute patient spending time together sharing experience patient hhc philosophy enacted 1992 hhc true need acknowledged common value among understanding real need patient employee japan overseas spending motivation innovation time patient understanding true need fulfilling hhc need innovation motivates employee becomes source finding ricchi eisais innovation employee recommended spend 1 business hour patient establishment center line additionally since inauguration eway 2025 ricchi innovation patient socialization program included internal training program motivated ricchi employee contribute patient eway 2025 eisai selected two therapeutic area real patient need area focus fulfill patient unmet need still unmet eisai neurology oncology two area become frontrunner believe important find ricchi area real patient need still unmet ricchi neurology area eisai become frontrunner establishing center line ricchi innovation core concept 1 early minimallyinvasive diagnostics 2 novel neurotransmission pathway eway 2025 3 proteinopathy eisai identified 6 ricchi neurology area 4 neuroinflammation immunogenetics 2 ricchi oncology area focus effort 5 synapse microenvironment producing innovation 6 neuronal regeneration ricchi oncology area 1 cancer microenvironment mesenchymal cell tumor stromal cell endothelial cell myeloid cell river gene mutation aberrant splicing 2 cancer cell 18 accelerate development flagship pipeline neurology oncology area business group structure eisai established business group endtoend structure business group organization integrate function research development commercial two major area president neurology oncology upon initiation eway 2025 one objective establishment business discovery strategy group enhance productivity business early development clinical commercial planning decision making another develop scientific acumen important organizational culture integrated business structure includes discovery research development flagship drug based ricchi neurology oncology area accelerating since organizational shift business group structure made flagship drug neurology area ricchi proteinopathy ricchi novel neurotransmission pathway elenbecestat12 bace beta secretase cleaving enzyme inhibitor lemborexant5 dual orexin receptor antagonist phase ⅲ study ongoing patient early alzheimers disease phaseⅱstudy ongoing patient irregular sleepwake rhythm ad japan u europe disorder associated alzheimers disease dementia simultaneously implementing two phase ⅲ study phase ⅲ study ongoing patient insomnia disorder study design e2027 pde9 inhibitor ban240113 antiaβ beta amyloid protofibrils antibody phaseⅱstudy preparation potential indication largescale phaseⅱstudy ongoing 856 patient early ad dementia lewy body dlb initial indication aducanumab4 antiaβ antibody e2082 next generation ampa receptor antagonist phase ⅲ study ongoing patient early ad plan submit investigational new drug ind fiscal 2017 seek potential various neurological disorder 1 codevelopment biogen inc 2 generic name e2609 generic name yet fixed time 5 codevelopment purdue pharma lp 3 licensedin bioarctic ab 4 development biogen inc eisai option jointly develop commercialize ricchi neuroinflammation immunogenetics e6011 antifractalkine antibody phaseⅱstudy ongoing patient rheumatoid arthritis phaseⅰⅱ study ongoing patient crohn disease flagship drug oncology area ricchi cancer microenvironment mesenchymal cell tumor stromal cell cell differentiation cancer stemness endothelial cell abnormal tumor blood vessel halaven microtubule dynamic inhibitor lenvima vegfrfgfrret kinase inhibitor approved indication breast cancer6 60 country approved indication thyroid cancer 50 country approved indication soft tissue sarcoma7 40 approved indication renal cell carcinoma secondline country combination therapy everolimus 35 country phaseⅰⅱ study8 ongoing combination therapy submitted treatment hepatocellular carcinoma antipd1 therapy pembrolizumab patient metastatic japan june 2017 u europe july 2017 triple negative breast cancer submission china planned second half fiscal 2017 morab202 antibodydrug conjugate adc phase ⅲ study ongoing 2 combination therapy plan initiate phase study targeting cancer type folate lenvatinibeverolimus lenvatinibpembrolizumab patient receptor alpha fra expression fiscal 2017 renal cell carcinoma firstline phaseⅰⅱ8 study ongoing combination therapy pembrolizumab patient renal cell carcinoma endometrial myeloid cell immunosuppressive myeloid lineage cancer melanoma head neck cancer urothelial cancer non e7046 ep4 antagonist small cell lung cancer phaseⅰ study ongoing combination therapy preoperative radiotherapy colorectal cancer ricchi driver gene mutation aberrant splicing cancer cell 6 indication vary country territory unresectable recurrent breast cancer japan third line therapy locally advanced metastatic breast cancer u secondline therapy hsb6527 fgfr4 inhibitor locally advanced metastatic breast cancer eu phaseⅰ study ongoing patient hepatocellular carcinoma 7 approved indication u eu advanced liposarcoma approved indication japan soft tissue sarcoma h3b8800 splicing modulator 8 codevelopment merck co inc kenilworth nj usa phaseⅰ study ongoing patient hematological malignancy 19 eisai integrated report 2017 cto message eisais strategy development human resource yasushi okada representative corporate officer chief talent officer cto basis development human resource understand true need patient socialization eisai regard employee important stakeholder basis incorporates socialization patient asset realization corporate philosophy training program throughout region effort namely hhc strengthen development human resource perspective basis development global talent management policy formulated human resource lie socialization word along launch eway 2025 defines involves employee spend time patient aspiration eisai employee training promotion understand true need socialization also motivates recruitment workplace climate based employee deliver innovation fulfill philosophy hhc socialization also set basis patient need mediumterm business plan eway development human resource policy 2025 launched april 2016 constituted based eisai global talent management policy eisais employee understands patient true need socialization gain strong driving force innovation think wherehow convert knowledge innovation fulfill need science also wider scope make happen eisai endeavor provide meaningful work innovation development opportunity foster corporate culture without discrimination harassment embrace diversity inclusion encourage challenge trial error success attract acquire great talent feel hhc maximize satisfaction patient find develop talent observe current real world trend publication academic conference etc interpret ability decode time opportunity new business opportunity ricchi without adhering status quo area real patient need still unmet eisai become frontrunner effort develop human resource lead business global scale globalization eisai rapidly expanding fact 111 egold graduate playing active role half 10000plus employee eisai management corporate officer work overseas local employee assigned overseas transfer longterm business top management position overseas trip global system actively offer subsidiary seven 27 corporate officer opportunity employee go beyond national outside japan executive committee meeting border pursue career develop skill highest decisionmaking body eisai conducted global mobility last four year 60 english decade employee participated program addition order expand contribution patient program offer opportunity employee around world development leader run study abroad acquire mba study law school business global scale beyond national border nearly 120 employee studied abroad imperative eisai regard management candidate system lead eisai future global leader young program supporting employee early stage career demonstrate development ability decode time opportunity regarded global human resource top management nextgeneration talent human resource systematically developed various assignment egold global leader management candidate training program lead future eisai eisai global opportunity leadership development middle manager egold eisai agile change excellence eace important training program led ceo cto respectively former designed global leader eace nextgeneration talent young employee early stage career latter nextgeneration talent nine demonstrate ability decode time opportunity 20 company introduction management strategy value creation activity business base esg appendix diversity imperative fulfilling patient need believe diversity source innovation w h diffe r e nt v lue w uld imperative human resource eisai grow facilitate better understanding group diverse talent utilizes diverse value patient feeling health business activity care environment instance anticancer agent halaven since 2012 eisai treatment metastatic breast cancer primarily advocated eisai diversity affect woman therefore value womens point declaration endeavor view significant fulfilling true need develop organizational climate time embrace patient obvious concerted effort people utilizing diverse value eisai diversity effort toward advancement woman workplace u chinese subsidiary assign woman top workplace enacted april 1 management position woman also account 2016 eisai encourages female employee 45 management position u european pursue career setting target chinese subsidiary show many proportion woman management position fiscal female employee pursued successful career 2020 10 overseas subsidiary past japan many female ratio female employee management position employee promoted managerial position recent eisai co ltd year male female employee promoted 10 comprehensive position prospect promotion almost equal proportion year year female employee potential candidate managerial position implementing selective 59 training program female employee 52 46 47 career perspective developed midcareer 41 37 recruitment proactively seek woman would 29 30 work executive candidate position year woman account greater part management fy2020 position japan eisai co ltd reaching 59 target end july 2017 compliance act end end end end end end end end promotion womens participation advancement fy2011 fy2012 fy2013 fy2014 fy2015 fy2016 fy2017 july 2017 diversity initiative outcome womens career pursuit supporting worklife balance october 2012 ceo issue eisai diversity declaration determination diversity lead improvement patient benefit shared companywide basis diversity committee considered numerous different action human resource development headquarters currently charge promoting diversity inclusion stratified career training designed female employee time management system introduced employee improve provided since 2014 effectiveness efficiency way working greater mentoring system introduced focus time effort adaptation diversity included system allow nonmanageriallevel employee choose performance appraisal criterion scope work location accordance lifestyle life diversityrelated training provided department event introduced manager flextime childcare caregiving made applicable internal website introduces various case employee employee working offsite serve role model shorter working hour childcare caregiving made applicable manageriallevel employee training provided medical representative mr return work childcare leave reinstatement training accompanying mr raising child end end fy2011 result fy2016 result march 2012 july 2017 ratio female employee 226 211 average length service 190 year 204 year ratio woman malesfemales 197 years168 year 214 years169 year 30 59 management position average length paid leave numberratio woman taken 00 3111 139 day 124 day corporate officer position per nonmanageriallevel outcome employee average monthly overtime numberratio woman hour 19 19 11 hr 1 min 8 hr 34 min director position per nonmanageriallevel employee fy2011 result fy2016 result including new graduate midcareer employee ratio female employee entered company 30 38 fiscal year 21 eisai integrated report 2017 effort japan taking initiative developing individual continue make reform new personnel system april 2016 simultaneously launched new 2 achieving diverse way working personnel system japan along launch ensure equal relationship employee eway 2025 new personnel system designed employer employee provided greater scope encourage employee take initiative facilitate choice make based value development individual continue make scope choice also expanded reform order eisai continue creating innovation employee certain restriction due childcare need rapidly changing business environment personal reason maximize skill utmost encourage employee drastically adapt awareness action ensure example system allow diverse work style development strong energetic individual highly regarded professional internally introduction job challenge system externally introduced internal recruitment system allows personnel change specific role position fiscal 2016 three employee used system three pillar new personnel system transferred department wished 1 producing professional work define professional person quickly adapt introduction mobility choice system environmental change capable generating introduced system employee choose expected outcome solving problem opportunity location would like work based proactively offered skill development lifestyle life event employee may choose either employee become professional global domestic location specified former based idea payforperformance employee limit place employee work would rewarded corresponding favorable outcome whereas latter employee life event generated professional childcare caregiving marriage may choose work specific location limited period request transfer specific location example skill development program producing professional introduction professional development review introduced system supporting 3 actively supporting diverse human resource employee set career path encourage reform eisai proactively developing climate human resource become professional field willing diverse background pursue career moreover position future three year based employee provided opportunity expose selfanalysis discussion supervisor employee global value annually formulate implement action plan fill gap want future example effort encourage diversity strengthening career training levelspecific training program facilitating woman pursuing career career training provided employee age 30 ewin eisai womens innovative network 40 50 enter big milestone career program supporting female employee develop encouraged function professional career conducted since 2014 basic socialization patient program also program designed young employee develop introduced levelspecific training new joiner career vision whereas advanced program designed department manager program fully train leader 83 employee participated renewed last three year 13 female employee assumed manageriallevel position mentoring program mentoring motivated employee mentee seek example promoting globalization advice work colleague mentees immediate supervisor mentor provides global leadership program japan pharmaceutical advice support mentees development fiscal business 2016 28 young employee participated mentoring eisai initiated global leadership program 2015 program support personal growth employee wanting take active role global stage future internal internship program program involves acquiring business skill cross program designed employee develop cultural communication negotiation presentation career vision experiencing work another skill well training eisai site overseas fiscal department several day fiscal 2016 nearly 50 2015 2016 30 employee participated program young employee participated program participant encouraged seek selfimprovement global businessperson course daily work actively get involve interact member inside outside company visit japan abroad 22 company introduction management strategy value creation activity business base esg appendix initiative japan facilitating work style reform accordance slogan dynamic engagement continue best develop citizen government japan pushing environment employee work actively forward work style reform eisai also committed satisfaction enabling employee enrich life enhancing productivity work fiscal 2017 chose average monthly overtime hour per nonmanagement improvement long working hour promotion employee 12hrs 11mins flexible work style represented telecommuting development environment facilitating womens 10hrs 46mins 10hrs 27mins active participation improvement working condition nonregular employee nine 9hrs 11mins 8hrs 34mins goal set forth government defined important goal deepening discussion work style reform exchanging opinion labor union particular effort improve long working hour strengthened recent year employee overtime hour decreasing continue improvement action based encouraging time management take measure strengthening individual monitoring work long hour encouraging employee take leaf considering introduction system taking record arriving leaving time work place fy2012 fy2013 fy2014 fy2015 fy2016 introduction employee used job challenge system looking ahead future undertaking new business previous job sale representative used challenge however go job challenge system transferred hhc solution back basic try stay business october 1 2016 since joined eisai active learning undertake interested community networking current job job engaged numerous related activity learned estimate four year medical association worked might happen year later time concluded threeparty agreement remain updated effort government eisai cooperation facilitation issue different community coexistence community dementia act accordingly patient based perspective began strive clarify problem work solving issue community development community undertake new takuya iihama became motivated spread activity business focusing providing hhc solution headquarters area comprehensive community believing would certainly product solution solution department take greater importance soon found fulfill solve problem announcement job challenge decided apply detail community networking hhc solution business please refer working new organization entail many obstacle page 4041 introduction employee participated global leadership program maximizing networking skill developed training u worked sale representative applied obtained internal global leadership program japan pharmaceutical networking business business part program participated japan believe sharing best training program organized u subsidiary practice japan business gave opportunity analyze understand overseas colleague return health care system market access promotional expand perspective strategy particular u various marketing help enhance aspect currently engage global marketing patient contribution around oncology product headquarters tokyo world greatest advantage gained program networking skill training learned mariko endo oncology business group various function within eisai well planning department informed one role responsible planning office utilize valuable information 23 eisai integrated report 2017 hhc special feature socialization patient program employee eisai seek realize innovation satisfy seci model patient need daily work exercising ingenuity based organizational knowledge creation spiral theory knowledge creation aim fulfill hhc tacit tacit corporate philosophy share direct socialization externalization express tacit experience knowledge two type knowledge tacit explicit build tacit environment e dialogue explicit knowledge reflection tacit former subjective easily expressible latter empathizing individual group conceptualizing expressible seci model core framework knowledge creation creates organizational innovation internalization combination repetitive mutual conversion implicit knowledge explicit explicit practice e organize tacit g knowledge model knowledge creation captured four model g relevant concept narrative g org g prototype phase first phase socialization process building accumulate e g model tacit knowledge narrative tacit knowledge directly sharing experience others practicing modeling explicit explicit second phase externalization process expressing individual g group organization e environment tacit knowledge individual dialogue concept iconography third phase combination spirally process combine explicit knowledge organizational level eisai place particular importance socialization model narrative fourth phase internalization understanding reality patient emotion recommends process creating new tacit knowledge practicing employee around world spend 1 business explicit knowledge important repeat four phase hour patient overview socialization patient program japan member public relation pr investor relation ir department participated eight member visited jasmin ogi adachiku tokyo residential complex elderly smallscale multifunctional home care service implemented socialization facility offer support functional training daily life homelike environment well interaction local people user remain independent possible member participated program spent time dementia patient learned feeling understanding reality patient pr ir department member learned dementia patient strong motivation dementia patient communicate others even though met first time patient shared many story u experience youth family health also seemed worried conflicted time forgot said minute earlier difficulty finding appropriate word looked confused occasion talked nodded smile helped feel relieved continue story deep inside patient wish stay connected society needed recognized others common feeling patient apparently tried conceal memory problem fully accepting saw many smile face afraid becoming incapable taken granted finding appropriate word speaking time want stay really exposed feeling sensed personality dementia patient making someone else smile also make smile patient looked shy praised staff facility seeing renewed understanding importance helping patient get isolation stay caring community find person spend time live peacefully feeling secure addition socialization patient program mr baba director facility taught u issue environment surrounding dementia patient change system relating nursing care deepened understanding problem facing practice health care nursing care shared one another feeling got program carried externalization combination participation training program renewed understanding importance closely considering patient feeling year ahead pr ir department seriously endeavor communicate benefit eisais pharmaceutical solution patient easytounderstand manner 24 hhc special feature global hhc best practice november 2016 eisai held hhc initiative 2016 head office tokyo approximately 130 person group company worldwide participated event shared respective best practice among introduce example best practice activity south korea canada satisfying unmet need person disability music put concept song south korea based data south korean ministry health welfare eisai korea inc eisai korea team learned aimed contribute social understanding people disability insufficient creation although acquire disability due variety disease society coexists eisai treatment including cancer dementia person disability epilepsy moreover interacting people disability releasing original song eisai korea team member also learned many entitled closer person disability suffer social prejudice become call realization psychologically dispirited condition society people live comfortably reluctant seek medical treatment thus low quality holding concert perform song creating guide life interacting person disability given situation eisai korea team wondered result series activity eisai korea could provide person disability transcended boundary corporate activity earned solution supplying pharmaceutical high acclaim disabilitiesrelated organization workshop person disability eisai korea team also reported various medium eisai korea also received learned many people disability love music excellence award csr category pharmaceutical music power move people accordingly team industry advertisement pr award ceremony launched project campaign raise awareness disability music delivers message society please access url youtube korean japaneseenglish unmet need word originated subtitle view video original song closer koreanlanguage naleul issge haneun uli meaning httpsyoutubevnxknpgadsm voice employee eisai korea participated project able take first step toward linking future korea eisai certainly large business operation tacit knowledge obtained company however following interacting patient person disability startup project project participating witnessed increase project gained sense selfawareness job application excellent involved activity truly meaningful society human resource also able sense happiness working project provided great company think seriously creating good society opportunity become aware also felt joy living meaningful human life joy participating socially pride trust company well joy working significant purposeful activity together outstanding colleague increased south getting close feeling person epilepsyproject hope canada interchange epilepsy patient employee program patient show numerous improvement eisai ltd canada learned instance increased awareness tie people society patient suffer misunderstanding prejudice restoration selfrespect increased liveliness society isolated society develop symptom program employee gained deep anxiety depression accordingly held discussion understanding social psychological issue faced epilepsy association nova scotia introduced epilepsy patient carrying activity extensively supported project hope health person epilepsy region provides opportunity promote disease promotes social acceptance epilepsy patient awareness epilepsy restores selfconfidence targeting patient lost also make widely selfrespect isolated epilepsy project known value eisai hope comprehensive program feature art therapy provide epilepsy freely drawing picture yoga getting good patient family physical shape instruction account bookkeeping raise daily life skill well improves verbal expressive capability patient better express participating 25 eisai integrated report 2017 cfo message linking nonfinancial capital mediumtolongterm corporate value creation ryohei yanagi senior vice president chief financial officer chief ir officer global investor asking japanese company mediumtolongterm capital efficiency roe relevance nonfinancial capital value creation japanese version stewardship code february 2014 corporate governance code june 2015 formulated principle setting forth responsibility institutional investor corporation perspective mediumtolongterm growth japanese economy ito review august 2014 also released ministry economy trade industry meti aim seeking continuous value creation recommends company strive improve mediumtolongterm roe core target company management promote dialogue company investor contributes sustainable corporate value creation result suggestion numerous company undertaking initiative improving roe purposeful dialogue company investor promoted note global longterm investor asking japanese company introduce result one survey global investor survey2017 survey period january 10 february 22 2017 survey subject 139 world major institutional investor 77 japan 62 overseas q agree ito review recommendation q thought japanese company esg csr company commit achieving roe 8 disclosure integrated report higher medium tolongterm e e 全体 回答数 全体 strongly agree 回答数e f b e f b 全体 全体 回答数 回答数 unconditionally concentrate company c c 4 1 4 1 64 643 2 2 1 3 2 2 1 aon 3 esg proactively 3 make disclosure 2 2 b generally agree b b 65 65 b b b c2ompanies 2 prioritize esg capital c agree c c2 2 c 102c 102 efficiency roe disclose explain esg neutral d6 6 c 26 company should26 emphasize capital e e 19 19 efficiency roe e2 2 e e 2 2 esg show value 46 46 relevance two 合計 合計 139 139 f f4 4 b b company first prioritize capital 合計 139合計 139 47 47 c c efficiency roe given lag behind global peer 73 73 e interestnot important f 90 investor seek roe 8 70 investor responded company higher medium tolongterm emphasize capital efficiency roe esg show value relevance two source based following reference global investor look japanese company corporate accounting chuokeizaisha may 2017 issue result survey clearly show longterm investor basically asking japanese company generate roe 8 level mediumtolongterm demonstrate value relevance non financial capital capital efficiency roe suggests company must make continuous effort toward sustainable corporate value creation eisais roe management target positive equity spread mediumtolongterm eisai working improve mediumtolongterm roe since beginning 2000s specific target eisai aim avoid shorttermism achieve roe cost equity mediumtolongterm eg 10year average word eisai aim create positive equity spread roe cost equity cost equity return demanded shareholder eisai conservatively assumed cost shareholder equity 8 eisai generating historical 10year average roe 107 positive equity spread 27 26 company introduction management strategy value creation activity business base esg appendix trend roe fiscal year mediumtolongterm value creation equity spread roe cost equity coe key indicator shareholder value creation based 1 20 historical 10year average roe 107 residual income model2 eisai conservatively assumes cost equity 8 risk 164 free rate 2 risk premium 6 15 143 historical 10year equity spread 132 114 historical 10year average roe 107 coe 8 27 109 94 result fiscal 2007 removed serve 10 96 appropriate reference due impact mgi pharma inc acquisition 76 result fiscal 2011 calculated pursuant generally accepted 77 68 5 8 cost equity accounting principle japan jgaap result fiscal 2012 2013 2014 2015 2016 calculated pursuant international financial reporting standard ifrs 0 1 result fiscal 2007 included 2006 2008 2009 2010 2011 2012 2013 2014 2015 2016 2 roe revolution financial strategy chuokeizaisha 2015 fiscal year relation mediumterm business plan eway 2025 financial indicator mediumterm business plan financial kpis eway 2025 eway 2025 aim attain roe kpis fy2020 target 10 level equity spread 2 level fiscal 2020 midpoint roe 10 level plan fiscal 2025 final year equity spread 1 2 level plan eisai mindful attaining roe 8 level 15 level back dramatic growth doe2 maintain 150 dividend per share spurred contribution flagship drug neurology area oncology area ratio equity attributable 5060 owner parent doe kpi pursue optimal dividend policy based optimal net der3 003 capital structure work maintain 15 level roe fy2025 dividend 150 yen per share optimal capital structure perspective dividend per share subject approval board director 1 equity spread roe cost equity eisai conservatively assumes cost equity 8 tradeoff theory maintaining financial 2 doe dividend equity attributable owner parent integrity principle eisai maintain ratio 3 n et der net debt equity ratio interestbearing debt bond borrowing cash cash equivalent time deposit exceeding 3 month parent company holding investment security equity attributable owner parent equity attributable owner parent 5060 net der range 003 single level credit rating criterion financial strategy map1 sustainable maximization shareholder value eisai set financial strategy map cfo policy continuously maximize shareholder value strategy consists three key theme roe management valuecreative investment criterion vcic dividend policy investor relation financial strategy dividend policy roe management valuecreative investment signaling effect2 margin fam4ma criterion vcic catering effect3 business development partner tax policy npv irr balance sheet management leverage riskadjusted hurdle rate turnover ccc5gcms6 rahr optimal capital structure cost equity optimal dividend policy based optimal tradeoff theory7 pecking order theory capital structure credit rating single level cost equity 8 kpi8 doe model net der 003 equity spread reduction cost equity pbrper roe ir activity maximization shareholder value 1 source based following reference financial accounting literacy enhance corporate value 2016 nikkei publishing inc 2 signaling effect potential impact stock price showing management belief achievement revenue forecast dividend policy 3 catering effect potential impact stock price meeting expectation shareholder preference dividend 4 fam fixed asset monetization 5 ccc cash conversion cycle 6 gcms global cash management system 7 tradeoff theory idea pursue optimal capital structure debt finance equity finance use balancing cost benefit 27 eisai integrated report 2017 roe management turnover financial margin improve asset leverage controlling net der improve ratio efficiency utilize financial leverage roe controlling working operating profit operating capital converting mediumterm target efficiently fixed asset 003 cash financial integrity cfo policy placed mediumtolongterm roe management center line corporate value creation dupont method roe analyzed three element consisting margin ratio profit revenue turnover total asset turnover ratio financial leverage eisai focusing optimizing three element increase margin eisai focus expanding highprofit global brand discovered developed inhouse lenvima halaven fycompa eisai also strive improve margin emphasizing selection concentration priority project utilizing partnership improve turnover eisai manage cash conversion cycle ccc control working capital strive improve asset efficiency step including selling asset encompassing investment security streamlining inventory using financial leverage eisai pursue optimal capital structure maintaining financial integrity maintaining single level credit rating set kpis net der 003 ratio equity attributable owner parent 5060 net debtebitda 03 year undertaking business activity based financial discipline steadily reducing interestbearing debt secured net cash end fiscal 2016 first time approximately nine year net der negative 005 ratio equity attributable owner parent 57 net debtebitda negative 031 year based view secured sufficient financial integrity believe resume leverage strategy end fiscal 2016 possessed investment security amount 363 billion broaderbased net cash includes investment security stood 636 billion net der negative 011 initiative pursue sustainable roe mediumtolongterm 10year average basis rather focus shorttermism cfo policy roe management based corporate philosophy hhc enlightened value maximization theory michael c jansen 2001 vcic valuecreative investment criterion investment become even important company achieve growth reason eisai determined value creative investment criterion vcic ensure strategic investment create shareholder value making investment use net present value npv internal rate return irr spread using riskadjusted hurdle rate kpis principle naturally select investment positive npv set certain spread irr assure value creation setting hurdle rate factor risk element particular investment project investee country liquidity approximately 200 type hurdle rate apply riskadjusted hurdle rate appropriate respective investment project formula riskadjusted hurdle rate riskadjusted hurdle rate risk free rate β risk premium liquidity premium risk free rate 10 year average yield 10 year government bond β defined investment category risk profile dividend policy eisai return profit shareholder stable sustainable manner based factor healthy balance sheet comprehensive consideration consolidated financial result dividend equity doe ratio equity attributable owner parent free cash flow well consideration signaling effect strive optimal dividend policy based optimal capital structure depends longterm balance sheet management rather dividend payout ratio based shortterm performance kpi dividend perspective balance sheet management eisai adopted doe indicates ratio dividend consolidated net asset 28 company introduction management strategy value creation activity business base esg appendix principle eisai strives maintain dividend within range free cash flow multiyear level kpis maintaining healthy balance sheet eisai set target net der 003 equity attributable owner parent 50 60 net debtebitda 03 year based policy eisai maintaining healthy balance sheet present condition therefore plan maintain dividend 150 yen1 per share fiscal 2017 expectation numerous shareholders2 intention protecting shareholder value acquisition treasury stock carried appropriately factor market environment capital efficiency roe taken account 1 dividend per share subject approval board director 2 based result past survey individual institutional investor trend free cash flow dividend dividend within range free cash flow multiple year free cash flow fcf dividend annual total amount billion yen 1003 100 794 811 820 714 593 604 529 545 50 427 427 428 428 429 429 427 427 399 0 2008 2009 2010 2011 2012 2013 2014 2015 2016fy strong balance sheet dividend sustainability maintaining optimal capital structure billion yen 700 70 062 5987 600 5737 5846 60 063 5263 049 4694 57 59 57 500 54 50 4280 4159 4168 4042 47 400 41 40 37 38 39 038 300 027 30 200 014 20 100 006 10 001 0 0 005 49 100 end end end end end end end end end 10 fy2008 fy2009 fy2010 fy2011 fy2012 fy2013 fy2014 fy2015 fy2016 equity attributable owner parent net interestbearing debt1 ratio equity attributable owner parent net debt equity ratio net der2 result end march 2013 calculated pursuant jgaap result end march 2014 onward calculated pursuant ifrs et interestbearing debt interestbearing debt bond borrowing cash cash equivalent time deposit exceeding three month 1 n 2 net debt equity ratio net der interestbearing debt bond borrowing cash cash equivalent time deposit exceeding three month equity attributable owner parent eisais funding policy eisais funding policy based pecking order theory defines priority order funding follows cash hand come first second funding debt funding new equity last option efficient funding measure eisai adopts global cash management system gcms effective cash utilization among group company therefore consider cash hand debt come top equity financing could damage existing shareholder value last option 29 eisai integrated report 2017 striving sustainable corporate value creation enhancing nonfinancial capital according multicapital model international integrated reporting council iirc framework iirc 2013 corporate value composed six capital broadly divided two category namely nonfinancial capital intellectual capital human capital manufactured capital social relationship capital natural capital financial capital create sustainable corporate value besides financial capital eisai also work enhance nonfinancial capital nonfinancial capital linked corporate value let u examine relevance pbr price book value ratio proxy variable shareholder value nonfinancial capital iircpbr model value relevance six capital compose corporate value major esgrelated external evaluation net asset book value accounting basis related financial capital selection index september 2017 market value added mva related nonfinancial capital msci esg rating aa eisais pbr trend end fiscal 2006 end fiscal 2016 msci japan esg select leader index f tse4 good index selected 16 nonfinancial capital time intellectual capital consecutive year since 2002 4 human capital ftse blossom japan index 3 manufactured capital ow jones sustainability asia pacific social index selected 5 consecutive year 2 relationship capital since 2013 market value added mva amount natural capital access medicine index atm index 1 2014 2016 ranked 1st among financial capital japanese pharmaceutical company net asset book value accounting basis 11th among global pharmaceutical 0 company end fiscal 2006 end fiscal 2016 eisais pbr generally 2 past 10 year recently maintained slightly 3 mean assessment eisais market value significantly exceeded net asset book value accounting basis based assumption shareholder value equal longterm total market capitalization also equal book value shareholder equity bv plus mva eisais present financial capital equivalent bv nonfinancial capital consisting intellectual capital human capital manufactured capital social relationship capital natural capital related mva portion exceeds pbr 1 also called future financial capital nonfinancial capital becomes mva sort selfcreated goodwill cannot recorded accounting also considered intangible invisible value created effort management called iircpbr model perspective latest pbr eisais selfcreated goodwill earning high acclaim centering esg nonetheless recognize must enhance value effort focused rd pipeline value relevance nonfinancial capital equity spread cfo proposed synchronized model regarding financial capital nonfinancial capital value relevance based corporate philosophy hhc prior announcement iirc international integrated reporting council framework consideration mediumtolongterm capital efficiency roe equity spread sustainability importance nonfinancial capital nonfinancial capital equity spread value relevance model 1 toward visualization invisible value ① intrinsic value model2 ② iircpbr model shareholder value cost equity reduction intellectual capital sustainability value nonfinancial capital value esgcsr market value added mva human capital margin improvement customer value manufactured capital book value shareholder equity bv human value social relationship capital organizational value natural capital financial capital iirc framework ③ residual income modelrim sum present value equity spread mva residual income net income coe bv t1 equity spead bv shareholder value bv roe coe bv 1 1coet return equity attribute owner parent cost equity 1 source based following reference roe revolution financial strategy chuokeizaisha 2017 2 financial strategy maximizing corporate value doyukan 2009 30 company introduction management strategy value creation activity business base esg appendix first ①intrinsic value model market value added mva defined esgcsr1 value cost capital reduction effect customer value human value organizational value contrast aforementioned ②iircpbr model explains relevance six capital iirc framework positioning book value shareholder equity bv financial capital relating mva nonfinancial capital consisting intellectual capital human capital manufactured capital social relationship capital natural capital based assumption shareholder value equal longterm total market capitalization also equal book value shareholder equity bv plus mva ③residual income model rim thought mva converges total present value equity spread therefore considered future financial value creation based equity spread long term conflict nonfinancial capital value esg mva creation mutually contradictory synchronized conjunction nonfinancial capital equity spread value relevance model intrinsic value model relates nonfinancial capital mva iircpbr model residual income model rim implicates relation mva equity spread mutually complementary creation mva also many publicized academic research paper prove positive correlation pbr roe non financial capital substantiates model 1 csr corporate social responsibility 2 research paper example nonfinancial capital linked corporate value yoshikazu tomizuka corporate accounting july 2017 issue chuo keizaisha study relationship humanintellectual capital corporate valuepbr yanagi yoshino monthly capital market october 2017 issue capital market research institute etc enhancing nonfinancial capital lead corporate value creation improvement roc return capital eisai input six capital include nonfinancial capital aim create two output namely provision solution development new drug mainly neurology area oncology area undertaking business based corporate philosophy hhc strengthened initiative toward esg nonfinancial value additionally strive create outcome fulfilling patient need prevention cure care well make contribution local community providing security safety believe outcome lead elimination gap hinder enjoyment highquality medical treatment care also contribute attainment sustainable development goal sdgs advocated united nation enhancing nonfinancial capital depends corporate philosophy hhc lead highlevel output realization outcome ultimately result improvement financial nonfinancial roc furthermore cfo believe activity lead improvement roe financial capital deferred effect longterm eventually converge improvement pbr proxy indicator shareholder value lead creation sustainable corporate value bsc balanced score card roc return capital financial perspective roe return roe equity customer perspective corporate principle pbr transition deferred corporate value effect longterm internal process perspective creation productivity manufactured capital intellectual capital rd sdgs esg social contribution output outcome learning growth perspective roc iircs 6 capital esg financial capital human capital natural capital input promoting engagement emphasizes premium total approximately 700 dialogue per year cfo believe promoting understanding nonfinancial information essential realizing objective engagement corporate value assessed perspective mediumtolongterm corporate value creation nonfinancial information cover area intellectual capital centering pipeline patent human capital handle operation initiative improving access medicine corporate governance attain objective eisais ir team hold total approximately 700 dialogue investor analyst annual basis among cfo hold approximately 200 interview including overseas investor every year cfo ir team strive reduce cost equity committed promoting engagement based idea ir cost center contributes corporate value creation regarding point report issued smbc nikko security inc senior analyst yasuhiro nakazawa june 19 2014 eisais per noted 10 industry average report referred ir premium attributed investor high regard eisais clear capital policy adept ir activity promoting engagement hold discussion sophisticated financial theory capital policy cost equity optimal capital structure likewise engagement addition pipeline nonfinancial capital actively emphasize discussion point value correlation esg capital productivity cfo pursue synchronization model nonfinancial capital corporate value supported experimental research aim sustainable longterm shareholder value creation repeatedly promoting engagement based corporate philosophy hhc 31 eisai integrated report 2017 intellectual capital message corporate officer charge neurology area develop next generation dementia treatment sense mission ivan cheung left senior vice president president neurology business group teiji kimura right vice president chief discovery officer neurology business group strength weakness 1 industryleading rd pipeline dementia area igh development investment dementia area 1 h 2 abundant experience knowledge drug creation developing new drug particularly difficult disease awareness activity dementia area elays expanding patient contribution fycompa 2 3 g lobal collaboration enable higher success rate belviq acceleration development improved efficiency development commercialization cost opportunity threat xpansion market dementia treatment population age 1 e ompetitive product entering market 1 c xpansion potential market dementia diagnosis technology 2 e 2 increasing pressure lower price government promote improves policy reduce expenditure drug q eisais strength neurology kimura starting 1983 began researching dementia area tsukuba research laboratory accumulated 30 year knowledge knowhow drug creation cheung greatest strength possess activity dementia area one greatest industryleading pipeline dementia area collaboration strength one reason general low success rate biogen inc four project development drug development neurology highorder function based beta amyloid aβ tau hypothesis unique human like cognition evaluated using currently leading theory dementia treatment development behavior modification animal model indicator eisai including six project target progress focusing vivo substance called biomarkers aggressive factor accumulation also five project using change biomarkers indicator make target early symptom sleep behavioral accurate prediction clinical trial human based disorder precede diagnosis dementia 1020 result obtained animal study purpose eisais year thus total 11 project development accumulated clinical sample blood sample dementia area accompanying clinical data used enhance also currently codeveloping next generation process addition actively using ipsderived neural cell alzheimers disease ad treatment bace inhibitor made clinical sample eisais strength combination elenbecestat12 e2609 antiaβ protofibrils antibody accumulated knowledge accumulated data latest ban240113 hold option antiaβ antibody technology use strength accelerate aducanumab antitau antibody biib076 development next generation dementia treatment currently developed biogen inc also jointly developing lemborexant treatment insomnia disorder cheung another major strength knowledge gained irregular sleepwake rhythm disorder associated disease awareness campaign community alzheimers disease dementia purdue pharma lp building activity dementia area since launch believe global collaboration also one aricept 1997 estimated global level eisai strength conducted 10000 disease awareness event japan furthermore developing treatment dementia entered partnership agreement dementia 102 believe important target aggressive factor townscities promote community networking activity also focus brain maintenance system simply developing providing drug also working purpose accelerating discovery project novel drug improve quality life qol patient family target brain maintenance system creating community coexist dementia 1 c odevelopment biogen inc 2 g eneric name e2609 generic name yet fixed 3 l icensedin bioarctic ab 32 company introduction management strategy value creation activity business base esg appendix q drug development dementia area q problem current diagnostic considered difficult method development status new diagnostic method kimura u fda approved treatment dementia since 2003 surmise drug kimura present dementia diagnosed using pet development area incredibly challenging imaging cerebrospinal fluid analysis however one reason highorder function like cognition issue method cerebrospinal fluid analysis unique human difficult create highly invasive enough facility equipped applicable experimental scenario using animal model perform pet imaging next generation dementia example even aβ tau accumulates mouse brain treatment target early ad patient strong need guaranteed mouse develop dementia less invasive diagnostic method blood test need confirm correlation including biomarkers thought aβ blood includes small amount reaction animal model change occur specific soluble aβ aggregate come brain inside dementia patient brain core symptom present conducting structure observation using accumulate data another reason difficulty despite sysmex corporation superresolution fluorescence advance made diagnostic imaging technology like pet microscope attempt identify uniquely structured soluble positron emission tomography still way directly aβ aggregate blood way aiming observe change inside human brain develop diagnostic method place burden patient currently eisais accumulated clinical trial sample used examine possibility utilizing measurement aβ aggregate diagnosis dementia q many dementia treatment q expansion plan neurology candidate failed clinical trial eisai differently cheung along rapid aging population company global market dementia treatment also expanding business opportunity eisai also large threat kimura said four element right drug mankind need develop next generation dementia discovery target right patient right dosage right clinical treatment sense mission order make eisai evaluation indicator important clinical trial top runner development next generation dementia meet primary endpoint treatment aggressively investing industry leading strong human evidence aβ target including pipeline pathological finding postmortem ad brain familial ad gene order contribute early stage ad patient early mutation discovery gene mutation prevent noninvasive diagnostic technology indispensable onset ad finland surmise failed trial currently codeveloping blood test sysmex issue one three factor multiple corporation succeed creating simple diagnostic factor example clinical trial patient whose ad method think greatly increase opportunity advanced stage beyond mechanism action additionally focusing expanding effective patient whose aβ disposition unknown contribution patient fycompa belviq fy may gotten dosage wrong endpoint 2017 approval fycompa monotherapy use partial selected sensitive enough patient population epilepsy u administration restriction lift japan clinical study considered possible opportunity lead huge increase sale belviq failing following factor think contribute acquired development marketing right based success clinical development incorporated agreement arena pharmaceutical inc december 2016 elenbecestat ban2401 study give u greater freedom development application strategy aim accelerate contribution patient 1 identifying positive aβ disposition early stage ad patient enrolling trial 2 setting appropriate dos antibody small molecule compound 3 selecting suitable endpoint evaluating effect early stage ad patient 33 eisai integrated report 2017 intellectual capital 6 ricchi ongoing project neurology area diverse range ongoing project area dementia ricchi 1 early minimallyinvasive diagnostics pet positron emission tomography imaging measurement using cerebrospinal fluid utilized detect accumulation beta amyloid aβ early diagnosis dementia major challenge number facility pet imaging available limited cerebrospinal fluid must drawn inserting needle spinal cord cavity hip place large burden patient eisai therefore undertaking various project developing method early detection dementia using blood biomarkers reduce burden patient main ongoing project collaboration sysmex corporation blood diagnosis utilizing sysmex corporation superresolution fluorescence microscope attempting identify brain derived soluble aβ aggregate blood currently eisais accumulated clinical trial sample used examine possibility utilizing measurement uniquely structured aβ aggregate diagnosing dementia way aiming develop early diagnostic method dementia place burden patient sysmex corporation superresolution fluorescence microscope aβ aggregate aβ aggregate seen seen super regular fluorescence resolution fluorescence microscope microscope ricchi 2 novel neurotransmission pathway eisai possesses molecular targetingrelated drug creation main ongoing project base technology comprehensive analysis method area neurology cultivated indication expansion ampa antagonist development aricept fycompa lemborexant fycompa additionally eisai capability designing pediatric monotherapy lennoxgastaut syndrome creating compound efficiently based knowledge detail please refer page 12 42 interaction compound living organism dual orexin receptor antagonist lemborexant eisai leveraging knowhow technology pde9 inhibitor e2027 various ongoing project next generation ampa receptor antagonist e2082 ricchi 3 proteinopathy accumulation abnormal protein inside main ongoing project brain pathological finding common many neurodegenerative disease eisai possesses abundant bace inhibitor elenbecestat knowledge cultivated 30 year approach anti aβbeta amyloid protofibrils antibody dementia aricept elenbecestat ban2401 ban2401 representative example follows detail please refer page 37 research correlation nonclinical research measuring brainwave behavior genetically modified animal model pathophysiology pet imaging molecular toxicology measurement cerebrospinal fluid accurate prediction clinical trial patient stratification translational research human based result obtained animal study utilizing pharmacodynamic biomarkers development highly sensitive clinical scale clinical trial eisai leveraging knowledge development next generation dementia treatment 34 company introduction management strategy value creation activity business base esg appendix ricchi 4 neuroinflammation immunogenetics glial cell brain spinal cord play important role maintaining neuron interference reactive glial cell homeostasis regulating immune function replenishing nutrient central nervous system activated pathological condition move disease site attempt devour damaged cell extracellular protein aβ however maintain activated state long period time become reactive glial cell release excessive inflammatory factor thought interfere neuron process thought one cause neurodegenerative disease alzheimers disease fact genomewide association study gwas alzheimers disease revealed genetic risk reported mechanism associated neuroinflammation eisai focusing project related reactive glial cell creation treatment dementia area main ongoing project antifractalkine antibody e6011 antifractalkine antibody e6011 currently developed rheumatoid arthritis inflammatory bowel disease expanding indication include alzheimers disease consideration e6011 bind fractalkine chemokine induced vascular endothelial cell inflammation suppressing either inflammation immune cell activity prevents reactive glial cell interfering neuron ricchi 5 synapse microenvironment tip neuron called synapse swelled nodular synapse microenvironment shape synapsis appress adjacent neuron slight gap neuron called synaptic gap synaptic gap electric signal changed chemical substance neurotransmitter transmits information next neuron electric signal transmitted synapse neurotransmitter synapse vesicle secreted synaptic gap bind receptor cell membrane next neuron electric signal impulse occurs information transmitted next neuron dementia patient accumulation abnormal protein aβ overreaction neuroinflammation interfere synapsis lead loss synapsis death neuron eisai working project revitalize neuron improving synapse microenvironment restoring synapse function way reactivation residual function aiming cure alzheimers disease prevent neuron death main ongoing project epha4 synapse modulator one approach investigating development alzheimers disease treatment work inducing stabilization synapsis enhancing cleavage epha4 protein regulates maintenance formation synapse thought severed epha4s cterminal fragment play important role maintenance synapsis fact report reduced epha4 cleavage observed alzheimers disease patient ricchi 6 neuronal regeneration brain composed neuron glial cell blood vessel glial cell account largest part brain cell human astrocyte account largest number cell cerebral cortex manner neuron astrocyte receive neurotransmitter synapsis point contact neuron release various neurotransmitter process believed regulate efficiency information transmission influence memory learning company academic attempting treat neurodegenerative disease neuron transplant eisai set sight astrocyte focusing maintenance brain durability field eisai working project develop next generation treatment method 35 eisai integrated report 2017 intellectual capital development new potential dementia treatment industryleading abundant pipeline development everincreasing number dementia patient 2015 estimated 4678 million trend number dementia patient world million person dementia patient worldwide aging number dementia patient high income country global population gather pace number number dementia patient low middle income country dementia patient expected continue trending upward increase approximately expansion 28 time 13145 16 time 7469 million patient 2030 approximately 28 time 13145 million 4218 2050 particular note rate increase expansion 16 time dementia patient lowand middleincome country projected significantly exceed 7469 rise high income country therefore 2795 promoting initiative address dementia 4678 8928 global issue hope therapeutic 1950 agent satisfy unmet medical need 4674 developed quickly 2728 0 2015 2030 2050 year source world alzheimer report 2015 global impact dementia dementia dementia condition characterized occurrence variety disorder emergence impediment everyday life due death brain cell worsening cognitive function resulting various cause different type dementia symptom alzheimers prevalent dementia mainly related memory impairment core symptom behavioral psychological symptom bpsd delusion hallucination violence wandering depression also observed type disease include dementia lewy body vascular dementia among others characteristically progressive medicine creation targeting accumulation aggressive factor marketed treatment alzheimers disease ad including eisais aricept designed delay progression disease unmet medical need dementia treatment still remain high eisai currently collaborates biogen inc pharmaceutical company focused neurodegenerative disease developing next generation agent targeting beta amyloid aβ tau socalled causal substance ad ad associated occurrence neuronal cell death result gradual accumulation protein brain called aβ long onset symptom memory impairment accumulation aβ considered accelerate tau pathology might cause neuronal cell death resulting accumulation tau accumulation aggressive factor aβ tau considered potential target ad treatment pathogenic mechanism alzheimers disease accumulation beta amyloid aβ inside brain accumulation tau inside brain change brain structure impairment memory impairment clinical function accumulation aβ begin 15 20 year prior appearance alzheimers disease symptom various change occur within brain point abnormality clinical cognitive function observed dementia mild cognitive impairment mildmoderatesevere 36 company introduction management strategy value creation activity business base esg appendix five next generation alzheimers disease treatment project including collaboration biogen inc antitau antibody biib0762 elenbecestat1e2609 antitau antibody bace inhibitor amyloid precursor biogen inc protein app betasecretase bace cut app nterminal side hyperphosphorylation accumulation tau neuronal cell aducanumab2 gammasecretase antiaβ antibody biogen inc cut app cterminal side beta amyloid neuronal cell function disorder monomer aβ greater tendency bond together amyloid aβ fibril plaque neurofibrillary insoluble fibrous aggregate tangle ban2401 deposit form amyloid plaque antiaβ protofibrils antibody may cause neuronal cell death neuronal cell death aβ protofibrils decline large soluble aggregate cognitive function highly neurotoxic induce neurodegenerative process cause neuronal cell death 1 generic name e2609 generic name yet fixed 2 eisai option jointly develop commercialize investigational bace inhibitor developed inhouse elenbecestat1 e2609 codevelopment biogen inc discovered tsukuba research laboratory compound inhibits betasite amyloid precursor protein cleaving enzyme bace enzyme involved production aβ elenbecestat currently phase ⅲ study aim launch shortly fiscal 2020 investigational antiaβ protofibrils antibody ban2401 codevelopment biogen inc antiaβ protofibrils antibody inlicensed bioarctic ab ban2401 unique characteristic bind reduce toxic aβ protofibrils ban2401 currently phase ⅱ study aim launch shortly fiscal 2020 investigational antiaβ antibody aducanumab development biogen inc eisai option jointly develop commercialize biogen inc currently developing antiaβ antibody conducting phase ⅲ study eisais option exercise condition aducanumab eisai right exercise option aducanumab time 1 2 1 postphase ⅱ biib037 option completion aducanumab phase ⅰb clinical trial ban2401 phase ⅱ clinical trial 2 postphase ⅲ biib037 option completion aducanumab phase ⅲ clinical trial detail condition exercising option held eisai please refer press release httpwwweisaicomnewsnews201507html ntitau antibody development eisai antitau antibody biib076 development biogen inc eisai independently conducting preclinical study antitau antibody targeting tau considered one causal substance ad biogen inc conducting phase ⅰ study antitau antibody biib076 eisai option jointly develop commercialize option right regarding joint developmentjoint sale promotion 37 eisai integrated report 2017 new paradigm drug discovery dementia three pillar 11 project development aducanumab1 elenbecestat23 ban240124 antitau antibody biib0761 e6011 early ad early ad early ad addementia addementia addementia antiaβ antibody bace inhibitor antiaβ protofibrils new mechanism new mechanism antifractalkine antibody action action antibody ideation stage reactive aβ progress aggressive factor accumulation tau intracerebral glial cell clearance enhancer reinforcing protective mechanism genetic background brain homeostasis brain maintenance protective improving agent system mechanism environmental targeting astrocyte factor neural stem cell transformation symptom time sleep behavioral cognitive activation agent disorder disorder disorder lemborexant5 e2730 e2082 e2027 epilepsy treatment behavioral epha4 iswrd6 associated epilepsy cognitive disorder due new mechanism next generation synapse modulator alzheimers disease dementia ampa receptor lewy body disease action dementia dual orexin receptor antagonist antagonist pde9 inhibitor 1 developed biogen inc eisai option jointly develop commercialize 2 codevelopment biogen inc 3 generic name e2609 generic name yet fixed 4 licensedin bioarctic ab 5 codevelopment purdue pharma lp 6 iswrd irregular sleepwake rhythm disorder development next generation ad treatment focused aggressive factor aβ tau eisai collaborates biogen inc developing bace inhibitor elenbecestat e2609 anti aβ protofibrils antibody ban2401 target aβ eisai also option right antiaβ antibody aducanumab antitau antibody biib076 developed biogen inc furthermore eisai conducting study inhouse antitau antibody aβ tau accumulate multilayered manner glial cell play part phagocytosis aβ tau excessively release inflammatory factor others causing disorder nerve cell remaining active long time reactive glial cell eisai conducting drug discovery study e6011 targeted reactive glial cell recent year occurrence transformation symptom time become increasingly known start sleep disorder 10 20 year diagnosis dementia followed behavioral disorder cognitive impairment order possible form sleep disorder beside basic one include rem sleep behavior disorder rbd irregular sleepwake rhythm disorder iswrd among others rbd iswrd considered closely related dementia depression epilepsy anxiety dysosmia form behavioral disorder considered follow sleep disorder due accumulation aβ brain mechanism protection known fact protective gene positive environmental factor function maintain homeostasis reported protective mechanism include function phagocytizing eliminating aβ foreign matter occurs within brain function healing damaged nerve cell function facilitating regeneration nerve cell differentiation neural stem cell among others brain maintenance system may new target drug discovery aimed curing dementia eisai considers future effort develop dementia treatment focus process accumulation aggressive factor aβ tau reactive glial cell transformation symptom time occurs order sleep disorder behavioral disorder cognitive impairment brain maintenance system 38 company introduction management strategy value creation activity business base esg appendix medicine creation targeting transformation symptom time known sleep facilitates excretion aβ brain sleep disorder may also accelerate accumulation aβ potentially lead ad eisai conducting clinical study lemborexant antagonist dual orexin receptor involved regulation sleep awakening two phase ⅲ study insomnia disorder phase ⅱ study irregular sleepwake rhythm disorder iswrd associated alzheimers disease dementia sleep disorder behavioral disorder may occur form depression epilepsy anxiety dysosmia relation accumulation aβ tau inhibiting disorder might delay onset dementia eisai also develops new drug epilepsy neurological disorder example e2082 next generation ampa receptor antagonist e2730 novel mechanism action furthermore eisai develops e2027 pde9 inhibitor behavioral disorder cognitive impairment due dementia lewy bodiesdementia eisai also conduct study drug discovery targeting epha4 concern synapse stabilization medicine creation targeting brain maintenance system known fact brain many protective mechanism maintain robustness brain consists nerve cell glial cell blood vessel glial cell function facilitate survival nerve cell maintain metabolically support intracerebral environment glial cell said nearly 10 50 time larger nerve cell quantity occupy largest part cell human brain astrocyte common type glial cell known receive neurotransmitter release different transmitter nerve cell astrocyte also considered structurally support brain act mechanism stimulating neural transmission nourishment microglia type glial cell known cell immunity function nerve center normal state monitor surrounding environment moving slender process activated pathological condition move disease site play role phagocytizing damaged cell extracellular protein aβ brain maintainance system supported protective mechanism considered important new target drug discovery aimed curing dementia eisais resource based maximum use experience knowledge toward development dementia treatment considered achieving primary endpoint clinical study requires satisfaction four element right drug discovery target right patient right dosage right clinical evaluation indicator targeting aβ based strong human evidence pathological finding ad postmortem brain gene mutation familial ad gene mutation prevent onset ad eisai practice unique invention leading development success leveraging three decade accumulated knowledge knowhow since company launched dementia study tsukuba research laboratory 1983 innovative approach development next generation ad treatment based aβ hypothesis hoosing appropriate patient earlyonset ad specifically mild cognitive c impairment intracerebral aβ deposition accurate screening risk failure increase clinical trial patient excessively advanced stage disease mechanism action yet diagnosed aβ deposition onsideration dose setting c minimize arm setting possible confirm efficacy utilization biomarkers small molecule compound development prudently consider dose setting phase ⅱ study antibody entail fear low intracerebral extraction rate due bloodbrain barrier hoosing endpoint sensitive clinical evaluation earlyonset ad patient c select clinical scale evaluation clinical effect high sensitivity targeted patient population cdrsb adcoms implement two pivotal study study design simultaneously aiming fulfilling regulatory requirement 39 eisai integrated report 2017 intellectual capital social relationship capital initiative dementia area offering solution go beyond providing pharmaceutical eisais initiative dementia area extend beyond merely providing pharmaceutical eisai also undertakes variety activity solving issue faced patient community building foundation society coexists dementia section introduce specific activity 20year journey aricept enhancing recognition dementia world eisai launched inhouse developed dementia treatment spread simple diagnostic method mmse aricept 1999 introduction aricept japan first suitable practical clinical stage alzheimers disease treatment provided patient 2000 eisai launched japan academy alzheimers family great hope following section dr kazuo disease together doctor set order hasegawa director emeritus tokyo dementia care promote discussion various issue regarding dementia research training center describes difference among medical specialist primary doctor transcend situation today time prior launch field medical care support proper paradigm shift aricept treatment dementia academy attended 300 people first session attended approximately 1500 doctor donepezil ray light darkness year practicing day doctor available treatment alzheimers disease even disease diagnosed early type initiative produced positive result stage doctor would express regret patient helped significantly increase awareness dementia family sense powerlessness futility throughout world dr shigeki kuzuhara professor clinical study donepezil administered providing patient family well doctor sense emeritus mie university describes change hopeful fulfillment hopefulness one major difference feeling powerlessness recall past notable greaterthanexpected effect aricept dr kazuo hasegawa 2009 japanese society major change spurred approach director emeritustokyo dementia care research training center awareness dealing dementia prior launch aricept dementia regarded symptom aging little awareness disease needing therapeutic intervention back however dementia still described japan arrival aricept transformed awareness believe senility understanding disease major turning point led effort overcome dementia involvement medical practitioner patient diagnostic method adequately spread throughout caregiver also participation citizen japan society eisai acutely aware environment limitation drug therapy aricept also clearly demonstrated surrounding dementia patient would never change time helped promote wide acceptance importance care coping peripheral symptom behavioral providing aricept acting recognition eisai proactively psychological symptom dementia bpsd promoted variety initiative break status dr shigeki kuzuhara 2013 professor department medical welfare faculty health science quo approach toward dementia suzuka university medical science first eisai repeatedly carried disease education activity professor emeritus neurology mie university school medicine civic forum website raise awareness alzheimers disease date eisai held meeting dementia disease awareness approximately 2000 mmse mini mental state examination developed u 1974 diagnosing dementia disease examination mainly measuring recall calculation occasion japan around 10000 time globally ability language ability orientation dementia diagnosis eisai actively worked promote supporting community building forming partnership agreement recognized importance activity extend numerous achievement include implementing beyond framework providing pharmaceutical product community need survey formulate asahi ward welfare 2008 eisai started fullscale activity nationwide plan participating home medical care liaison council supporting building community coexist holding study workshop area comprehensive dementia community building requires cooperation support center consulting doctor convening study medical caregiving specialist government administration workshop specialist achievement earned high local government community resident realize acclaim expanded partnership agreement patientfriendly community convening study group region across japan end july 2017 partnership supporting interprofessional collaboration eisai built agreement dementia relationship trust healthcare provider caregiver formed 102 town local government supported community building city japan 2010 eisai entered community development partnership asahi ward yokohama city first agreement support dementia patient community signing ceremony dementia cooperation level japan agreement compiled agreement mie prefecture 40 company introduction management strategy value creation activity business base esg appendix developing human health care hhc solution business aiming build foundation society coexists dementia undertake activity transcend framework interprofessional collaboration cloud service hikari one team sp providing pharmaceutical april 2016 eisai also july 2016 began providing interprofessional collaboration support cloud service enable timely sharing patient information sale promoting business provide solution satisfactorily ntt technocross corporation respond issue faced local government reporter administration adverse event physical activity vital sign purpose establishing social system enables doctor coexist dementia nurse numerous unmet patient family need clinical question frontlines medical care aim pharmacist hhc solution business deeply consider need care worker together people variety profession beginning care manager image healthcare provider continuously provide solution family information shared need eisais partnership agreement dementia 102 townscities across japan fulfill crucial role hhc medication administration support device eokusurisan solution business dementia cooperation agreement january 2017 launched medication administration support device inform patient time take medicine voice partner exchange opinion resident respective others also equipped function support looking community discover various type specific clinical patient via cloud service question additionally eisai established living laboratory variety stakeholder community resident company government university medical institution participate repeatedly considering developing evaluating solution living laboratory eisai aim swift development solution bring high outcome therapeutic effect economic efficiency eisai also successively launching tool used providing solution hikari one team sp eokusurisan goal hhc solution business eisai undertaking various initiative dementia hhc solution quarter century course headquarters striving initiative patient family well medical fulfill mission aiming care nursing care provider told personally establish social system thanks creating aricept hope also create enables coexist dementia new treatment close cause dementia solving problem aspired company image fiscal 2025 eisai providing solution real strive become medico societal innovator world dementia area become increasingly important contribute clinical question found based communitybased health care delivers safety true need patient peace mind patient family providing family yoshiro den new solution addition satisfying patient need senior executive director hhc solution headquarters prevention cure care developing next generation alzheimers disease treatment raising patient satisfaction level approximately every five year since fiscal 1994 japan trend treatment satisfaction level medicine health science foundation implemented questionnaire contribution level alzheimers disease survey mainly targeting physician asks treatment 60 satisfaction level medicine contribution level medicine contribution level 60 socially important disease according survey treatment satisfaction level medicine contribution level 40 fy2014 fy2010 alzheimers disease steadily rising even though fy2005 still lower compared disease eisai belief fy2000 increase manifestation positive result 20 fy1994 eisais activity centering disease awareness activity support community building addition provision 0 aricept eisai make utmost effort raise patient 0 20 40 60 satisfaction level treatment satisfaction level apan health science foundation fiscal 2015 domestic basic source j technology survey report survey medical care need 60 disease new medical care need ii 41 eisai integrated report 2017 global brand neurology area intellectual capital antiepileptic agent fycompa firstinclass antiepileptic drug aed developed inhouse fycompa generic name perampanel highly selective noncompetitive ampa receptor antagonist inhibits action glutamate receptor subtype known ampa thereby helping control neuronal hyperexcitation approved worldwide adjunctive initial treatment typically replaced different treatment monotherapy combination therapy however approximately 30 patient unable control seizure fycompa launched europe september 2012 existing treatment option unmet need aeds novel u january 2014 adjunctive treatment partial mechanism action still remain patient refractory onset seizure without secondarily generalized seizure epilepsy epilepsy patient aged 12 year older additionally fycompa contributed patient epilepsy june 2015 eisai received approval u europe novel mechanism action compared existing aeds indication expansion regarding use fycompa adjunctive treatment primary generalized tonicclonic seizure newly approved monotherapy use japan fycompa also launched adjunctive partialonset seizure u treatment partialonset seizure including secondarily generalized seizure primary generalized tonicclonic july 2017 eisai received approval monotherapy use seizure patient epilepsy showing inadequate response treatment partialonset seizure without aeds fycompa currently approved 55 secondarily generalized seizure u estimated country territory adjunctive treatment partial approximately 70 patient partialonset seizure onset seizure also approved 45 undergoing monotherapy treatment eisais internal estimate country adjunctive therapy primary generalized eisai aim contribute patient epilepsy tonicclonic seizure benefit fycompa approved diagnosed epilepsy patient undergo adjunctive therapy monotherapy use monotherapy treatment aed case treatment efficacy seizure control inadequate contribution patient epilepsy fycompa russia since fycompa introduced russian market innovative approach used 2014 number different project carried training specialist medical community population aiming deliver information establishing fycompa new standard medical care benefit treating epilepsy patient suffering epilepsy raising awareness fycompa neurologist eisai partner treatment epilepsy throughout whole country eisai initiated creation scientific practical thanks complex community epileptologists russia auspex measure aimed increasing leading specialist field community gather knowledge new regular basis discus latest achievement drug fycompa patient treatment epilepsy share accumulated experience suffering epilepsy olga drepa review various aspect use innovative russia chance fycompa brand director drug fycompa moreover eisai implementing control disease limited liability company eisai russia digital project allrussian social medical network improve quality life doctor russian federation providing distance education healthcare professional result 42 global brand neurology area intellectual capital antiobesity agent belviq discovered arena pharmaceutical inc belviq lorcaserin hci antiobesity agent sold eisai belviq thought encourage feeling fullness selectively activating serotonin 2c receptor brain launched u june 2013 acquired global development marketing right belviq january 2017 belviq launched u june 2013 adjunct reducedcalorie diet increased physical activity eisai reached agreement arena pharmaceutical chronic weight management adult patient initial inc january 2017 revise marketing supply body mass index bmi 30 kgm2 greater obese 27 agreement concluded arena belviq new kgm2 greater overweight presence least one agreement eisai becomes solely responsible decision weightrelated comorbid condition additionally belviq xr making implementation related global development oncedaily formulation belviq launched submission regulatory approval well global u october 2016 eisai received approval mexico marketing belviq previously negotiated financial july 2016 lorcaserin marketed mexico term purchase price based net sale brand name venespri eisai also received approval brazil regulatory sale milestone arena also december 2016 reduced modified addition technology transfer take place allow eisai participate manufacture belviq eisai also assume arena exclusive distribution obesity major global health problem agreement thirdparties develop market belviq two third adult u south korea taiwan israel eisai serve overweight obese third party exclusive supplier receive income form payment supply product distributor recent year obesity emerged one seeking development belviq expand world major health problem 14 billion availability patient eisai anticipates new adult worldwide believed overweight agreement give greater freedom development approximately 500 million number obese region submission strategy support goal making contribution approximately 170 million people u around address unmet medical need increase benefit 150 million europe believed either overweight patient family worldwide obese approximately 100 million people china approximately 25 million people japan fall category eisais internal estimate cardiovascular outcome trial ongoing according u center disease control prevention two third adult u either cardiovascular outcome trial cvot enrollment overweight obese percentage obese people approximately 12000 patient currently underway several doubling approx 15 36 1980 country including u trial focus incidence 2010 obese overweight may accompanied major adverse cardiovascular event mace myocardial comorbid condition diabetes hyperlipidemia infarction stroke cardiovascular death conversion hypertension therefore currently becoming major type2 diabetes incidence mace mace social issue hospitalization due unstable angina heart failure coronary revascularization result eisai pursue potential belviq strive maximize value 43 eisai integrated report 2017 intellectual capital message corporate officer charge oncology area taking maximum advantage superior inhouse product creation ability terushige iike left senior vice president president oncology business group takashi owa right vice president chief medicine creation officer oncology business group chief discovery officer oncology business group strength weakness 1 ability create product supported superior organic lan submission halaven lenvima 1 p synthetic chemistry drug discovery science successor still midway 2 aximization product value based ricchi elays contributing patient due rapidly increasing 2 strategy emphasizes competitive superiority competitive landscape differentiation 3 p rogress pipeline h3 biomedicine inc adc taskforce etc opportunity threat xpansion oncology market based creation high 1 e aunch competitor innovative product 1 l valueadded drug 2 increasing pressure lower drug price government xpansion oncology market along economic growth 2 e promote policy reduce healthcare cost developing emerging country q eisais strength area retracing halavens discoveryinvention oncology marine sponge iike greatest strength ability create halichondria okadai product supported superior organic synthetic chemistry drug discovery science pharmaceutical rd finding innovative candidate compound basic research stage course important halichondrin b equally important technology efficiently synthesize h h h h compound link commercial production h h ho sense think halaven truly innovative h h h h h ho h created via successful industrial synthesis natural ho product derivative complex chemical structure groundbreaking achievement time pharmaceutical optimization superior drug discovery science lenvima novelhalichondrin binding mode b target kinase halaven meo fgfr ret inhibitory effect result approved generic name eribulin oh distinctive tyrosine kinase inhibitor h2n h h h owa order develop halaven eisais first inhouse molecular weight 826 anticancer agent several challenge needed chiral carbon 19 total synthetic step 64 surmounted origin halaven go back discovery natural product antitumor property called halichondrin b extracted marine sponge called halichondria okadai however halichondrin extremely powerful antitumor activity discovery b could obtained sponge small amount lead creation halaven eisai research order provide stable supply drug made institute andover total synthesis process halaven class compound determined important established consisting 60 step led milestone would achieving total synthesis natural halavens regulatory approval medicine creation product finding structurally simple analog process unprecedented series challenge u two point professor yoshito kishis research group precisely say creation harvard university played decisive role joint halaven result passion brilliance eisai research kishis laboratory eisai determined researcher right half halichondrin analog exhibited 44 company introduction management strategy value creation activity business base esg appendix summary result phase ⅲ study lenvima treatment hepatocellular carcinoma lenvima arm sorafenib arm hazard ratio o median 95ci 136121149 month 123104139 month 092079106 pfs median 95ci 746988 month 373646 month 066057077 ttp median 95ci 897492 month 373654 month 063053073 orr median 95ci 115 people 24 44 people 9 p000001 cheung et al 53rd annual meeting american society clinical oncology asco june 2017 abstract no4001 lenvima created high level fusion q development status next innovative highly unique vitro vivo model generation product follow system established tsukuba research laboratory halaven lenvima biology team extremely intricate drug design chemistry team project team didnt focus iike apart expanding indication halaven creation vegf vascular endothelial growth lenvima would like increase number late clinical factor pathway inhibitor rather design concept stage project several promising next generation look entire tumor angiogenesis process project feel potential equal inhibiting produce life extending effect vivo halaven lenvima currently phaseⅰstudies result lenvima unique mechanism action preparation enter phaseⅰ continue selectively inhibits kinase involved maintaining develop tumor microenvironment kinase involved proliferation cancer cell wellbalanced way owa h3 biomedicine inc working creating new cancer treatment leading precision medicine iike another one strength maximization pipeline extremely promising narrowing product value based ricchi strategy target cancer genomics aberrant splicing emphasizes competitive superiority differentiation clinical study proceed shorter period fewer indication expansion second inhouse developed patient two project phaseⅰstage h3b anticancer agent lenvima proceeding smoothly 8800 h3b6527 another preparation stage 2015 began marketing lenvima treatment h3b6545 expected enter phaseⅰwithin fiscal thyroid cancer japan u europe 2016 2017 taking advantage boston location secure approved secondline treatment advanced renal diverse talent promoting revolutionary drug discovery cell carcinoma u europe january 2017 project rooted human cancer genome information h3 phase ⅲ study lenvima sorafenib first biomedicine able move several project line treatment patient unresectable hepatocellular clinical phase extremely short period time since carcinoma met primary endpoint inception 2010 noteworthy achievement present sorafenib firstline treatment unresectable hepatocellular carcinoma pipeline h3b biomedicine inc treatment demonstrated noninferiority h3b8800 currently conducting phaseⅰstudy sorafenib past 10 year however splicing modulator includes chemical structure hematological malignancy aiming launch fiscal 2020 long period darkness lenvima light derived natural product end tunnel according result phase ⅲ h3b6527 currently conducting phaseⅰstudy hepatocellular carcinoma study lenvima met statistical criterion noninferiority fgfr4 inhibitor aiming launch fiscal 2020 overall survival compared sorafenib showed plan initiate phaseⅰstudy h3b6545 statistically significant clinically meaningful improvement firstinclass estrogen receptor breast cancer fiscal 2017 aiming launch shortly fiscal progression free survival time progression antagonist 2020 objective response rate submitted application treatment hepatocellular carcinoma japan june 2017 u europe july 2017 also furthermore development eisais first antibody planning submit application china second half drug conjugate adc important pipeline fiscal 2017 strategy adcs next generation antibody drug antibody drug low molecular drug payload chemically conjugated via suitable linker antibody drug advantage high target selectivity side effect problem act target molecule outside cell cell membrane hand improving selectivity low molecular drug constant issue due membrane permeability advantage able target substance protein inside cell adcs receiving much attention hybrid treatment antibody drug low molecular drug combined way cover others weakness enhance others strength 45 eisai integrated report 2017 eisai currently developing adc namely progression free survival comparator morab202 combine antibody drug think sufficient evidence farletuzumab developed antibody technology competitive lenvima granted subsidiary morphotek inc eribulin breakthrough therapy priority review designation halaven masterpiece modern organic synthetic fda approved indication based chemistry novel mechanism action result phase ⅱ study doctor impact tumor microenvironment halaven prescription experience recognition combination chemotherapeutic agent demonstrated extension therapy low currently strengthening measure overall survival o monotherapy largescale clinical counter problem first would like improve study treatment refractory breast cancer soft prescription ratio among patient tissue sarcoma usage payload thought treatment produced sufficient result end extremely useful morab202s nonclinical data suggests important raise share voice also excellent efficacy safety profile dosage collaborate medical access organization one fifth halaven great expectation create real world evidence additionally expect development whats adc project increased recognition lenvima ongoing phase limited onceoff morab202 morphotek inc owns ⅲ study first line treatment renal cell carcinoma proprietary technology two different antibody site hand hepatocellular carcinoma specific conjugation addition diverse antibody drug submitted first line monotherapy treatment candidate believe future hold various based headtohead comparison existing possibility including possibility contract research product sorafenib however sufficient evidence outsourcing business obtained phaseⅲ study potentially first choice expecting swift expansion eisais first antibodydrug conjugate adc morab202 receive regulatory approval adc combination farletuzumab inhouse discovered antibody currently clinical development eribulin masterpiece modern synthetic organic chemistry q opportunity threat oncology area iike thought creation groundbreaking high valueadded drug antibody drug leading precision medicine expand oncology market addition expect market expand along economic growth developing emerging country owa launch innovative product competitor large threat one necessarily take growth opportunity u current anticancer treatment strategy often make use combination therapy obtain higher clinical effect demonstrate scientific rationality using agent combination antibody farletuzumab internalized new product dramatically increase farletuzumab cell growth potential halaven lenvima actively developing combination therapy antipd1 antibody linker cleaved enzyme cell molecular targeted drug detail please refer page 48 key case demonstrate rational combination mechanism clinical non unique mechanism action natural derived product targeting clinical study payload cancer micro environment eribulin iike social welfare cost rising globally many form aggregate due high water solubility government around world implementing policy agent bind antibody linker reduce healthcare cost result increasing pressure lower drug price threat business high priced anticancer agent appearing one q marketing challenge another market setting reasonable price expansion lenvima important issue u feel drug price determined based fundamental value iike regard second line treatment provide patient striving create drug advanced renal cell carcinoma largest market bring true value patient time believe u due intensifying competition following value innovation also appropriately emergence antipd1 antibody able reflected price make planned contribution patient yet however combination therapy lenvima everolimus second line treatment unresectable metastatic renal cell carcinoma demonstrate significant extension 46 intellectual capital 2 ricchi ongoing project oncology area establishment new technology platform continuous creation innovative program ricchi 1 cancer microenvironment periphery cancer cell surrounded tissue called stroma stroma connective tissue including immune cell inflammatory cell tumor vessel lymphatic vessel collagen form distinctive structure called cancer microenvironment halaven reported unique mechanism action cancer microenvironment including effect inhibits cell division promoting epithelial state breast cancer cell meanwhile lenvima known demonstrate antitumor effect inhibit angiogenesis cancer microenvironment mesenchymal cell stromal cell cell differentiation cancer stemness eisai possesses technological capability cultivated main ongoing project development halaven synthesizing highly complex compound well diverse natural productbased morab202 antibody drug conjugate adc based combination farletuzumab compound library also developed research tool halaven include bioimaging technology performing image analysis protein distribution tissue organism halichondrin origin well super immunedeficient mouse model implanted human tissue sample furthermore approach cancer stem cell thought cause cancer relapse metastasis establishing animal model cellbased evaluation system investigate cell differentiation epigenetic control tumor metabolism addition subsidiary morphotek inc possesses antibody technology unique site specific conjugation technology vascular endothelial cell abnormal tumor vessel eisai possesses original diverse small molecule library main ongoing project targeting kinase cultivated development lenvima tsukuba research laboratory lenvima antipd1 therapy pembrolizumab combination regimen also retained biomarkers clinical sample order identify new molecular target involved abnormal tumor lenvima everolimus combination regimen vessel cancer microenvironment drug resistant detail please refer page 48 mechanism myeloid cell immunosuppressive myeloid lineage believed prostaglandin acting receptor main ongoing project induces promotion immunosuppression immune inflammation tolllike receptor patternrecognition ep4 antagonist e7046 ep4 receptor prostaglandin e2 receptor 4 family receptor recognizes aberration living system virus bacteria malignant tumor transmits signal lymphocyte believed control immunoregulatory mechanism maintains immunological system eisai possesses unique compound library related prostaglandin tolllike receptor combination cellular noncellular based assay evaluation system evaluate myeloid cellmediated cancer immunity ricchi 2 cancer cell driver gene mutation aberrant splicing cancer cell established 2010 h3 biomedicine inc built cutting main ongoing project edge cancer genome platform identify evaluate gene play important role occurrence fgfr4 inhibitor h3b6527 progression cancer cancer driver gene gene splicing modulator h3b8800 already developed drug resistance anticancer agent estrogen receptor antagonist h3b6545 target gene cause aberrant splicing additionally splicing platform possess library compound regulate splicing well unique screening system identify compound target abnormal protein splicing variant caused incorrect order different pattern splicing aim obtain approval within short timeframe fast unique decision making scheme ascertain chemical compound potential target molecule based human biology detail aberrant splicing please refer page 94 47 eisai integrated report 2017 global brand oncology area intellectual capital anticancer agentmolecular targeted agent lenvima inhouse developed multiple receptor tyrosine kinase rtk inhibitor novel binding mode selectively inhibits kinase activity lenvima generic name lenvatinib inhouse developed selective tyrosine kinase inhibitor novel binding mode show anticancer effect specifically inhibiting action three molecule vegfr fgfr ret anticancer molecular targeted agent contribution patient thyroid cancer renal cell carcinoma around world liver cancer second leading cause cancer related death mortality related cancer february 2015 lenvima launched successively use treatment thyroid cancer u lung cancer 194 liver cancer approved thyroid cancer 50 country stomach cancer 390 eisai received approval additional indication 91 colorectal cancer combination everolimus treatment patient breast cancer advanced renal cell carcinoma following one prior anti 88 esophageal cancer angiogenic therapy u may europe pancreas cancer 85 september 2016 product name europe kisplyx cancer 40 64 49 globally submitted treatment hepatocellular carcinoma aim expand contribution patient eisai submitted application treatment development combination therapy hepatocellular carcinoma japan june u europe july 2017 liver cancer second leading cause eisai currently undertaking phase ⅲ study two cancer related death estimated responsible combination therapy antipd1 therapy approximately 750000 death per year globally pembrolizumab everolimus firstline treatment renal approximately 780000 case newly diagnosed year cell carcinoma also phaseⅰⅱ study combination large regional difference 80 new case therapy antipd1 therapy pembrolizumab solid occurring asian region including china japan tumor renal cell carcinoma endometrial cancer melanoma hepatocellular carcinoma account 85 90 liver head neck cancer bladder cancer nonsmall cell lung cancer hepatocellular carcinoma associated chronic liver cancer ongoing disease particular cirrhosis major cause cirrhosis include eisai aim maximize value lenvima expand hepatitis b virus hepatitis c virus however according contribution patient recent investigation nonbnonc hepatocellular carcinoma rise surgery first option treatment however patient unresectable hepatocellular carcinoma amenable potentially curative therapeutic intervention often difficult treat additionally solafenib currently approved medicine sorafenib frontline treatment patient underscoring great unmet medical need globocan2012 estimated cancer incidence mortality prevalence worldwide 2012 httpglobocaniarcfr development status lenvima combination therapy anti pd1 therapy pembrolizumab thyroid cancer target cancer type renal cell first line treatment carcinoma endometrial cancer renal cell carcinoma second line treatment melanoma head neck cancer biliary tract hepatocellular bladder cancer nonsmall cell combination therapy renal cell carcinoma lung cancer cancer japan pembrolizumab everolimus carcinoma combination therapy everolimus phaseⅰⅱ study phase ⅱ study phase ⅲ study submission approval 48 global brand oncology area intellectual capital anticancer agent microtubule dynamic inhibitor halaven inhouse developed anticancer agent derived natural product halaven generic name eribulin halichondrin class microtubule dynamic inhibitor novel mechanism action halaven synthetic analog halichondrin b derived marine sponge halichondria okadai show antitumor effect arresting cell cycle inhibition growth microtubule reported recent nonclinical study show novel mechanism action include improving vascular perfusion tumor inducing cell epithelization breast cancer cell reducing metastatic potential breast cancer cell worldwide contribution patient breast cancer one common type cancer breast cancer soft tissue sarcoma among woman worldwide estimated approximately one million woman newly diagnosed breast cancer halaven launched indication metastatic breast year approximately 40 go develop cancer1 u november 2010 subsequently locally advanced metastatic disease incidence rate approved use treatment breast cancer start rise woman thirty peak 60 country including japan u europe incidence among woman late forty early fifty asia additionally halaven approved soft tissue breast cancer pose compelling problem sarcoma2 u january 2016 subsequently soft tissue sarcoma collective term diverse group approved 40 country malignant tumor occur throughout soft tissue including fat muscle nerve fibrous tissue blood 1 indication vary country territory unresectable recurrent breast vessel treatment soft tissue sarcoma focused cancer japan thirdline therapy locally advanced metastatic breast cancer u secondline therapy locally advanced curative surgery stage disease advanced metastatic breast cancer eu 2 approved indication u eu advanced liposarcoma approved treatment becomes combination chemotherapy indication japan soft tissue sarcoma radiation therapy outcome relatively poor patient advanced soft tissue sarcoma remains disease significant unmet medical need approved indication halaven halaven chemotherapy confirmed prolong overall survival o monotherapy multiple large scale clinical study metastatic breast cancer breast cancer soft tissue sarcoma advanced soft tissue sarcoma eisai aim expand approved approved contribution patient breast cancer soft tissue 60 country 40 country sarcoma delivering importance prolonged overall survival o confirmed clinical study providing solution along product information toward realization community networking aiming society coexist cancer since halaven launched july 2011 japan nurse pharmacist clinical communicating physician medical staff phycologists social worker proper use product others toward improvement believe goal eisais medical representative patient care willing provide providing drug information physician integrated support covering pharmacist also providing solution taking initiative treatment care community networking patient improving delivering product information quality life qol patient family together providing solution issue physician medical staff involved surrounding patient cancer various project far created booklet enhance member eisai oncology takuya kagawa breast cancer screening achieve early detection sale team oncology tokyo medical improve screening rate issue many district department regional cooperation community needed resolve also arranged shutoken tokyo meeting interprofessional collaboration physician metropolitan headquarters eisai japan 49 eisai integrated report 2017 intellectual capital global drug creation activity drug creation rd framework within endtoend business group structure identified neurology oncology area eisais drug creation system focus eisai aim find ricchi front runner drug creation system 4 division tackling disease treatment yet fully established actively concentrating rd neuro business group resource area eisai continues dedicate discoverydevelopment clinical medical commercial strategyplanning discovering new highly effective treatment april 2016 eisai established new endtoend medicine development center business group covering function rd sale oncology business group company also restructured drug creation discoverydevelopment clinical medical commercial strategyplanning framework four division neurology business group nbg oncology business group obg hhc data creation center medicine development center mdc hhc data creation center hdac nbg obg strategic division including function ranging drug discovery commercial business development licenseinout structured able make quick decision nurture scientific acumen mdc meanwhile provides basic platform drug creation providing essential technology support area nonclinical safety pharmacokinetics cmc chemistry manufacturing control pharmaceutical regulation clinical development support hdac serf big data center using ai artificial intelligence advanced analytical technology assess clinical nonclinical data internal external source aim enabling new drug creation research underpinned ictdriven innovation eisais drug discovery research development site worldwide eisai carry drug discovery research drug development research clinical research throughout world eisai pursues innovative new drug creation promoting exchange various knowledge idea around world european knowledge centre koishikawa knowledge center tsukuba research laboratory h3 biomedicine inc eisai inc andover innovative drug discovery research clinical research tokyo japan drug discovery drug discovery research u medicine institute clinical research uk development research ibaraki japan drug discovery development research u eisai china inc ea pharma co ltd clinical research china clinical research tokyo japan ea pharma co ltd research institute knowledge centre india drug discovery development drug development research research kanagawa japan india eisai clinical research singapore pte ltd clinical research singapore kan research institute inc kawashima laboratory kashima laboratory eisai inc morphotek inc drug discovery research drug development research drug development research clinical research u drug discovery development kobe japan gifu japan ibaraki japan research clinical research u 50 company introduction management strategy value creation activity business base esg appendix review eisai scientific advisory board esab eisai set esab consisting worldrenowned scientific advisor 2007 aim improving quality drug creation activity esab meeting held regularly attended ceo member leadership team concerned drug creation enables ongoing discussion regarding subject project review validity research plan backed latest scientific insight reducing rd expenditure per approval targeted project partnership according study published tuft university u total rd expenditure per approval cost required develop single drug estimated around 26 billion moving average five year including indication expansion additional formulation etc approximately 290 billion period 2000 2010 increased phenomenal rate last decade proof billion yen developing pharmaceutical becoming increasingly difficult every year 40 eisai put creation new drug right heart innovation actively invests around 20 consolidated revenue rd since 30 fiscal 2009 eisai selecting focusing priority project making proactive partnership improve rd productivity 20 36 efficiency resulting reduction rd expenditure per approval 26 10 20 21 18 17 16 18 however amid accelerating development nextgeneration flagship drug spending started increase gradually since fiscal 2015 0 journal health economics 47 2016 2033 2009 2010 2011 2012 2013 2014 2015 2016fy recruiting human resource developing skill drug creation eisai employ diverse range human resource regardless nationality carry drug creation activity facility around world important aspect drug creation creating drug contribute patient quickly possible key motivating factor toward achieving spending time socialization patient something eisai committed putting practice aim motivating employee contribute patient developing new drug quickly possible eisai also implement following program designed improve skill human resource working drug creation increase motivation international assignment program mainly young researcher japan program aimed improving experience knowledge global drug creation activity extend overseas study opportunity additional one two employee every year regularly assign employee work overseas facility shortterm medium longterm basis tsukuba hakunetsu seminar tsukuba research laboratory one hour week series inhouse seminar give speaker various age group chance talk passionately range subject including latest technology personal experience researcher new venture exchanging knowledge participant boost motivation also produce concrete result including technical partnership operational improvement crossdivisional leader training egold eace etc detail please refer page 20 unique incentive scheme reward innovation ethical transparent drug creation activity eisai group carry pharmaceutical rd maintaining high sense ethic based hhc corporate philosophy complying spirit declaration helsinki various regulation country international standard including ichgcp standard undertaking clinical trial drug well relevant regulation standard human right furthermore eisai internally established research ethic review committee institutional animal care use committee give thorough consideration morality wellbeing animal research respectively especially clinical research eisai adheres ichgcp obtains informed consent patient conduct clinical research accordance regulatory requirement country internal standard well trial implementation protocol furthermore choosing contract research organization cro outsource various kind work relating clinical trial eisai conduct audit beforehand according eisai group policy standard continuously assesses cro activity take responsibility management addition fiscal 2015 eisai group determined policy clinical trial data access disclosure clinical trial information promotes responsible sharing clinical trial data facilitate advance medicine chemistry detailed information please access following page website research ethic review committee httpwwweisaicomresponsibilitygenomehtml promoting animal testing take account animal welfare httpwwweisaicomresponsibilityresearchhtml clinical trial data disclosure httpwwweisaicomresearchclinicalpolicyhtml compliance handbook httpwwweisaicomcorporatemissioncompliancehtml 51 eisai integrated report 2017 intellectual capital neurology area major rd pipeline end july 2017 development stage target disease region phaseⅰ phase ⅱ phase ⅲ filed approved aricept donepezile2020 treatment alzheimers diseasedementia lewy body inhouse oral agent severe alzheimers disease additional indication china february 2015 regression symptom people syndrome additional indication japan detail please refer page 12 fycompa perampanele2007 antiepileptic agentampa receptor antagonist inhouse oral agent u july 2017 monotherapy use partialonset seizure additional indication japan japanus lennoxgastaut syndrome additional indication europe japanus pediatric epilepsy additional indication europe detail please refer page 12 42 lemborexante2006 dual orexin receptor antagonist inhouse oral agent description antagonizing orexin receptor involved regulation sleep awakening expected alleviate wakefulness thereby induce maintain natural sleep japanus insomnia disorder codevelopment purdue pharma lp europe irregular sleepwake rhythm disorder associated alzheimers disease dementia co japanus development purdue pharma lp elenbecestate2609 antialzheimers agent beta secretase cleaving enzyme bace inhibitor inhouse oral agent japanus early alzheimers disease codevelopment biogen inc europe generic name e2609 generic name yet fixed time detail please refer page 37 ban2401 antialzheimers agent antiaβ protofibrils monoclonal antibody inlicense bioarctic ab injection japanus alzheimers disease codevelopment biogen inc europe detail please refer page 37 belviq lorcaserinapd356 antiobesity agentserotonin 2c receptor agonist inlicense arena pharmaceutical inc oral agent obesity japan detail please refer page 12 43 safinamideme2125 antiparkinsons disease agentmaob inhibitor inlicense meiji seika pharma co ltd oral agent description selective monoamine oxidase b maob inhibitor reduces degradation secreted dopamine helping maintain density dopamine brain additionally block sodium ion channel inhibits glutamate release potential new parkinson disease treatment possesses dopaminergic nondopaminergic mechanism parkinson disease japan e6011 antifractalkine antibody inhouse injection description world first humanized antifractalkine monoclonal antibody discovered eisai subsidiary kan research institute inc believed exert antiinflammatory effect neutralizing fractalkine fractalkine found vascular endothelial cell induces inflammatory response associated disease rheumatoid arthritis inflammatory bowel disease rheumatoid arthritis japan primary biliary cholangitis development conducted ea pharma japan crohn disease development conducted ea pharma japan detail seek potential indication alzheimers disease please refer page 35 e2027 inhouse oral agent alzheimers disease u e2730 inhouse oral agent epilepsy u 52 company introduction management strategy value creation activity business base esg appendix intellectual capital oncology area major rd pipeline end july 2017 development stage target disease region phaseⅰ phase ⅱ phase ⅲ filed approved halaven eribuline7389 anticancer agentmicrotubule dynamic inhibitor inhouse injection resubmission breast cancer china preparation bladder cancer additional indication useurope triple negative breast cancer combination antipd1 therapy pembrolizumab u codevelopment merck co inc kenilworth nj usa her2negative breast cancer combination pegph20 u codevelopment halozyme therapeutic inc liposome formulation additional formulation japaneurope detail please refer page 13 49 lenvimakisplyx lenvatinibe7080 anticancer agentmolecular targeted drug inhouse oral agent thyroid cancer china renal cell carcinomafirstline additional indication combination everolimus anti useurope pd1 therapy pembrolizumab japan june 2017 useurope july 2017 hepatocellular carcinoma additional indication submission chinaasia preparation japanus nonsmall cell lung cancer ret translocation additional indication europeasia biliary tract cancer additional indication japan select solid tumor endometrial cancer renal cell carcinoma head neck cancer urothelial cancer nonsmall cell lung cancer melanoma combination antipd1 u therapy pembrolizumab codevelopment merck co inc kenilworth nj usa select solid tumor hepatocellular carcinoma endometrial cancer etc combination antipd1 therapy pembrolizumab codevelopment merck co inc kenilworth nj japan usa renal cell carcinomasecondline additional indication combination everolimus japan detail please refer page 13 48 farletuzumabmorab003 anticancer agenthumanized antifra monoclonal antibody inhouse injection description humanized igg1 monoclonal antibody target folate receptor alpha fra expected show antitumor effect cancer overexpress fra japanus platinumsensitive ovarian cancer europe morab004 anticancer agenthumanized antiendosialin monoclonal antibody inhouse injection description humanized lgg1 monoclonal antibody target tumor endothelial marker 1 tem1endosialin expected show antitumor effect cancer express endosialin melanoma useurope amatuximabmorab009 anticancer agentchimeric antimesothelin monoclonal antibody inhouse injection description chimeric igg1 monoclonal antibody target mesothelin expected show antitumor effect cancer express mesothelin mesothelioma useurope e7777 anticancer agentinterleukin2 diphtheria toxin fusion protein inhouse injection description fusion protein combine interleukin2 il2 receptor binding domain diphtheria toxin specifically bind il2 receptor cell surface causing diphtheria toxin entered cell inhibit protein synthesis peripheral tcell lymphoma cutaneous tcell lymphoma japan e7090 inhouse oral agent solid tumor japan morab066 inlicense janssen biotech inc injection solid tumor u e7046 inhouse oral agent solid tumor useurope h3b6527 inhouse oral agent hepatocellular carcinoma u h3b8800 inhouse oral agent blood cancer useurope e7438 inlicense epizyme inc oral agent nonhodgkin bcell lymphoma japan e7386 collaboration prism pharma co ltd oral agent solid tumor europe 53 eisai integrated report 2017 gastrointestinal disease area intellectual capital major rd pipeline end july 2017 development stage target disease region phaseⅰ phase ⅱ phase ⅲ filed approved parietaciphex rabeprazolee3810 proton pump inhibitor ppi inhouse oral agent maintenance therapy proton pump inhibitor ppiresistant reflux esophagitis10 mg twice japan october 2016 daily additional dosage administration joint development ea pharma budesonideajg511 ulcerative colitis treatmentlocallyactive steroid inlicense dr falk pharma gmbh enema agent description first rectal foam product japan containing budesonide active ingredient budesonide locallyactive steroid thus expected reduce systemic side effect addition ajg511 foam type product reach inflamed site rectum sigmoid colon rectal administration characteristic feature preventing leakage administration budesonide rectal foam already available market europe ulcerative colitis joint development ea pharma kissei pharmaceutical co ltd japan october 2016 elobixibatajg533 chronic constipation treatmentbile acid transporter inhibitor inlicense albireo pharma inc oral agent description orally available constipation treatment novel action mechanism ajg533 inhibits bile acid transporter regulates reabsorption bile acid thereby increase spontaneous colonic motility chronic constipation joint development ea pharma mochida pharmaceutical co ltd japan february 2017 carotegrast methylajm300 ulcerative colitis treatment α4 integrin antagonist inhouse oral agent description α4 integrin antagonist novel mechanism action believed suppress adhesion infiltration lymphocyte aiming marketed first orallyavailable α4 integrin antagonist world effective ulcerative colitis ulcerative colitis joint development ea pharma kissei pharmaceutical co ltd japan ajg555 chronic constipation treatmentpolyethylene glycol preparation inlicense norgine bv oral agent description orally available constipation treatment consisting polyethylene glycol preparation facilitates bowel movement suppressing osmotic pressure intestine chronic constipation development conducted ea pharma japan livact granule isoleucine leucine valine granule branchedchain amino acid formula inhouse oral agent description branchedchain amino acid formula developed ajinomoto increase serum albumin level patient decompensated hepatic cirrhosis approved japan improvement hypoalbuminemia patient decompensated hepatic cirrhosis hypoalbuminemia despite adequate dietary intake marketed ea pharma hypoalbuminemia codevelopment ea pharma china e6007 ulcerative colitis treatmentintegrin activation inhibitor inhouse oral agent description compound novel mechanism action believed suppress adhesion infiltration multiple leukocyte type inhibiting integrin activation development conducted jointly university tsukuba industryacademia practical application project japan science technology agency ulcerative colitis development conducted ea pharma japan e6130 inflammatory bowel disease inhouse oral agent inflammatory bowel disease development conducted ea pharma japan research development activity gastrointestinal disease area mainly conducted ea pharma consolidated subsidiary eisai ea pharma gastrointestinal specialty pharma established april 2016 consolidation gastrointestinal disease area eisai group focused 60 year ajinomoto co inc pharmaceutical business amino acid core full value chain namely research development production logistics sale marketing function development pipeline progressed steadily focus inflammatory bowel disease area fy2016 ea pharma research laboratory kanagawa prefecture japan 54 intellectual capital intellectual property strategy protection reinforcement intellectual property legal protection effective utilization product technology develop essential sustained growth advancement eisai eisai continue provide stable supply pharmaceutical patient therefore pursue number strategic intellectual property activity strategy related product portfolio product creation operation 1 intellectual property activity intellectual property department stationed person responsible intellectual property eisais rd facility around world conduct activity globally relating patent trademark design copyright working closely group rd department furthermore filing patent application acquisition right prior art search carried close collaboration rd business division addition eisai introduces new technology promising new candidate compound cooperates relevant organization emphasizes steadfast protection patent right ensuring compliance relevant law regulation 2 drug creation activity intellectual property strategy besides exclusivity protects prescription pharmaceutical candidate investigational compound discovery active ingredient application manufacturing method formulation intermediate well intellectual property department cooperates closely rd department ensure pharmaceutical product properly protected launch focus strategic patent application acquisition right aim optimal patent portfolio management also includes screening method biomarker measurement drug creation activity additionally eisai place high importance patent search company intellectual property strategy also give sufficient consideration respecting right third party 3 contribution licensingrelated activity rather simply looking thirdparty licensing fee patent revenue source strive create strong patent portfolio contribute business regarding possible use treatment disease occurring specifically area inconvenient access medicine plan proactively outlicense patent neglected tropical disease ntds particular striving conduct efficient research drug discovery opening patent portfolio externally sharing goal commitment wide range partner organization combining idea technology knowledge 4 number registered patent protect outcome drug creation activity diligently file patent number patent application application japan overseas time efficiently manage fiscal 2014 fiscal 2015 fiscal 2016 resource carefully evaluate strategic importance inventive discovery determine whether file patent abroad many 87 65 55 country file 5 trademark eisai develops product name pharmaceutical protected trademark right implement brand strategy throughout world collaboration marketing division eisais perspective intellectual property right access medicine detail httpwwweisaicomcompanyatmapproach06html providing intellectual property royaltyfree basis global consortium sponsored world intellectual property organization wipo boost research development neglected tropical disease treatment httpwwweisaicomcompanyatmactivities13html 55 eisai integrated report 2017 human capital global marketing organization expand activity beyond developed country japan u europe emerging developing country eisais marketing activity expanded beyond developed country japan u europe emerging developing country lead neurology business group oncology business group eisai creates synergy global brand strategy local marketing region japan america china asia emea contribute patient revenue reporting segment fy2016 number employee region end fy2016 business 90 billion yen 17 emea 378 emea asia billion 347 yen 70 983 94 billion yen 64 asia 1231 118 china 493 billion yen consolidated 91 revenue consolidated number japan 5391 billion yen japan 5009 2911 billion yen america employee oveseas 540 1320 479 revenue ratio 126 10452 america 452 1172 billion yen 217 china 1909 183 note number total employee shown includes staff dispatched eisai co ltd group company excludes employee eisai co ltd loan group company aim secure appropriate pricing eisai aim secure appropriate pricing product order deliver medicine create many patient possible realizing corporate mission involves integration innovation discovery new medicine fulfill unmet medical need securing access medicine enable deliver newly developed product patient around world order ensure sustainability initiative necessary value innovation appropriately assessed however environment rising social welfare spending growing concern price innovative new medicine contributing factor increasing healthcare cost result greater demand evidence clinical trial comprehensively demonstrates appropriateness price new medicine various perspective eisai global value access unit gva implemented strategy pricing new medicine appropriately perspective health economics outcome research heor health technology assessment hta leadership unit president uk activity deployed globally u unit responsible evaluating economic efficiency new medicine regional national representative charge medicine price access medicine gva summarizes value new medicine creates value dossier based perspective economic efficiency obtained improvement patient quality life qol addition efficacy safety obtained clinical trial way gva ensures attainment appropriate medicine price market many different country aim secure patient access new medicine 56 company introduction management strategy value creation activity business base esg appendix fy2016 revenue business product japan pharmaceutical business america pharmaceutical business consumer healthcare business north central south america 190 billion yen 65 humira generic 377 billion yen 129 280 others billion yen 284 billion yen 96 aricept 243 295 billion yen aloxi 101 revenue fy2016 revenue fy2016 481 belviq 1172 billion yen billion yen 2911 billion yen lyrica 37 billion yen 410 102 yearonyear 243 32 96 yearonyear billion yen 106 local 83 fycompa currency basis others 53 billion yen pariet lenvima 1156 45 billion yen prescription medicine 212 151 397 billion yen billion yen halaven 73 129 166 billion yen lunesta 142 80 billion yen 28 halaven copromotion income 78 billion yen 27 business deployment 3 business prescription medicine aim drive ongoing growth u world biggest generic consumer healthcare business pharmaceutical market ea pharma co ltd gastrointestinal specialty pharma focus growth halaven lenvima fycompa belviq established april 2016 china pharmaceutical business emea pharmaceutical business europe middle east africa russia oceania others halaven 128 billion yen 109 259 billion yen methycobal 289 revenue fy2016 180 revenue fy2016 billion yen others 493 billion yen 365 378 billion yen 193 100 yearonyear billion yen 92 yearonyear pariet 117 local 511 39 billion yen currency basis 104 local 80 currency basis fycompa 42 billion yen aricept stronger neo 112 62 lenvima minophagen c kisplyx billion yen 125 glycyron tablet 33 84 billion yen billion yen 171 88 following establishment joint venture 1991 eisai seeking growth halaven lenvimakisplyx fycompa conducted business operation china 25 year four major product growing including methycobal accelerating expansion small midsized hospital inland area small midsized rural town lowtier market asia pharmaceutical business revenue growth target region fy 2020 mainly south korea taiwan hong kong india asean billion yen 900 compound annual growth rate fy2015 fy2020 aricept consolidated revenue approx 8 91 billion yen 98 261 billion yen others 281 lenvima 600 03 billion yen revenue fy2016 emea approx 14 09 347 billion yen 102 yearonyear asia approx 11 fycompa 113 local 04 billion yen 10 currency basis china approx 12 300 halaven 20 billion yen pariet 36 humira america approx 15 58 billion yen 96 104 billion yen 277 japan approx 4 0 seeking growth halaven lenvima fycompa addition fy2015 fy2016 fy2020 major product aricept humira result result target figure approximate focusing operation emerging country including vietnam myanmar well major country south korea taiwan 57 eisai integrated report 2017 manufactured capital global production system ensure stable supply highquality product global level eisais general policy product quality quality every single tablet capsule ampule produce integral life patient eisais general policy product quality employee keenly aware every medicine manufactured eisai directly linked patient life conviction reflected every aspect production activity believe long people around world need medicine exists mission responsibility continue assure stable supply highquality pharmaceutical product achieve eisai consistently strives high quality introduction robust management system oversees process drug substance formulation research production distribution global quality assurance activity eisai belief quality must assured pharmaceutical product delivered used patient consumer need product eisai implement quality control manufacturing phase accordance globally unified good manufacturing practice gmp standard international regulation production quality management placing emphasis maintaining product quality distribution phase global quality assurance system eisai carrying quality assurance activity supply pharmaceutical product used patient confidence every country region quality assurance department within eisai group strive supply product generate customer satisfaction pursuing quality satisfies apparent latent need patient customer initiative strengthen pharmaceutical quality system eisai working strengthen pharmaceutical quality system meet patient need stable continuous supply product met safety efficacy standard based ich q10 pharmaceutical quality system guideline initiative stable supply formulating business continuity plan bcp eisai formulated business continuity plan bcp ensure stable supply case risk natural disaster accident act terrorism even event large earthquake committed resuming plant operation soon possible continuing stable supply product consistently ensuring appropriate product inventory additionally undertaking initiative securing backup site enable alternate operation time emergency primarily specific product especially product high degree urgency importance 58 company introduction management strategy value creation activity business base esg appendix global production system innovation base eisai provides highquality product generate customer satisfaction establishing ricchi utilizing strength manufacturing site conducting demand innovation activity worldwide reform manufacturing site volume base innovation base volume base pursued optimization site operational rate logistics based volume transformation innovation base established ricchi utilizing strength manufacturing site conduct demand innovation activity worldwide hatfield uk suzhoubenxi china exton laboratory u pilot plant supply multilingual small volume satisfy demand enormous product quantity utilize experience fostered packaged product mainly china growing market addition lineup production investigational drug european market possesses generic supply product even wider quickly transition commercial integrated control system serial range region patient various production antibody treatment using number individual packaging income class original technology manages product traceability globally unit seek developmanufacture cuttingedge technology including ic chip product wearable device socialization conducted site aiming fulfilling hhc true need baltimore u specialize formulation technology unique wafer product intracranial use fukushima ea pharma co ltd japan mainly manufacture product gastrointestinal area possesses strength production technology large volume powder formulation organic solvent technology enable poorly soluble apis formulated aim quickly launch new vizag india product utilize original technology strengthen manufacture apis formulation level commissioned production conforming regulation developed country supply free charge dec tablet kashima japan treatment lymphatic filariasis plan manufacture apis require highly supply total 22 billion tablet 2020 advanced synthesis technology eribulin generic name launched original sitespecific coupling technology aiming inhouse production antibody kawashima japan representative base dementia treatment production developed bogor indonesia innovative continuous production technology differ aim satisfy latent need former batch manufacturing process aim proceed smoothly indonesian market development commercialization flexibly handle different muslimmajority population production volume obtaining halal certification established dementia café place discover hhc true need pharmaceutical product naito museum pharmaceutical science industry ten thousand people visit year demand innovation plus symbol aspiration aiming maximizing value product solution patient 59 eisai integrated report 2017 social relationship capital improving access medicine atm making medicine available need eisai promoting initiative improving atm contribute people developing emerging country number country supplied lymphatic filariasis treatment volume supplied june 2017 27 country over11 billion tablet want deliver many necessary medicine possible investing future emerging nurture hope many people possible putting developing country wish tablet eisai engaged activity improving atm aim ensuring people emerging developing country receive medicine need atm basic need people regardless nationality economic disparity social standing today approximately 2 billion people around world adequate access medicine poor developing emerging country also lack proper information health disease eisai belief improving atm developing emerging country longterm investment support health people living country ultimately lead future growth nation whole eisai utilizes resource including lowcost manufacturing supplying operation well publicprivate partnership continues implement various atm initiative unique business model source access medicine index website whobangladesh httpaccesstomedicineindexorg 60 company introduction management strategy value creation activity business base esg appendix health care eisai staff also distribute leaflet prevention effort help eliminate lymphatic filariasis treatment lf support mda indonesia supplying dec tablet implementing awarenessraising activity lymphatic filariasis lf neglected tropical disease ntd transmitted human via carrier mosquito estimated approximately 1 billion people worldwide mainly developing country exposed risk lf world health organization conduct mass drug administration mdas endemic area order eliminate lf used global shortage highquality dec diethylcarbamazine tablet three type lf medicine used mdas november 2010 eisai agreed supply total 22 billion dec tablet free charge 2020 2012 eisai became japanese company participate london declaration coordinated effort eliminate 10 ntds largest publicprivate partnership kind field interaction staff member vizag plant patient global health london declaration fifth anniversary event held april 2017 eisai announced plan supply cumulative quantity dec tablet supplied number dec tablet continuously 2020 lf completely patient contributed june 2017 eliminated endemic country dec tablet million cumulative quantity 11 billion needed tablet supplied tablet supplied 2013 eisai commenced production dec tablet vizag plant india obtaining prequalification 1000 drug june 2017 11 billion dec tablet provided 27 endemic country who contributing elimination program furthermore support smooth nearly 440 implementation mdas eisai engaging initiative million patient 500 raise public awareness lf endemic area staff member eisai subsidiary lf endemic country cooperate relevant representative national government concerned party activity supporting effort eliminate lf early possible indonesia order raise 0 awareness lf society eisai staff member given end end end end june 2013 2014 2015 2016 2017 annual lecture lf since 2015 faculty medicine number patient contributed estimated value gadjah mada university institution support local converted cumulative quantity tablet supplied based assumption average 25 tablet taken per caput accordance definition country dec tablet scheduled supplied 2020 country distribution commenced southeast asia region dec tablet india indonesia diethylcarbamazine myanmar sri lanka timorleste thailand bangladesh nepal region america dominican republic east mediterranean region guyana egypt haiti coordination brazil eisai head office vizag plant 2017年4月現在の供給予定 india african region western pacific region eritrea kenya madagascar fiji french polynesia kiribati zambia zimbabwe comoros lao malaysia papua new guinea são tomé príncipe philippine samoa micronesia tuvalu gambia distribution status june 2017 61 eisai integrated report 2017 trial experience addition network clinical facility rd initiative improving global health endemic region reason eisai actively engaging eisai proactively undertakes research pharmaceutical external collaboration partnership global treating ntds three major infectious disease research organization participating international malaria tuberculosis hivaids consortium share compound library eisai seek disease strike people low income developing develop new drug ntds three major infectious country causing leave work turn lead disease negative cycle poverty people become eisai aim develop new drug chaga disease incapacitated due disease become even poorer disease transmitted assassin bug prevalent international effort called upon tackle significant 21 country latin america purpose eisai global health issue conducting phase ⅱ study inhouse developed response eisai currently conducting various project antifungal agent fosravuconazole e1224 partnership aimed developing new treatment chaga disease drug neglected disease initiative dndi another filariasis leishmaniasis mycetoma well malaria phase ⅱ study agent conducted dndi tuberculosis undertaking research activity mycetoma considered one neglected disease requires specific expertise technology clinical disease mycetoma transmitted prick skin cause large lesion ntdsthree major infectious disease research project portfolio early research stage nonclinical clinical chaga vaccine novel compound e1224 chaga using eisais disease project chaga disease immunostimulant e6020 phaseⅱ study chaga disease chaga vaccine ntd drug discovery booster using eisais immunostimulant e6020 neglected tropical macrofilaricide novel antiwolbachia disease filariasis drug accelerator compound ntds leishmaniasis ntd drug discovery booster e1224 eumycetoma mycetoma project phaseⅱ study screening novel novel inhibitor sj733 inhibitor compound malaria plasmodium phe trna ligase plasmodium atp4 malaria vaccine inhibitor plasmodium using eisais immunostimulant e6020 gwt1 three major malaria infectious tlr9 antagonist disease cerebral malaria novel compound artemisinin resistant malaria tuberculosis tb drug accelerator updated june 2017 please visit following link detail project httpwwweisaicomcompanyatmapproach02html 62 company introduction management strategy value creation activity business base esg appendix addition eisai introduced tiered pricing pricing policy emphasizes affordability affordable pricing model anticancer agent halaven eisai formulated affordable pricing policy enables philippine hong kong india malaysia thailand patient developing emerging country purchase model copayment set several tier accordance eisais product affordable price based approach income level health insurance availability eisai pursuing pricing policy suited social patient ranging full purchase price provision free economic healthcare environment developing charge oneyear period april 2016 emerging country regard aricept eisai providing march 2017 halaven supplied 1000 patient product certain asian country india mean tiered pricing indonesia price take consideration living standard local patient creating corporate value solution social problem initiative improving atm input output outcome intellectual capital social relationship capital initiative creating new drug improving health welfare economic treatment ntds malaria supplying lymphatic filariasis treatment dec growth increasing number tablet free charge middleincome population developing emerging country human capital activity raising awareness lymphatic improving value eisais corporate staff strong motivation filariasis brand contribute patient supported hhc philosophy supplying product price patient afford based affordable tiered pricing strategy human capital production capital improving employee skill motivation utilization vizag plant india allows lowcost production social relationship capital partnership financial capital participation publicprivate partnership reduced cost manufacturing due increased operation rate vizag plant longterm perspective creating financial capital profit business developing longterm investment improvement emerging country atm developing emerging country purpose facilitating improvement atm internal outcome eisai belief effort improve atm developing emerging country eisai utilizes many increase capital extent greater amount different type capital input convert many input creation added value different form output product service eisais initiative improving atm go beyond dec tablet company business activity framework csr activity aim creating longterm result pursue creation positive outcome value supplying dec tablet free charge initially improvement health welfare economic growth loss thus negatively affect profit roe short increasing number middleincome population term however longterm perspective estimate developing country emerging country eisai also boost npv net present value positive level seek enhance value corporate brand improve creation outcome described employee skill motivation reduce cost increasing operation rate vizag plant positive access eisai ranked 11th among global medicine index pharmaceutical company 1st among recognised eisai japanese pharmaceutical company best practice access medicine index proactively building eisais initiative improve atm highly evaluated partnership international agency nonprofit organization access medicine foundation international nonprofit stakeholder aim thereby spurring organization aimed improvement atm biennially research development new drug ntds malaria research publishes access medicine index eisai tuberculosis globally improving atm encouraging ranked first among japanese pharmaceutical company employee around world spend 1 business 11th among global major pharmaceutical company hour patient practice lead creation consecutively 2014 2016 patient value 63 eisai integrated report 2017 initiative sustainable development goal sdgs 17 sustainable development goal sdgs 2030 agenda sustainable development adopted leader world september 2015 united nation summit officially came force january 1 2016 toward 2030 goal universally apply country mobilize effort end form poverty fight inequality tackle climate change ensuring one left behind corporate philosophy hhc mind eisai conducting various initiative limiting making medicine expanded improving access medicine providing solution regional healthcare system mediumterm business plan eway 2025 set goal eisai become medico societal innovator word company change society making medicine providing solution order realize corporate aspiration eisai work eliminating various gap treatment care exist throughout world eisai belief initiative lead achievement united nation 17 sustainable development goal sdgs initiative listed eisai endeavor contribute achievement sdgs 1no poverty aim contribute patient expanding middleincome class improvement access medicine health welfare page 6063 good health wellbeing 3 creation innovative medicine page 3239 4254 62 provision medicine also solution page 4041 initiative eliminate neglected tropical disease ntds spread developing country provision diethylcarbamazine dec tablet price zero free charge elimination lymphatic filariasis lf page 61 initiative create new medicine chaga disease filariasis leishmaniasis mycetoma malaria tuberculosis spread mainly among people lowincome class developing country page 62 provision eisai product based affordable pricing policy developing emerging country page 63 gender equality 5 initiative enhance diversity aim achieve target proportion woman company management position fiscal 2020 10 eisai co ltd page 21 6clean water sanitation handling risk water shortage efficient use water resource page 85 12responsible consumption production establishment recyclingoriented society initiative reduce amount waste generated increase rate recycling decrease amount waste page 85 climate action 13 formation lowcarbon society aim reduce domestic co2 emission 23 versus fiscal 2005 fiscal 2020 page 84 partnership 17 partnership academia corporation creating innovation priority area page 62 8283 partnership united nation organization nonprofit organization research institution academia others expand access medicine page 83 number bracket refer relevant page number integrated report 64 introduction example initiative sdgs inclusive activity toward elimination lymphatic filariasis lf yarada village india 2013 vizag plant eisai india started production high quality dec tablet distribution across globe price zero following agreement yarada beautiful coastal village population approximately 3500 people situated 30km away vizag plant 50 people suffering lf time poor health environment due lack awareness socioeconomic factor community causing mosquito breeding leading vector borne disease including lf eisai staff interacted villager learnt providing medicine also solving root cause disease inclusive activity local people essential various initiative started approach infrastructure october 2013 eisai entered publicprivate partnership state government health department support vector borne disease control activity yarada village improve sanitation infrastructure eisai staff supported antilarval operation ensuring regular spraying antilarval chemical water logged area open drain weekend eisai staff visited village monitor cleaning area conducive mosquito breeding also helped repair old public toilet measure prevent mosquito breeding mosquito repellant plant planted near home repaired pubic toilet yarada village open drain awareness created among villager staff regarding precaution taken vector borne disease proper disposal waste approach treatment drug important conduct disease awareness let people understand significance treatment drug area taking medicine uncommon disease awareness conducted thoroughly january 2014 60 eisai staff supported mass drug administraction mda program elimination lf yarada eisai staff visited village 3 night date making announcement mda dandora involves beating drum invite many villager participate day mda visited household ensure resident taken treatment drug zero incidence lf sentinel survey conducted february 2017 state health department screening patient wuchereria bancrofti parasitic worm cause lf new case lf identified village since previous survey november 2013 realizing child grandchildrens generation longer suffer lf villager feeling positive beyond lf sustainable growth inclusive development october 2014 massive cyclone hudhud hit yarada caused severe damage eisai supported educational institution zilla parishad school restoring school building donating drinking water tank newly built laboratory also class offered technician vizag plant restoration enabled student forced study school far home return local school december 2016 local english paper hindu reported eisai staff visit zilla parishad school article head master told pas percentage secondary school certificate exam last two year improved 97 percent 10th grade several student received memorial reconstruction zilla parishad scholarship government school increased motivation among employee interacting lf patient yarada understood severe condition patient suffering really proud eisai helping people contracting disease every morning come work feel contributing way caring patient family produce medicine vizag deliver patient likewise disease awareness activity saw people gain healthy life expect people overcome poverty eventually following success madanmohan invited state government participate similar public pavuluri private partnership area state andhra eisai pharmaceutical india pvt ltd vizag hindu article december 14 2016 pradesh provides u great motivation hudhudhit zp high school turn smart deputy manager rd picture courtesy hindu playing role develop sustainable society initiative 65 eisai integrated report 2017 corporate governance system supervisory executive function clearly separated decade pursuit system oriented toward independence neutrality eisai pursued best corporate governance practice remained committed improvement governance purpose fulfilling hhc company corporate philosophy since june 2000 eisai appointed director outside company june 2004 eisai revised article incorporation annual general shareholder meeting adopted company committee system currently company nomination committee etc system time number outside director increased account majority board director intended ensure fairness transparency business management consequence management supervision function strengthened eisai remains committed sustainable improvement corporate governance pursuit increasing benefit stakeholder including patient customer shareholder employee adopted company committee system 2004 clearly separated management oversight function business execution function since 2004 half eisais director outside director since 2005 chair board director chosen among outside director representative corporate officer ceo director serving concurrently corporate officer member nomination committee compensation committee comprise outside director majority member audit committee outside director chair committee outside director internal control system operation improved ensure credibility financial reporting others eisais corporate governance system annual general shareholder meeting board director 11 member 7 outside 4 inside chair outside director outside director meeting 7 member outside director others effectiveness board evaluation business execution power decisionmaking broad delegation management oversight nomination compensation audit committee audit committee committee committee proposal appropriate reporting 5 member 3 outside 2 inside 3 member 3 member chair outside director outside outside supervisioninspection management audit board director secretariat department reporting executing division representative corporate officer ceo corporate officer executive board responsible internal accounting accounting control corporate officer auditor audit internal corporate internal audit individual divisionssubsidiaries inside outside japan audit department development operation internal control system 66 company introduction management strategy value creation activity business base esg appendix feature eisais corporate governance ❶clear separation function supervision management execution business core aspect eisais corporate governance system clear separation supervision management execution business maximum benefit obtained eisais status company nomination committee etc system eisai established chair board director outside director ceo director serving concurrently corporate officer achieve goal board director able devote attention management entrusting large portion decisionmaking authority corporate officer enables corporate officer increase effectiveness flexibility business execution enhance dynamic management well ensuring autonomy establishing internal control corporate officer fulfill accountability making report board director status execution assigned activity quarterly upon request based report corporate officer board director keep uptodate matter progress business plan current status issue operation labor management occupational health safety effort environmental protection status effort meet compliance requirement prevention corrupt act bribery way board supervises execution operation system along checking status execution operation board director also inspects status internal control business execution decisionmaking process perspective shareholder society ❷ensuring independence neutrality outside director presence seven independent neutral outside director account majority member board director support effective operation eisais corporate governance system eisais nomination committee composed exclusively outside director nomination committee strictly applies requirement independence neutrality outside director stipulated committee selection candidate outside director ❸diversity outside director nomination committee emphasizes composing board director director diverse expertise experience background expectation board director contribute enhancement corporate value providing oversight efficiency appropriateness etc management viewpoint wide range stakeholder proportion outside directors1 tenure outside directors2 background outside directors1 outside director 7 11 since eisai adopted company expertise experience including one woman one nomination committee etc system 2004 experience corporate management foreign national none outside director held experience working overseas position five year experience serving outside director company corporate legal affair 12 years3 internal control internal auditing 3 3 year corporate governance 7 4 year risk management 5 year finance accounting international accounting standard 64 qualification 13 certified public accountant attorney frequency board director meeting committee meeting attendance meeting fiscal 20164 number time offered attendance board director 10 100 nomination committee 7 100 audit committee 12 100 compensation committee 10 100 independent committee outside director 3 100 1 pertains 11 director office june 21 2017 2 r epresents term office 23 outside director appointed role eisais director 2004 leaving position calculation term office includes term office director corporate officer 2004 3 outside director held position longer two year 4 pertains board director meeting committee meeting held period april 1 2016 march 31 2017 67 eisai integrated report 2017 ❹initiatives continuous enhancement corporate governance outside director meeting outside director meeting outside director attendance held regular basis meeting provide outside director valuable opportunity interact communicate profound level make discussion board director etc dynamic productive outside director meeting participant freely discus corporate governance businessrelated matter discussion may reported board director corporate officer necessary outside director meeting review effectiveness board director management supervision function annual basis issue operation board director etc identified improvement proposed board director b corporate governance review board director discusses effectiveness management supervision function annual basis also review corporate governance guideline rule relating internal control result self review summarized corporate governance review formulated board director corporate governance guideline code conduct term eisais corporate governance eleven director review duty board director defined guideline performance chair board director company director outside director nomination committee audit committee compensation committee outside director meeting operation board director committee result review summarized outside director meeting resolution board director outside director independent management wellinformed activity eisais board director discus summarize result review submitted eisais director ensures greater accuracy objectivity review result fiscal 2016 corporate governance review stated notice convocation 105th ordinary general meeting shareholder notice convocation 105th ordinary general meeting shareholder httpwwweisaicomirstockmeetinghtml compliance corporate governance code eisai ensures full compliance 73 principle corporate governance code adopted tokyo stock exchange june 2015 eleven principle require disclosure information detailed corporate governance report addition corporate governance report discloses company audit system compensation director corporate officer eg procedure determining compensation calculation method internal control system requirement concerning independence neutrality outside director detailed information see corporate governance report httpwwweisaicomcompanycgregulationshtml performancebased compensation corporate officer director position independent execution business duty compensation set fixed amount without incorporating performancebased compensation ensure content compensation appropriate enabling adequate deployment management monitoring function duty director compensation paid corporate officer made base compensation bonus stockbased compensation ratio 631 performancebased compensation account 40 total compensation compensation corporate officer fixed compensation performancebased compensation base compensation bonus stockbased compensation 60 30 10 stockbased compensation system mediumtolongterm incentive plan introduced fiscal 2013 stockbased compensation involves providing corporate officer stock annual basis trust accordance degree achievement companywide performance objective system motivates corporate officer share profit awareness based perspective shareholder remain aware performance stock price executing duty mediumtolongterm perspective amount bonus provided corporate officer calculated accordance degree achievement companywide performance goal corporate officer performance objective degree achievement companywide performance objective determined reviewing consolidated revenue consolidated operating profit consolidated profit year attributable parent company consolidated roe see notice convocation 105th ordinary general meeting shareholder detail stockbased compensation system corporate officer process decision performancebased compensation process decision compensation committee decision performancebased compensation corporate officer httpwwweisaicompdfeirestockeinv105_allpdf please refer following website detail eisais corporate governance guideline rule board director rule nomination audit compensation committee corporate governance report policy protection company corporate value common interest shareholder httpwwweisaicomcompanycgregulationshtml detailed information see notice convocation 105th ordinary general meeting shareholder httpwwweisaicomirstockmeetinghtml 68 company introduction management strategy value creation activity business base esg appendix interview outside director eisais corporate governance system toru yamashita chair board director outside director isais mediumterm business plan used qe run five year true switch 10 year suggestion outside director yes suggestion however told company change plan 10 year every company way formulating mediumterm plan whereas divide plan fiveyear period others set rolling plan every three year suggested formulating mediumterm plan reflects nature eisais business term development new medicine requires long period time could different vision target perhaps 10year vision numerical target every five year ceo naito sought opinion great many member staff within company validity 10year mediumterm plan result said thing happening moment could predicted decade ago q background led wrong say dont know happen 10 year appointment outside director eisai surprised see taken opinion outside director seriously gone talk really know background wasnt closely frontline staff well involved eisai company contacted puzzled wondered earth could exchanged business card ceo naito first time q impression eisais employee company already decided appoint corporate philosophy outside director genuinely surprised whole process think fellow outside director felt medical representative fycompa said general company appointing outside improves symptom epilepsy patient much ive director imagine someone management say something actually patient doctor thanking honestly like know someone reliable check jealous opportunity thanked customer issue independence neutrality also heard researcher real sense responsibility certainly case eisai eisai start narrowing saying relative died cancer made determined list candidate whose independence neutrality assured create new drug feel eisais employee nomination committee consist exclusively outside rewarding job wonderful environment thats something director selects new outside director aim striking hope employee appreciate balance example across area expertise may risky visited group home seen eisais patient ceo executing division point view socialization program action really felt like directly involve process requires corporate philosophy established large certain amount courage would say process truly extent think due ceo naitos many year reflects eisais commitment governance helm eisai determination establish corporate philosophy ability top management take initiative disseminate corporate philosophy across q impression eisai board frontline key factor determining company director run encountered sustainability issue eisai operates plandocheckact pdca cycle effectively real sense board meeting outside director opinion taken seriously executing division outside director raise question executing division provides detailed explanation sincere manner additional meeting held provide detailed explanation requested likewise new agenda added board meeting result new issue identified board think possible due follow executing division experienced member board director secretariat perspective outside director issue encountered minor technical interviewer yasukazu kanamori executive director investor one presentation readability document relation 69 eisai integrated report 2017 director june 30 2017 board director haruo naito executive officer director representative corporate officer ceo seven eleven director date birth age outside director december 27 1947 69 year age term office 34 year company share held 629380 oct1975 joined company apr1983 senior director rd promotion department company jun1983 director company apr1985 general manager rd company jun1985 managing director company jun1986 representative director senior managing director company jun1987 representative director deputy president company apr1988 representative director president company jun2003 representative director president chief executive officer ceo company jun2004 director president representative corporate officer ceo company jan2006 chair naito foundation current jun2014 director representative corporate officer ceo company current reason appointment director nomination committee determined mr naito appropriately matter relating outside director please see corporate governance explained resolution item report item meeting board director report director concurrent duty corporate officer sufficiently fulfilled role overseeing important management decision execution httpwwweisaicomcompanycgregulationshtml business suitable director company number company share held director march 31 2017 company corporate governance guideline call representative attendance board meeting committee section indicates corporate officer ceo serve concurrently director record fiscal 2016 attendance board director 100 1010 toru yamashita ikuo nishikawa chair board chair audit director member committee member independent committee independent committee outside director outside director date birth age date birth age october 9 1947 july 1 1951 69 year age 65 year age term office 3 year term office 3 year company share held 517 company share held 413 apr1971 joined nippon telegraph telephone public corporation known ntt sep1990 representative partner kpmg century audit corporation currently jun1999 senior vice president director ntt data corporation ernst young shinnihon llc jun2003 executive vice president director ntt data corporation jan 1993 japanese representative international accounting standard committee iasc jun2005 senior executive vice president representative director ntt data jul 1995 executive director japanese institute certified public accountant apr 2007 chairman accounting standard board japan asbj corporation apr 2012 professor faculty business commerce keio university jun2007 president ceo ntt data corporation jun 2014 outside member audit supervisory board nidec corporation jun2012 director chief corporate adviser ntt data corporation jun 2014 director company current chair audit committee current apr2013 cabinet office chair public interest commission current member independent committee outside director current jun2013 outside director mitsui fudosan co ltd current jun 2014 outside corporate auditor megmilk snow brand co ltd jun2014 chief corporate adviser ntt data corporation current jun 2016 outside corporate auditor mitsubishi corporation current jun2014 director company current member independent jun 2016 outside director daiwa security group inc current jun 2016 outside director megmilk snow brand co ltd audit committee outside director current member nomination supervisory committee member current committee member compensation committee apr 2017 visiting professor graduate school business commerce keio jun2015 chair nomination committee company university current jul 2015 outside director sumitomo life insurance company current jun2016 chair board director company current reason appointment director mr nishikawa certified public accountant specialist finance accounting reason appointment director international financial reporting standard involved creating japanese mr yamashita abundant experience executive company accounting standard many year although directly involved providing many year system japan abroad served management experience serving outside director another company outside director company high level insight management working abroad well strong international perspective high level insight excellent supervisory ability management excellent supervisory ability addition constructing board director composed diverse member addition constructing board director composed diverse member variety specialized knowledge experience etc nomination committee variety specialized knowledge experience etc nomination committee considered factor 1 practical accomplishment director chair considered factor 1 practical accomplishment director chair board director 2 qualification capability director 3 experience audit committee 2 qualification capability director 3 experience 4 4 age number year office etc nomination committee age number year office etc nomination committee determined capable objectively executing management oversight duty suitable determined capable objectively executing management oversight duty director company suitable director company attendance board director 100 1010 nomination committee 100 11 attendance board director 100 1010 audit committee 100 compensation committee 100 44 independent committee outside director 100 33 1212 independent committee outside director 100 33 70 director june 30 2017 noboru naoe eiichiro suhara chair nomination committee member member audit compensation committee committee member independent committee outside director date birth age february 8 1956 date birth age 61 year age july 19 1948 68 year age term office 3 year term office 2 year company share held 15617 company share held 588 apr1978 joined company aug1974 joined mitsubishi pencil co ltd apr2005 deputy general manager prescription drug division company mar 1980 director mitsubishi pencil co ltd jun2005 corporate officer company jun2005 general manager prescription drug division company mar 1982 managing director mitsubishi pencil co ltd apr2007 deputy assignment japan business headquarters company mar 1985 director executive vice president mitsubishi pencil co ltd apr2008 general manager prescription drug division japan business mar 1987 representative director president mitsubishi pencil co ltd headquarters company current jun2010 senior group officer company jun 2015 director company current member compensation apr2011 president eisai japan committee current member independent committee outside jun2011 senior vice president company director current member nomination committee apr2013 corporate officer company jun 2015 outside director yokohama shinko co ltd current apr2013 assigned alliance eisai japan jun 2016 chair nomination committee current oct2013 deputy president oncology hhc unit eisai japan executive director strategy planning department reason appointment director jun2014 director company current member audit committee current mr suhara abundant experience manager global corporation writing material industry well high level insight management reason appointment director excellent supervisory ability company corporate governance guideline call selecting inside director addition constructing board director composed diverse member abundant experience working within company serve member variety specialized knowledge experience etc nomination audit committee point mr naoe gained long experience committee considered factor 1 practical accomplishment knowledge regarding salesrelated business work closest director chair nomination committee member compensation eisais principal stakeholder patient consumer furthermore committee 2 qualification capability director 3 experience 4 obtained considerable knowledge experience related management age number year office etc nomination committee determined service corporate officer addition constructing board director composed diverse member capable objectively executing management oversight duty variety specialized knowledge experience etc nomination suitable director company committee considered factor 1 practical accomplishment director member audit committee 2 qualification capability director 3 inhouse experience 4 age number year office etc nomination committee determined capable objectively executing attendance board director 100 1010 nomination committee 100 management oversight duty suitable director company 77 compensation committee 100 1010 independent committee attendance board director 100 1010 audit committee 100 1212 outside director 100 33 yasuhiko katoh hirokazu kanai chair compensation committeemember nomination committee member audit member independent committee committee outside director date birth age january 28 1960 date birth age 57 year age may 19 1947 70 year age term office 1 year term office 1 year company share held 190 company share held 7305 apr 1973 joined mitsui engineering shipbuilding co ltd apr 1983 joined company apr 2004 ceo mitsui babcock energy limited apr 2003 manager accounting division company jun 2004 director mitsui engineering shipbuilding co ltd assigned mitsui jun 2006 administrator company babcock energy limited stationed united kingdom dec2006 director mitsui engineering shipbuilding co ltd assigned special apr 2007 manager finance accounting division company mission president jun 2010 manager accounting division finance accounting hq jun 2007 representative director president mitsui engineering shipbuilding company co ltd jun 2011 group officer company jun 2013 chairman representative director mitsui engineering shipbuilding co ltd jun 2011 manager accounting division company jun 2016 director company current member nomination jun 2012 parttime corporate auditor sunplanet co ltd committee current member independent committee outside jun 2016 director company current member audit committee director current member compensation committee current apr 2017 director senior advisor mitsui engineering shipbuilding co ltd jun 2017 chair compensation committee current reason appointment director jun 2017 senior advisor mitsui engineering shipbuilding co ltd current company corporate governance guideline call selecting inside director abundant experience working within company serve member reason appointment director audit committee mr kanai obtained considerable knowledge mr kato abundant experience manager global corporation shipping marine industry etc well high level insight experience work related accounting finance well management excellent supervisory ability service group officer addition constructing board director composed diverse member addition constructing board director composed diverse member variety specialized knowledge experience etc nomination variety specialized knowledge experience etc nomination committee committee considered factor 1 practical accomplishment considered factor 1 practical accomplishment director director member nomination committee compensation committee member audit committee 2 qualification capability director 2 qualification capability director 3 experience 4 age 3 inhouse experience 4 age number year office etc number year office etc nomination committee determined nomination committee determined capable objectively executing capable objectively executing management oversight duty suitable management oversight duty suitable director company director company attendance board director 100 88 nomination committee 100 attendance board director 100 88 audit committee 100 99 66 compensation committee 100 66 independent committee outside director 100 33 hirokazu kanai newly appointed director assumed post yasuhiko katoh newly appointed director assumed post 104th ordinary general meeting shareholder held june 17 2016 104th ordinary general meeting shareholder held june 17 2016 attendance meeting board director audit committee indicates attendance meeting board director committee meeting indicates attendance meeting beginning june 17 2016 attendance meeting beginning june 17 2016 71 eisai integrated report 2017 director june 30 2017 tamaki kakizaki daiken tsunoda member audit member audit committee committee member chair independent independent committee committee outside outside director director date birth age date birth age january 16 1961 january 29 1967 56 year age 50 year age term office 1 year term office 1 year company share held 63 company share held 0 apr 2002 associate professor faculty management atomi university apr 1994 admitted tokyo bar association attorney mori sogo law firm currently mori hamada matsumoto apr 2008 professor legal work post graduate course toyo university jan 2001 partner mori sogo law office currently mori hamada matsumoto apr 2012 professor graduate school international social science yokohama mar2003 founder partner nakamura tsunoda law office currently nakamura national university tsunoda matsumoto current jun 2004 outside corporate auditor atlus co ltd apr 2014 professor school law meiji university current sep2004 outside director polaris principal finance co ltd currently polaris capital group jun 2016 director company current member audit committee co ltd jun 2005 outside corporate auditor ines corporation current member independent committee outside jul 2007 outside corporate auditor sealy japan co ltd currently sleep select co director current ltd current jun 2016 outside director mitsubishi shokuhin co ltd current apr 2008 outside corporate auditor mitsui sumitomo insurance group holding incorporated currently msad insurance group holding inc jun 2017 outside auditor japan airport terminal co ltd current apr 2008 outside corporate auditor japan stockholder data service company limited apr 2010 outside director msad insurance group holding inc current reason appointment director mar2012 outside corporate auditor bilcom inc m kakizaki specialist internal control internal audit although apr 2014 outside director culture convenience club co ltd current directly involved management experience serving mar2015 outside corporate auditor bilcom inc current jun 2016 director company current member audit committee current chair outside director another company high level insight management independent committee outside director current excellent supervisory ability thanks extensive research background give deep knowledge corporate internal control corporate governance reason appointment director risk management mr tsunoda legal expert specialist company act although directly involved management served outside director addition constructing board director composed diverse member company rich experience related corporate law giving high variety specialized knowledge experience etc nomination level insight management excellent supervisory ability committee considered factor 1 practical accomplishment addition constructing board director composed diverse member director member audit committee 2 qualification capability variety specialized knowledge experience etc nomination committee director 3 experience 4 age number year office etc considered factor 1 practical accomplishment director nomination committee determined capable objectively executing member audit committee 2 qualification capability director 3 management oversight duty suitable director company experience 4 age number year office etc nomination committee determined capable objectively executing management oversight attendance board director 100 88 audit committee 100 99 duty suitable director company independent committee outside director 100 33 attendance board director 100 88 audit committee 100 99 independent committee outside director 100 33 tamaki kakizaki newly appointed director assumed post daiken tsunoda newly appointed director assumed post 104th ordinary general meeting shareholder held june 17 2016 104th ordinary general meeting shareholder held june 17 2016 attendance meeting board director committee meeting indicates attendance meeting board director committee meeting indicates attendance meeting beginning june 17 2016 attendance meeting beginning june 17 2016 bruce aronson yutaka tsuchiya member nomination committee member compensation committee member independent date birth age committee outside director june 29 1952 65 year age date birth age may 14 1952 65 year age term office 0 year term office 0 year company share held 0 company share held 30663 jun 1978 foreign associate nagashima ohno tsunematsu law firm apr 1975 joined company apr 2001 senior director clinical research planning department clinical research center company sep 1983 associate hill betts nash llp law firm oct 2004 president eisai europe ltd jun 2005 corporate officer company aug 1986 partner hughes hubbard reed llp law firm jun 2006 assigned pharmaceutical business europe company may 2004 visiting associate professor institute business law comparative mar 2008 chairman ceo eisai europe ltd jul 2009 assigned corporate regulatory compliance quality assurance environmental law politics graduate school law politics university safety affair company jul 2009 general manager corporate regulatory compliance quality assurance headquarters company tokyo jun 2010 senior vice president company jul 2004 professor law creighton university school law jun 2011 executive vice president company jun 2011 assigned quality assurance public affair company jun 2010 visiting scholar institute monetary economic study bank jun 2012 assigned quality assurance pr gr company jun 2012 executive vice president representative corporate officer company japan oct 2012 assigned global product emergency management company jul 2013 professor law hitotsubashi university graduate school oct 2012 assigned pr gr company apr 2013 assigned healthcare policy company international corporate strategy current jun 2013 representative corporate officer deputy president company jul 2017 director company current member nomination apr 2014 assigned global value access company jun 2014 representative corporate officer assigned healthcare policy company committee current member compensation committee current dec 2014 representative corporate officer assigned healthcare policy china business company member independent committee outside director current oct 2015 assigned consumer healthcare business company apr 2016 assigned hhc data creation japan asia medical company jun 2017 director company current reason appointment director mr aronson practicing attorney legal academic focus reason appointment director comparative corporate governance although directly involved company aim ensure optimum decisionmaking fairness management clear separation function management oversight business execution management high level insight management excellent board director dedicated management oversight achieve aim supervisory ability thanks extensive research background give company appoints inside director familiar company provide support deep knowledge corporate internal control corporate governance risk practical management board director regard mr tsuchiya experience working abroad also obtained considerable knowledge experience management addition constructing board director composed work well service corporate officer work experience encompasses area including diverse member variety specialized knowledge experience etc pharmaceutical quality assurance public relation government relation healthcare nomination committee considered factor 1 qualification policy rdrelated operation china operation japanese otc productrelated work addition constructing board director composed diverse member variety capability director 2 experience 3 age etc nomination specialized knowledge experience etc nomination committee considered committee determined capable objectively executing factor 1 qualification capability director 2 experience company 3 management oversight duty suitable director company age etc nomination committee determined capable objectively executing management oversight duty suitable director company mr aronson newly appointed director fiscal 2017 mr tsuchiya newly appointed director fiscal 2017 72 corporate officer june 30 2017 haruo naito shaji procida representative corporate officer ceo vice president president coo eisai inc hideki hayashi oncology commercial america representative corporate officer japan business cio teiji kimura japan business hhc solution headquarters chief information officer vice president yasushi okada chief discovery officer neurology business group head neurology tsukuba laboratory discovery medicine creation representative corporate officer cto industry affair china neurology business group business chief talent officer industry affair china business general affair hidenori yabune environmental safety affair vice president kenta takahashi head regional cooperation shutoken headquarters eisai japan senior vice president hiroyuki kato general counsel intellectual property vice president edward stewart geary head medicine development center hhc data creation senior vice president global product emergency management chief medical officer head corporate medical affair headquarters global safety board chair alexander scott gary hendler vice president chief strategy officer neurology business group senior vice president head strategy department neurology business group chief commercial officer oncology business group president emea region masayuki miyajima chairman ceo eisai europe ltd vice president terushige iike president eisai japan senior vice president tatsuyuki yasuno president oncology business group vice president ryohei yanagi corporate planning officer head corporate planning department senior vice president yanhui feng chief financial officer chief ir officer vice president ivan cheung president eisai china holding ltd president eisai china inc senior vice president president neurology business group yoshiteru kato president america region chairman ceo eisai inc vice president president eisai demand chain system takashi owa mitsuaki tanaka vice president chief medicine creation officer oncology business group vice president chief discovery officer oncology business group corporate strategy officer yasunobu kai shohei kanazawa vice president vice president chief planning officer oncology business group japan business strategy head planning department oncology business group president consumer hhc business division api solution lynn kramer masatomi akana vice president chief clinical officer neurology business group vice president chief medical officer neurology business group corporate affair global value access sayoko sasaki hiroyuki kobayashi vice president vice president president asia region chief medical officer japan asia head medical headquarters junichi asatani head neurology medical department medical headquarters vice president chief compliance officer internal control 73 eisai integrated report 2017 compliance risk management eisai defines compliance observance highest legal ethical standard position core management activity contain risk within acceptable level eisai carrying various initiative including establishing developing implementing internal control system well conducting internal audit eisai designates chief compliance officer also corporate officer responsible internal control supervise corporate compliance risk management department promote compliance risk management eisai defines compliance observance highest legal ethical standard position core management activity eisai implement compliance program consists delivering message top management developing code conduct relevant rule conducting educational activity establishing training system well providing consultation service risk management eisai defines risk threat probability action event adversely affect achievement corporate andor organizational objective contain risk within acceptable level eisai carrying various initiative including establishing developing implementing internal control system well conducting internal audit 1 compliance promotion corporate compliance risk management department work compliance department compliance personnel region promote compliance globally compliance promotion activity periodically undergo objective review compliance committee consists external expert lawyer consultant japan overseas furthermore compliance committee provides advice recommendation chief compliance officer stablishment code conduct relevant rule conducting ❶e educational activity foster compliance awareness eisai belief fostering compliance awareness officer employee essential ensuring officer employee always engages corporate activity based compliance reason eisai made revision compliance handbook fiscal 2016 outline eisai network company enw charter business conduct code conduct handbook available 17 language distributed officer employee eisai group handbook revised meet social requirement included change item related human right light enforcement uk modern slavery act compliance handbook eisai group also created compliance card contains contact information compliancerelated consultation service shared officer employee eisai network company japan eisai continues conduct training various mean compliance workshop including designed director officer elearning distribution case study order foster compliance awareness ❷ use compliance counter compliance counter serf point contact whistleblowing system eisai network company set respective company consultationcontact resource officer employee use seek assistance interpreting legal provision finding answer question whether conduct conduct supervisor coworkers conforms compliance policy harassment personal information protection copyright ethic guideline public servant industry selfregulation many topic compliance counter handle japan compliance counter also provides resource whistleblowing system operated outside lawyer contact desk operated external counselor creating environment serf promote compliance ❸ compliance awareness survey compliance awareness survey conducted regularly monitor compliance awareness status activity among employee eisai network company ensure effective use compliance program given result compliance awareness survey fiscal 2015 eisai focused activity increase reliability fiscal 2016 people could use compliance counter peaceofmind 74 company introduction management strategy value creation activity business base esg appendix ❹ prevention bribery corruption based strong determination undertake honest business activity eisai formulated corporate antibribery anticorruption abac policy eisai network company january 2012 policy provides common rule eisai network company dealing external party line effort carry business activity without bribery corruption across eisai network company one concrete initiative eisai introduced abac due diligence system us webbased system receiving response globally common questionnaire possibility bribery corruption sent beforehand company plan newly undertake transaction using system already achieved certain result reducing risk associated new business transaction based thinking riskbased approach system operated giving priority america region includes mexico brazil canada emea region encompasses russia eastern europe china eisai gradually rolling system india asian country additionally eisai moving ahead advanced introduction system overseas subsidiary detects sign potential fraud monitoring accounting financial data ❺ compliancebased promotion eisai conduct ethical promotion globally accordance compliance requirement disclose information payment medical institution patient group accordance japan pharmaceutical manufacturer association jpma guideline regulation guideline country order broad societal understanding corporate activity undertaken based highest ethic setting forth code conduct compliance handbook eisai set forth code conduct compliance handbook distributed employee ensure compliance based promotion following excerpt handbook eisai market promotes pharmaceutical product worldwide provide accurate balanced scientific information promote product us approved applicable regulatory authority offlabel false misleading promotion promotion preapproved drug prohibited may raise legal regulatory product liability issue relevant department must approve content promotional material must avoid improper promotional activity engaged promotional activity expected familiar rule governing promotional activity formulation eisai co ltd code practice march 2012 international federation pharmaceutical manufacturer association ifpma announced ifpma code practice ifpma code code covering marketing activity also interaction healthcare professional medical institution patient organization well promotion medicine line intent ifpma code jpma code practice established implemented jpma eisai member jpma established eisai co ltd code practice line aforementioned code executive employee eisai engage corporate activity aim earning trust society ensuring high level transparency ethic corporate accountability corporate activity involving researcher healthcare professional patient organization disclosure information based transparency guideline eisai formulated guideline accordance transparency guideline relation corporate activity medical institution transparency guideline relation corporate activity patient group established jpma eisai policy ensure transparency relationship medical institution etc japanese httpwwweisaicojppdfsocialdisclosureinfo201508_01pdf guideline transparency relationship company activity patient group japanese httpwwweisaicojppdfsocialdisclosureinfo201304_01pdf disclose payment medical institution healthcare professional patient group accordance aforementioned guideline corporate website disclosure payment medical institution etc healthcare professional japanese httpwwweisaicojpsocialdisclosuredisclosurehtml disclosure payment patient group japanese httpwwweisaicojpsocialdisclosuredisclosure02html similar disclosure required u eu country implemented region accordance local law regulation 75 eisai integrated report 2017 2 risk management promotion accordance company act eisais board director formulated rule preparing necessary system ensuring suitability performance duty corporate officer rule stipulate corporate officer identify risk duty establish develop implement internal control system response corporate officer responsible internal control established enw internal control policy establishing developing implementing internal control system covering eisai network company well implementing initiative containing risk within acceptable level ❶ promoting risk management system response risk risk identified corporate officer department manager control selfassessment csa critical risk evaluating degree risk impact uniformly managed risk management committee large also eisai quickly detects potential risk priority level large continuous monitoring external corporate misconduct risk response prevents risk occurring promptly responding high degree risk impact identified risk evaluated term degree medium medium impact based magnitude inherent risk impact likelihood occurrence level internal control low status establishment development implementation priority level risk response determined risk small management efficiently undertaken low medium high high probability occurrence eisais risk management system board director formulates rule preparing necessary system ensuring suitability performance duty corporate officer monitor status establishment development implementation internal control system corporate officer report corporate officer charge internal control corporate internal risk management committee corporate compliance audit department chaired corporate officer charge internal control office risk management department implement internal audit integrated management riskrelated information provision internal external riskrelated information make recommendation support corporate officer corporate officer corporate officer corporate officer establish develop implement internal control department charge risk management provide support establishment csa control selfassessment person charge promoting csa development implementation internal control promote csa division department ❷ csa control selfassessment one tool used eisai risk management csa csa conducted yearly department manager eisai network company identify evaluate risk structure identified risk dealt workshop others addition csa ensures effectiveness risk management identifying critical companywide risk interview submitting report corporate officer following implementation risk response corporate officer ❸ internal audit activity based international standard internal audit voluntary audit differ audit conducted audit committee accounting audit corporate internal audit department established corporate officer responsible internal control implementing internal audit globally department cooperates internal audit department japan u europe china asia internal audit independently objectively assess whether execution duty corporate officer undertaken appropriately efficiently result reported executive committee audit committee assure highquality audit conform global standard corporate internal audit department undergoes assessment every year external assessment committee composed outside expert accordance standard institute internal auditor international professional association internal auditor based u 76 company introduction management strategy value creation activity business base esg appendix ❹ serious risk measure taken following table outline risk could potentially serious impact eisais business activity measure taken response risk risk included table selection deemed serious based risk assessment risk management committee carry risk assessment compare risk yearonyear focus particularly risk relating information management outsourcing risk outline measure taken potential impact patient health stable eisai working strengthen pharmaceutical product supply result concern quality system line patient need regarding safety quality product due order reliably continuously produce risk relating product raw material manufacturing process supply compliant product safety quality factor confirmed safe effective potential impact company result due accordance ich q10 pharmaceutical product recall suspension sale etc quality system guideline detail please refer page 5859 eisai obligated scientifically evaluate eisai established global notify regulatory authority regarding pharmacovigilance system working adverse event safety precaution ensure product used associated eisais product appropriate manner activity risk relating potential impact patient health due spearheaded safety executive pharmaceutical safety issue safety monitoring activity committee consists safety management side pharmacovigilance provision safety management supervisor key area effect information etc information global safety board consists safety medical evaluation supervisor product detail please refer page 81 potential impact eisais competitiveness eisai set policy including enw andor reputation potential disadvantage confidential information security policy risk relating concerned stakeholder event continues organize training seminar information leak involving confidential technical business ensure confidential information handled management information personal information held properly company also put place company personal information protection system potential serious impact eisais division examine verify suitability operation andor result event outsourcing partner outsourcing research manufacturing selected operation eisai also conduct regular audit risk relating operation outsourced group ensure outsourcing partner carry outsourcing suspended reason event ing operation appropriate manner issue research result manufactured output provided outsourcing partner potential largescale damage plant sale division formulates enw business office facility potential impact continuity plan bcp ensure business risk relating group activity event continue quickly restoredreinstated disaster etc natural disaster earthquake addition bcp measure eisai also carry typhoon accident fire regular review make plan effective potential serious impact local eisai set enw environmental community environment event protection policy established company environmental contamination stemming wide environment safety committee one group facility order discus make decision regarding risk relating potential serious impact result due important matter relating protecting environment factor legal action closure environment individual facility also establish facility etc remedial environmental management system including measure compensation local obtaining iso 14001 carry community environmental activity detail please refer page 84 potential stakeholder sustain eisai compliant standard unexpected loss significant loss evaluating auditing implementing internal confidence company due inaccurate control relation financial reporting financial reporting accordance financial instrument risk relating exchange act applicable legislation financial reporting eisai put place effective internal control system relation financial reporting ensures operated appropriate manner 77 eisai integrated report 2017 human capital initiative human right development working environment occupational safety health providing employee environment maximize capability respect human right based international law placing value united nation human right law universal declaration human right international treaty related civil political right well international treaty related economic social cultural right eisai formulated eisai network company enw charter business conduct encompasses global internal rule compliance handbook summarizing charter compliance handbook set forth fair treatment employee development environment employee work enthusiasm based idea eisai strives follow laborrelated law country operates example term minimum wage appropriate working hour respect human right individuality employee ensure workplace free unjust discrimination form unfair treatment based race gender age physical mental disorder nationality religion sexual orientation marital status presence child circumstance thinking also reflected recruitment human resource development promotion based position respecting protecting human right explicitly stay true attitude tolerating child labor forced labor human trafficking slavery act may compromise dignity respect individual enw business partner eisai become member industrial federation human right tokyo aim promoting understanding global human right issue raising awareness human right company member company proactively take part meetings1 lectures2 events3 initiative discus global trend problem topic within eisai established human right awareness committee chaired chief talent officer committee conduct variety activity enlighten employee mean human right training elearning human right catch phrase based policy promoting awareness human right devised aiming fulfill social responsibility company instilling respect human right part corporate culture eneral assembly international movement form discrimination racism japan committee imadra jc universal declaration human right commemorative gathering tokyo 1 g uman right seminar 2 h uman right festa tokyo 3 h creating good working environment eisai aim create workplace every employee work toward achievement hhc philosophy rewarding sense satisfaction eisai co ltd various working option available employee depending workplace ensure worklife balance flexible work hour discretionary working arrangement addition company provides employee extensive leave shortworking hour beyond legal requirement support life event childcare nursing care recovery injury furthermore volunteer organ donor leave offered encourage employee social contribution activity health consultation industrial physician mental health care service also provided promote well employee endeavor striving create workplace environment enables employee play active role program supporting employee life event selffulfillment pregnancy morning allows expectant employee difficulty working due morning sickness take leave three time sickness leave per pregnancy total 15 day allows employee take leave child third birthday addition maternity leave leave childcare leave available immediately childbirth allows employee family member require caregiving take five day paid leave per caregiving leave year leave one year shorter working allows employee work shorter hour reduction two hour per day childcare caregiving shorter working hour childcare available end march following time childcare child ninth birthday program used flexible working hour program make caregiving adjustment working hour month temporary allows employee preschool age child take five day paid leave per year attend childcare leave sick child vaccination health checkup child allows employee take five day paid leave per year participation volunteer activity volunteer activity involving health care welfare environmental protection led organization social public leave nature allows employee become bone marrow donor take many day paid leave necessary donor leave period registration donor checkup performed bone marrow harvesting 78 company introduction management strategy value creation activity business base esg appendix relationship labor union since establishment eisai co ltd employee considered valuable asset end ensure employee feel ease devoting daily work duty eisai co ltd working maintain fair healthy relationship labor union based mutual trust understanding build good working environment recent year talk labor management led common understanding governmentled reform working style seriously considered eisai co ltd must set changing awareness worker exploring new plan without delay end eisai continues improve working environment instance correcting practice long working hour introducing system allow employee take care family member one work athome day weekly basis based healthy relationship labor management respecting others circumstance eisai co ltd labor union work one achieve common goal ensuring happiness employee development company occupational safety health eisai established eisai network company enw safety health policy based fundamental principle undertaking corporate activity respect human dignity highest priority placed safety health policy stipulate code conduct safety health seven article prepare safety health management plan every year accordance policy sharing fundamental principle among employee carry activity secure safety health aim realizing workplace hurt cause sickness anyone industrial safety health act committee established eisais office japan 50 employee committee periodic discussion occupational safety health held labor union representative furthermore environmental safety committee installed every company order eliminate industrial accident throughout eisai group environmental safety committee set annual plan improve quality activity carry monitoring result issue initiative every six month case industrial accident obligatory submit report shared office order prevent similar accident recurring future similarly major research production facility eisai group outside japan established occupational safety health management system undertaking relevant activity site facility striving raise level occupational safety health appropriately operating respective management system voluntarily continually going pdca cycle furthermore risk assessment carried new facility building based industrial safety health act amendment june 2016 also carried position involve handling chemical substance cooperation industrial physician health insurance association eisai also engages effort help employee stay good health grow even healthier physically mentally fiscal 2016 industrial accident previous year significantly fewer accident subsequently necessitated absence work effort continue seek completely eliminate industrial accident method continually improving management operation repeating plandocheckact pdca cycle eisai network company enw safety health policy fundamental safety health policy eisai group company hereafter enw place safety health top priority promote business operation respecting human life dignity support worklife balance safety health guideline 1 e nw place safety health top priority business operation continuously pursues policy accident injury disaster 2 e nw place safety health top priority stage corporate activity research development production distribution sale product usage disposal 3 e nw construct operates safety health management system promotes operation 4 e nw complies applicable law regulation agreement concerning safety health group company implement voluntary standard exceed minimum standard set forth applicable law regulation agreement 5 e nw actively introduces advanced technology forefront safety technology 6 e nw share fundamental safety health policy implement educational training strengthen specialty workplace progressively continuously 7 e nw actively discloses information policy objective program result concerning safety health 79 eisai integrated report 2017 social relationship capital social contribution activity conducting various social contribution activity beyond scope business operation go without saying eisai contributes life patient product eisai also work earn trust member society good corporate citizen eisai strives contribute society based corporate hhc philosophy beyond scope business operation undertaking program contribute advancement medical science interaction local community naito museum pharmaceutical science health care science institute industry health care science institute established 1990 naito museum pharmaceutical science industry funded donation marking 50th anniversary gifu japan first museum devoted pharmaceutical foundation eisai co ltd aim promoting established 1971 toyoji naito founder progress medical therapy human welfare japan eisai admission free charge visitor view conducting economic survey research related approximately 2000 item selected museum medical therapy pharmaceutical conducting survey collection 65000 material 62000 book research focused rd manufacturing distribution adjacent museum medicinal herbal garden subject related pharmaceutical promoting 700 different type medicinal herb tree grown academic research survey related pharmaceutical addition 50 type endangered medicinal herb associated science addition publishing healthcare cultivated preservation biodiversity fiscal 2016 society periodical outlining research achievement 40480 people visited museum institute organizes research convention symposium july 21 2016 orange café opened museum provide venue discussion among specialist venue gathering dementia patient family httpwwwikenorgenglishmessagehtml well resident local community café established based concept place affected dementia also gather full eisai hhc hotline good cheer spirit café open 21st month eisai employee participate café event hold april 1990 eisai co ltd established customer hotline conversation various participant patient consumer healthcare provider ahead company industry afterward hotline renamed eisai hhc hotline responding inquiry wider range product tollfree hotline available 365 day year february 2017 number inquiry exceeded 2 million total mission eisai hhc hotline relieve concern patient healthcare provider provide precise information proper use eisai product addition inquiry opinion hotline shared within company utilized development improvement product well provision information service order address diverse potential need patient healthcare provider httpwwweisaicojpinquiryproducthotlinehtml japanese httpwwweisaicojpmuseumenglishindexhtml total number inquiry eisai hhc hotline exceeded naito foundation 2 million million 2 naito foundation established 1969 eisai founder toyoji naito contribute advancement science human welfare encouraging basic research natural science related prevention treatment 1 disease year foundation provides financial support leadingedge researcher fiscal 2016 foundation provided financial support totaling 54813 million 242 project including science promotion prize science 0 incentive grant 1990 1995 2000 2005 2010 2016 fiscal year httpswwwnaitoforjpen 80 social relationship capital initiative pharmaceutical product safety side effect fulfilling responsibility pharmaceutical company pharmaceutical product safety japan risk management plan jrmp side effect information pharmaceutical value pharmaceutical product fully deployed risk management plan rmp pharmaceutical proper usage upon correctly understanding risk identifies issue discussion concerning safety benefit pharmacovigilance pharmaceutical product individual pharmaceutical product addition document safety monitoring defined science initiative reducing risk survey information action relating detection assessment understanding gathering product safety monitoring activity prevention adverse effect drugrelated utilizing postmarketing surveillance early postmarketing problem pharmacovigilance indispensable properly phase vigilance well providing additional information evaluating balance risk benefit healthcare professional eisai operating jrmp since pharmaceutical product 2013 order promote proper use pharmaceutical eisai work ensure product used properly product country around world providing updated product information healthcare professional patient timely manner updating continually collect evaluate initiative counterfeit drug product safety information worldwide spanning initial stage pharmaceutical product development post globalization development distribution launch pharmaceutical product accelerates remarkably report increasing risk counterfeit drug developing country emerging country also developed country addition regular qualityassurance activity eisai implementing global product security activity ensure product reliably delivered patient collaboration regulatory authority company industry industry group eisai actively participating monitoring establishing measure counterfeit drug illegal distribution drug actual case detected eisai responds quickly undertaking investigation taking various legal step assuring stable supply effort led product security execution committee prevent counterfeit drug illegally distributed drug reaching frontlines medical care necessary accurately ascertain actual state global safety information management system drug distribution ensure proper safe supply use pharmaceutical reason initiative eisai established global pharmacovigilance system ensure traceability pharmaceutical distribution product centered safety executive committee implemented region worldwide country mainly composed person responsible safety region already established regulation eisai proactively management main region global safety board participating type initiative promoted regulatory mainly composed person responsible safety authority pharmaceutical company frontlines evaluation product system eisai medical care also responding quickly regulation prescribed global standard uniform product safety country china india looking ahead eisai profile making response thoroughly assure start internal project region proceed proper usage product discussion issue preparation making quickest possible response concerning pharmaceutical safety consider latest u europe traceability system part information healthcare regulation country around social infrastructure scheduled introduction world 81 eisai integrated report 2017 social relationship capital eisais partnership initiative aiming improve business efficiency productivity leveraging partnership eisai belief partnership extremely effective mean improving business efficiency productivity engage diverse array collaboration model partnership broadly divided partnership aimed creating innovation therapeutic area focus partnership aimed expanding access medicine eisai continue make effective use partnership endeavor fully satisfy patient need around world detail agreement end may 2017 partnership aimed creating innovation therapeutic area focus neurology area arena pharmaceutical inc u corporation novartis ag switzerland corporation change licensing agreement exclusive commercialization license agreement worldwide development manufacturing sale antiobesity agent lorcaserin hydrochloride generic name name antiepileptic agent inovelonbanzel generic name rufinamide u belviqbelviq xr hereafter belviq concluded orion corporation finland corporation december 2016 based change agreement eisai acquired development marketing right belviq arena 1 comprehensive marketing agreement concerning parkinson disease pharmaceutical treatment eldepryl generic name selegiline hydrochloride china corporation 2 marketing distribution agreement concerning parkinson disease bialportela ca sa portugal treatment comtan generic name entacapone stalevo license marketing copromotion antiepileptic agent zebinix levodopaentacaponecarbidopa threecompound combination agent generic name eslicarbazepine acetate europe china bioarctic ab sweden corporation pfizer inc u corporation exclusive license agreement worldwide research development copromotion pain treatment lyrica generic name pregabalin manufacturing sale antibeta amyloid aβ protofibril antibody japan ban2401 treatment alzheimers disease purdue pharma lp u corporation biogen inc u corporation agreement global codevelopment copromotion dual orexin 1 j oint developmentjoint sale promotion related betasite amyloid receptor antagonist lemborexant development code e2006 precursor proteincleaving enzyme bace inhibitor e2609 sysmex corporation japan corporation antibetaamyloid abeta protofibril antibody ban2401 2 cquisition option right related joint developmentjoint sale comprehensive nonexclusive collaboration agreement creating new promotion antialzheimers agent antiaβ antibody aducanumab diagnostics dementia area biib037 antitau antibody development biogen inc sunovion pharmaceutical inc u corporation chugai pharmaceutical co ltd japan f hoffmanla roche ltd switzerland corporation exclusive license development marketing antiinsomnia agent lunesta generic name eszopiclone japan acquisition right two company manufacturing active pharmaceutical ingredient api japan insomnia treatment john hopkins university u academia anaesthesia induction agent flunitrazepam eisai product name silece collaboration agreement neurological drug discovery research chugai product name rohypnol well marketing authorization held chugai rohypnol japan keio university japan academia sumitomo dainippon pharma co ltd japan corporation implementation new joint research discovery development new drug targeting dementia license agreement manufacturing sale antiepileptic agent zonegran generic name zonisamide europe asia university college london ucl uk academia jcr pharmaceutical co ltd japan corporation 1 neurodegenerative disease field encompassing biomarker research carry joint research includes 1 research concerning agreement feasibility study applying jcrs bloodbrainbarrier neuroinflammation 2 research concerning neurovascularmitochondria bbb penetration technology jbrain cargo discovery new 3 research concerning proteostasis treatment 2 agreement form major drug discovery alliance develop new meiji seika pharma co ltd japan corporation therapeutic neurological disease license agreement commercialization safinamide development code me2125 japan asia currently clinical development japan treatment parkinson disease 82 company introduction management strategy value creation activity business base esg appendix oncology area epizyme inc u corporation prism pharma co ltd japan corporation partnership development commercialization anticancer joint research development concerning cbpcatenin inhibitor e7386 therapy targeting ezh2 including e7438 within japan well others regarding right first negotiation licensing right asia symbio pharmaceutical limited japan corporation halozyme therapeutic inc u corporation 1 exclusive license joint development marketing anticancer collaboration agreement evaluating halaven firstline her2negative agent treakisymsymbenda generic name bendamustine japan advanced breast cancer combination halozymes investigational 2 exclusive development marketing license singapore south new drug pegph20 pegylated recombinant human hyaluronidase korea helsinn healthcare sa switzerland corporation license antiemetic agent aloxi generic name palonosetron area gastrointestinal disease others u canada transferred following acquisition mgi pharma inc corporation abbvie deutschland gmbh co kg germany january 28 2008 development sale copromotion fully human antitnfα huya bioscience international llc u corporation monoclonal antibody injectable agent humira generic name adalimumab acquisition exclusive license develop market oral histone japan taiwan south korea ea pharma abbvie undertake co deacetylase hdac inhibitor hbi8000 japan south korea thailand promotion indication area gastrointestinal disease ulcerative malaysia indonesia philippine vietnam singapore colitis crohn disease intestinal bechets disease corporation ajinomoto co inc japan corporation merck co inc kenilworth nj usa agreement joint research combination therapy merck co agreement integrating absorption type split eisais gastrointestinal inc kenilworth nj usa antipd1 therapy pembrolizumab disease treatment business ajinomoto pharmaceutical co ltd eisais anticancer agent lenvima generic name lenvatinib halaven establishment ea pharma co ltd generic name eribulin corporation minophagen pharmaceutical co ltd japan novartis ag switzerland corporation exclusive right development marketing liver diseaseallergic agreement novartis pharmaceutical corporation u co disease agent stronger neominophagen c generic name glycyrrhizic promotion lenvima combination everolimus u acid combination preparation glycyron tablet generic name treatment patient advanced renal cell carcinoma glycyrrhizic acid combination tablet euroasian country product yet sold well exclusive first negotiation right orion corporation finland corporation exclusive marketing right china euroasian country product already sold comprehensive marketing agreement concerning orion breast cancer drug fareston generic name toremifene citrate china university tsukuba japan academia agreement industryacademia joint research development new drug inflammatory bowel disease use biomarkers partnership aimed expanding access medicine access accelerated global partnership medicine malaria venture mmv switzerland nonprofit publicprivate partnership participation multistakeholder global partnership advance access noncommunicable disease ncds prevention treatment care agreement joint research development new antimalarial drug low lowermiddle income country research institution fundação oswaldo cruz fiocruz brazil broad institute u research institute identify research development collaboration project targeting eisai 1 joint research aimed development new treatment chaga developed compound treatment malaria ntds disease malaria conduct joint research development 2 concluded new jointresearch agreement develop new hospital university kentucky u antimalarial medicine based antimalarial drug target joint research team identified 2016 agreement joint research aimed developing new antimalarial agent drug neglected disease initiative sabin vaccine institute u research institute dndi switzerland notforprofit rd organization agreement joint research development new vaccine chaga 1 collaboration licensing agreement new drug development disease chaga disease eumycetoma 2 participation drug discovery booster consortium formed dndi tuberculosis drug accelerator tbda global partnership aim accelerating discovery new drug leishmaniasis participation global partnership aimed creating innovative new drug chaga disease tuberculosis global health innovative technology fund world health organization switzerland un agency ghit fund japan nonprofit publicprivate partnership agreement providing free charge dec diethylcarbamazine tablet participation publicprivate partnership aimed bringing japanese treatment lymphatic filariasis participation partnership innovation accelerate development new medicine cure infectious providing lymphatic filariasis diagnostic kit free charge endemic disease developing world area liverpool school tropical medicine uk academia world intellectual property organization university liverpool uk wipo switzerland un agency 1 agreement joint research creating wolbachia inhibitor new antifilarial agent participation consortium sponsored wipo promoting 2 agreement joint research developing antimalarial drug development new drug tropical disease macrofilaricide drug accelerator global partnership participation global partnership aimed developing new drug filariasis especially river blindness 83 eisai integrated report 2017 natural capital business consideration global environment eisai conduct business operation seeking coexistence global environment based eisai network company enw environmental protection policy employee recognize importance environmental protection incorporate environmental perspective working solve social issue promoting business expansion country across world eisai fulfill corporate social responsibility focusing reducing environmental impact stage business developing management system protecting global environment eisai established companywide environment safety business location acquired iso14001 certification committee decisionmaking body deliberation kawashima plant japan kashima plant japan ea pharma important environmental protection issue moreover eisai fukushima office research institute head office japan develops management system office suzhou plant china vizag plant india effort facilitate environmental activity serious problem detected external environmentrelated major production base japan overseas engage review agency fy2016 0 activity based acquisition iso14001 check validity environmental management number administrative measure lawsuit relating environment system external review addition observing fy2016 0 environmentrelated law ordinance agreement environmental communication periodically conduct internal environmental audit publication environmental report organizing local meeting organization specializing internal auditing identify administrative committee meeting others solve issue formation lowcarbon society aiming reduce domestic co2 emission 23 compared fiscal 2005 fiscal 2020 eisai promoting initiative formation lowcarbon eisai co2 emissions2 society help solve problem climate change eisai co2t overseas operation site participating commitment low carbon society 200000 eisai group japan initiated federation pharmaceutical manufacturer 160736 163782 association japan fpmaj eisai group japan 153952 150000 145250 implementing relevant initiative based medium 139015 131282 123135 120536 118943 term plan reduction co2 emission specifically aim reducing domestic co2 emission 23 compared 100000 fiscal 2005 fiscal 2020 fiscal 2016 even though domestic co2 emission increased following increased number production 50000 research base due establishment ea pharma kawashima plant drastically reduced co2 emission 0 taking action proactively introducing energysaving 2008 2009 2010 2011 2012 2013 2014 2015 2016 fy equipment improving operation result total co2 emission slightly reduced fiscal 2016 compared 2 emission business activity office outside japan vehicle sale use included previous year domestic co2 emission fiscal 2016 reduced 3311 compared fiscal 2005 furthermore revenue per co2 emission one eco revenue co2 emissions3 efficiency index increasing recent year 500 result medium longterm effort reduce co2 emission 400 455 453 395 357 366 300 domestic co2 emission reduction target 23 reduction compared fiscal 2005 200 fiscal 2020 100 domestic co2 emission fiscal 2016 result 0 331 reduction1 compared fiscal 2005 fy2012 fy2013 fy2014 fy2015 fy2016 1 carbon emission factor based use electricity assumed 3 consolidated revenue million yen global co2 emission co2t 0403tco2mwh evaluation eisai group target 84 company introduction management strategy value creation activity business base esg appendix establishment recyclingoriented society zero emission achieved japan nine consecutive year eisai conducting waste disposal three goal mind total waste ratio amount waste sent landfill japan reduce amount waste generated increase rate recycling decrease amount waste sent landfill 10000 total waste 25 also sort waste recycling select best waste disposal amount waste sent landfill total waste 9000 contractor possible timely manner furthermore working process recycling value market 8000 7410 20 reduce disposal cost fiscal 2016 domestically attained zero 7000 6555 6280 emission indicates ratio amount waste 6000 15 sent landfill total waste less 1 nine 4917 5000 consecutive year 4001 079 3481 4000 10 2935 waste reduction target japan 3000 045 050 050 continuation zero emission amount waste 043 2000 035 05 sent landfill total waste 1 1000 028 fiscal 2016 result attained nine 0 2010 2011 2012 2013 2014 2015 2016 00 consecutive year fy data revised due recalculation handling risk water shortage efficient use water resource recent year number region suffering global water consumption amount wastewater severe water shortage due climate change thousand ｍ3 water consumption environmental change increasing worldwide 4500 amount wastewater importance effective use water resource rising year 4000 year 3786 3820 handle risk water shortage eisai try secure 3562 3500 3453 3225 3323 quality water discharged plant laboratory 3125 3147 2948 perform regular measurement ensure amount 3000 2770 2693 pollutant emission domestic water 2446 2500 standard defined water pollution control law agreement pollution prevention also committed 2000 reducing water consumption drainage facilitating 1500 reuse water result water consumption drainage facility japan decreasing recent 1000 year 500 also result internal research indicate site eisais plant laboratory situated high 0 risk area would force suspend operation due 2011 2012 2013 2014 2015 2016 fy water shortage near future rated cdp climate change report 2016 highest rating among company health care sector japan 2016 cdp evaluation system rated eisai equivalent leadership level cdp evaluation system evaluates status implementation company environmental management activity scale one eight four different level including leadership management recognition information disclosure leadership highest level rated company classified highest rating japanese health care sector five company achieved also see following link cdp information energysaving activity may lead reduction greenhouse gas emission httpswwwcdpneten formerly known carbon disclosure project nonprofit organization based london run collaboration institutional investor request information relating climate change water forest company top ranking market capitalization principal country discloses information government investor see environmental report detailed information environmental activity httpwwweisaicomirannualindexhtml 85 eisai integrated report 2017 financial capital consolidated financial highlight result fiscal 2016 achieved increase profit fiscal 2016 secured financial integrity balancing stable dividend strategic investment billion yen reference data billion yen financial indicator ifrs fy2016 fy2015 fy2014 fy2013 financial indicator jgaap fy2013 fy2012 fy2011 fy2010 fy2009 fy2008 fy2007 income statement item income statement item revenue 5391 5479 5485 5995 net sale 6004 5737 6480 7689 8032 7817 7343 cost sale 1959 1945 1936 1947 cost sale 1882 1741 1734 1678 1607 1525 1188 gross profit 3432 3535 3549 4048 gross profit 4122 3996 4746 6011 6424 6293 6155 research development expense 1172 1223 1319 1363 research expense development 1305 1204 1251 1450 1791 1561 2254 selling general administrative expense 1749 1928 1945 2033 selling expense general administrative 2105 2087 2537 3430 3769 3814 3723 income 136 177 10 41 expense 56 41 11 28 operating profit 591 519 283 664 operating income 711 705 957 1131 864 918 177 profit year 422 550 435 385 ordinary income 649 656 900 1052 797 826 189 profit year attributable owner parent 394 549 433 383 net income loss 330 483 585 674 403 477 170 comprehensive income 368 165 1142 845 year fiscal 2017 eisai clarified definition research development expense order accurately reflect condition business resulted portion expense relating medical affair activity creation provision scientific evidence health care provider apportioned research development expense figure fiscal 2016 revised restated reflect change cash flow statement item cash flow statement item net cash operating activity 759 956 760 913 net cash operating activity 857 732 906 1232 1079 1050 732 net cash investing activity 286 67 188 209 net cash investing activity 262 217 26 588 698 550 4764 net cash financing activity 354 729 597 1151 net cash financing activity 1148 818 780 680 492 310 3754 free cash flow 820 811 604 794 free cash flow 664 545 714 1003 529 593 4159 free cash flow net cash operating activity capital expenditure cash basis financial position item balance sheet item total asset 10308 9740 10538 9738 total asset 9455 9902 10047 10463 11019 11482 11239 equity attributable owner 5846 5737 5987 5263 shareholder equity 5068 4694 4168 4042 4159 4280 4489 parent noncontrolling interest 180 32 33 31 total liability 4282 3972 4518 4444 revenue operating profit profit year free cash flow billion yen billion yen attributable owner parent billion yen 5995 664 billion yen 820 5485 5479 5391 549 794 811 591 519 433 383 394 604 283 fy2013 fy2014 fy2015 fy2016 fy2013 fy2014 fy2015 fy2016 fy2013 fy2014 fy2015 fy2016 fy2013 fy2014 fy2015 fy2016 86 company introduction management strategy value creation activity business base esg appendix reference data managerial index ifrs fy2016 fy2015 fy2014 fy2013 managerial index jgaap fy2013 fy2012 fy2011 fy2010 fy2009 fy2008 fy2007 ratio rd expense ratio rd expense net sale 217 223 241 227 217 210 193 189 223 200 307 revenue return equity attributable 68 94 77 76 return equity roe 68 109 143 164 96 109 34 owner parent roe return sale ratio 78 100 79 64 return sale ratio 55 84 90 88 50 61 23 leverage time 18 17 18 19 leverage time 19 21 24 26 26 27 25 total capital turnover ratio total capital turnover ratio 05 05 05 06 06 06 06 07 07 07 08 time time ratio equity attributable 567 589 568 540 shareholder equity ratio 536 474 415 386 377 373 399 owner parent net debt equity ratio net der 1 005 001 006 014 net debt equity ratio net der time 014 027 038 049 062 063 064 time dividend equity attributable 74 73 76 85 dividend equity doe 88 96 104 104 101 91 74 owner parent doe2 dividend payout ratio dpr 1090 780 990 1118 dividend payout ratio dpr 1298 886 731 634 1059 837 earnings per share basic eps 1376 1922 1516 1341 earnings per share eps yen 1156 1694 2053 2365 1416 1673 598 yen dividend per share dp yen 1500 1500 1500 1500 dividend per share dp yen 1500 1500 1500 1500 1500 1400 1300 1 net debt equity ratio net der interestbearing debt cash cash equivalent time deposit exceeding 3 month equity attributable owner parent 2 dividend equity attributable owner parent doe dividend payout ratio dpr x return equity attributable owner parent roe statement income achieved increase profit increase recorded following growth lenvima anticancer agent product name renal cell carcinoma indication europe kisplyx fycompa antiepileptic agent well contribution newly added consolidated subsidiary ea pharma co ltd group revenue fiscal 2016 finished overall 539097 million 16 year year due part impact national drug price revision japan foreign currency fluctuation segment revenue group japan pharmaceutical business asia pharmaceutical business increased similarly local currency basis overseas pharmaceutical business also achieved growth operating profit totaled 59064 million 137 year year owing improved performance efficiency operation well oneoff income following acquisition ea pharma share gain bargain purchase receipt milestone payment progress joint rd project profit year came 42246 million 233 year year owing reduced tax expense following transfer share u subsidiary previous fiscal year profit year attributable owner parent came 39358 million 284 year year statement financial position secured financial integrity total asset end fiscal year amounted 1030764 million 56777 million end previous fiscal year asset held sale decreased following transfer sannova co ltd countered increase total asset following acquisition ea pharma co ltd total liability end fiscal year amounted 428173 million 31014 million end previous fiscal year despite decrease liability directly related asset held sale following transfer sannova co ltd part due increase total asset following acquisition ea pharma co ltd total equity end fiscal year amounted 602591 million 25762 million end previous fiscal year due increase noncontrolling interest capital surplus following acquisition ea pharma co ltd result ratio equity attributable owner parent 567 22 percentage point end previous fiscal year furthermore net debt equity ratio net der end fiscal year improved 006 percentage point end previous fiscal year 005 net cash position statement cash flow secured free cash flow exceeding annual dividend payment 42905 million net cash provided operating activity amounted 75851 million 19766 million previous fiscal year net cash used investing activity amounted 28596 million outflow 21896 million previous fiscal year net cash inflow acquisition sale subsidiary 19346 million 6459 million respectively capital expenditure etc resulted inflow 6102 million net cash used financing activity amounted 35440 million 37504 million previous fiscal year amount dividend paid 42905 million result cash cash equivalent end fiscal year stood 81953 million 836 million end previous fiscal year 87 eisai integrated report 2017 esg index aiming sustainable increase corporate value eisai publishes social responsibility index esg environment social governance index stakeholder make comprehensive assessment corporate activity objective viewpoint scope data eisai group eisai co ltd group company outside japan eisai co ltd eisai group japan eisai co ltd group company japan data subsidiary business transferred included date transfer completed corporate governance compliance index index period fy2014 fy2015 fy2016 number director fiscal year end 11 11 11 number outside director fiscal year end 7 7 7 ratio outside director director fiscal year end 636 636 636 ratio female director director fiscal year end 91 91 91 number corporate officer fiscal year end 22 25 27 ratio female corporate officer corporate officer fiscal year end 91 80 148 average age corporate officer fiscal year end 531 536 529 director internal fiscal year end 114 million 113 million 113 million remuneration base salary director outside fiscal year end 76 million 74 million 74 million bonus retirement benefit corporate officer fiscal year end 976 million 1310 million 1247 million number time offered annually 56 47 62 number time compliance number executive training course annually 2 2 2 training offered total participant annually approx 5000 approx 4600 approx 5800 number time human right number time offered annually 28 30 34 training offered participant annually 2405 5001 5457 number case subject investigation authority due violation anticorruption act fiscal year end 0 0 0 number employee disciplinary dismissal due violation anticorruption act fiscal year end 0 0 0 1 fine penalty cost settlement related violation anticorruption act fiscal year end 0 0 0 1 u foreign corrupt practice act fcpa uk bribery act unfair competition prevention act japan etc environmental index index period fy2014 fy2015 fy2016 amount co2 emission annually 139015t 120536t 118943t amount electricity consumption annually 181057mwh 161927mwh 165417mwh amount waste generated annually 4001t 3481t 2935t amount chemical substance handled subject prtr system annually 499t 476t 258t wasterecycling rate annually 506 577 628 number administrative penalty litigation related environment annually 0 0 0 social index involvement patient index period fy2014 fy2015 fy2016 number pending prescription drug japan fiscal year end 1 0 3 application overseas fiscal year end 2 4 3 1 number prescription drug japan fiscal year end 4 3 1 approved overseas fiscal year end 4 4 3 number patent number patent application annually 87 65 55 number inquiry hhc hotline annually 91286 97444 90742 number inquiry via online inquiry form annually 739 719 749 number complaint concerning product quality annually 336 314 323 number product complaint committee pcc meeting held annually 12 12 12 hospital fiscal year end 5739 5732 5730 clinic fiscal year end 81723 79232 77735 dispensing pharmacy fiscal year end 11103 10794 10650 number customer drugstore etc fiscal year end 96683 95582 97577 2 distributor fiscal year end 78 88 87 vendor fiscal year end 232 224 227 1 includes additional indication formulation 2 includes partner company handle food item 88 company introduction management strategy value creation activity business base esg appendix involvement society index period fy2014 fy2015 fy2016 roundtable discussion number discussion held annually 1 1 1 community neighboring eisai co ltds domestic production site number people attendance annually 11 11 11 amount fund donated annually 2073 million 2602 million 2118 million amount tax paid annually 4628 million 5764 million 14095 million visitor naito museum pharmaceutical science industry annually 35705 36325 40480 number participant plant tour annually 3178 2443 2456 involvement shareholder index period fy2014 fy2015 fy2016 number shareholder fiscal year end 66190 59996 62335 number share issued fiscal year end 296566 thousand 296566 thousand 296566 thousand percentage holding foreign company etc fiscal year end 309 289 275 percentage holding individual others fiscal year end 974 971 973 return equity roe attributable owner parent annually 77 94 68 dividend payout ratio dpr annually 990 780 1090 dividend equity doe attributable owner parent annually 76 73 74 total dividend paid annually 42836 million 42889 million 42917 million dividend per share annually 150 150 150 involvement employee index period fy2014 fy2015 fy2016 number employee fiscal year end 10183 9877 10452 japan fiscal year end 4712 4523 5009 america north central fiscal year end 1745 1316 1320 south america number employee region emea europe middle east fiscal year end 893 913 983 africa russia oceania china fiscal year end 1607 1875 1909 asia excluding japan fiscal year end 1226 1250 1231 china total fiscal year end 3583 3577 3508 male fiscal year end 2845 2838 2775 number employee female fiscal year end 738 739 733 management fiscal year end 1359 1370 1389 number temporary employee fiscal year end 215 136 156 ratio temporary employee total employee fiscal year end 57 37 43 ratio woman management role total management fiscal year end 46 47 52 average age fiscal year end 437 441 448 total fiscal year end 194 199 204 1 average year employment malefemale fiscal year end 203159 208162 214169 turnover rate annually 14 26 31 number user nursing care leave caregiver leave short annually 1701 2020 2220 working hour system nursing care number user shortterm nursing care leave annually 132 150 165 total annually 90 95 89 number user childcare leave malefemale annually 189 293 089 number user short working hour system childcare annually 73 93 80 average annual salary according annual security report annually 10403 thousand 10939 thousand 10389 thousand personal development expense per employee annually 175800 198400 210200 12 percentage employee disability annually 256 253 265 total annually 14 105 55 number new employee per year malefemale annually 122 7035 3421 1 normal working hour per person per year annually 1895 1887 1879 average monthly hour overtime annually 12 hour 11 minute 9 hour 11 minute 8 hour 34 minute per nonmanagement employee number workrelated accident annually 7 13 15 frequency workrelated injury employee contractor annually 00 0290 00 result 4 day work lost number workrelated fatality employee contractor annually 00 00 00 number case workrelated employee contractor annually 00 00 00 occupational illness percentage employee employee annually 9975 9986 9948 undergo health check family member annually 7445 7116 8057 3 average number paid vacation day taken annually 121 121 124 per nonmanagement employee 1 based number fulltime eisai co ltd employee 2 personal development expense include training studying abroad participation academic conference 3 health check eligibility includes dependent spouse nondependent family member aged 40 older 89 eisai integrated report 2017 fundamental knowledge terminology pharmaceutical industry healthcare system country healthcare system mechanism pricing reimbursement pharmaceutical differ greatly country country section contains brief summary healthcare system japan u england germany france china information included section supplemental assist understanding business operation management strategy cannot guarantee accuracy impartiality information assembly drug listed national health 1 japan insurance drug price list additionally accordance 1 healthcare system characteristic revision medical payment system basically listed drug healthcare system japan social insurancebased price must revised every two year based drug public health insurance system citizen required price calculation rule enroll implemented 1961 currently divided employee insurance unionmanaged health insurance japan 2 u health insurance associationmanaged health insurance 1 healthcare system characteristic mutual aid association etc based one occupation u private health insurance norm public national health insurance based one place residence healthcare system limited medicare medicaid advanced elderly medical service system childrens health insurance program chip medicare senior citizen 75 year age required join premium tax funded insurance program run federal every citizen must enroll one three system pay government senior citizen 65 disabled people insurance premium system primarily funded 65 patient severe renal failure medicaid tax insurance premium enrollee business owner funded assistance program operated state government government also making contribution national treasury lowincome individual regional general rule patient cover 30 incurred patient protection affordable care act medical fee child yet started compulsory ppaca passed obama administration uninsured education cover 20 senior citizen age 70 population dropped 10 based ppaca 75 cover 20 30 depending income company certain size required offer health senior citizen 75 cover 10 30 depending insurance employee general rule individual income additionally ensure medical expense burden required enroll insurance program facing penalty become onerous high cost medical insurance system limit outofpocket expense 2 mechanism pricing pharmaceutical way citizen gain access sophisticated medical service pharmaceutical company may set price based benefit kind paying fixed amount general rule discretion however negotiate system applied receiving treatment enter contract pharmacy benefit manager pbms medical organization japan insurance intermediary handle prescription drug social insurancebased enrollee contribute insurance premium receive benefit component health plan primarily drug benefit return listed formulary list determines insurance echanisms pricing reimbursement pharmaceutical 2 reimbursement japan order pharmaceutical product claimed 3 mechanism reimbursement pharmaceutical health insurance must first listed national generally pharmaceutical company sell pharmaceutical health insurance drug price list serf wholesaler supply pharmacy product list price list drug price used medical reimbursement insurance company pharmacy organization pharmacy make insurance claim handled pbms pbms serve intermediary prescribed medicine fixed national level insurance company pharmacy insurance general rule determined based brand formulation reimbursement pharmaceutical company also conclude specification drug price determined minister contract pbms product included health labour welfare based drug price calculation formulary rule stipulated ministry document drug price health insurance company use pbm formulary calculation standard drug price calculation rule reference determining reimbursement coverage judged approved central social insurance medical copayment insurance plan one council chuikyo advisory organization minister drug formulary largely impact number prescription health labour welfare hold right determine outofpocket expense patient fixed drug price paid medical organization health insurance general rule price new drug 3 england added list four time year within 6090 day 1 characteristic healthcare system regulatory approval pharmaceutical company submits based national health service nh act passed request listed regulatory authority 1946 government established public healthcare system chuikyos drug pricing organization made expert idea providing free medical service citizen various background including medical science pharmaceutic nh us taxation primary source funding operating health economics evaluate request term taxbased system systematically provide necessary various field draw drug price calculation draft service within budget addition private draft deliberated approved chuikyos general insurance program cover treatment private medical 90 company introduction management strategy value creation activity business base esg appendix facility medical expense arzneimittelmarktneuordnungsgesetz first line treatment second line treatment distinctly pharmaceutical market reorganisation act amnog separated exception emergency situation came effect 2011 amnog originator general practitioner gps provide first line treatment drug released germany must undergo additional patient undergo second line treatment beyond based benefit assessment conducted gemeinsamer introduction gp private insurance program bundesausschuss federal joint committee gba based seldom provide benefit first line treatment since additional benefit assessment level assigned gba largely covered nhss gps price negotiation conducted gkvspitzenverband 2 mechanism pricing reimbursement pharmaceutical national association statutory health insurance fund english government association british general rule reimbursement price determined pharmaceutical industry agreement called within year drug launch hand pharmaceutical price regulation scheme pprs pharmaceutical deemed offer recognizable additional pprs profit ratio participating pharmaceutical benefit additional benefit cannot proven company regulated within regulated profit range reference pricing applied drug assigned may freely set price additionally overall cost reimbursement price based cheapest equivalent acceptable growth level originator drug bought pharmaceutical including generic drug nh participating pharmaceutical company agreed pharmacy reimbursed insurance company based upon beforehand expense exceeding amount reimbursement price must paid pharmaceutical company ministry drug deemed offer additional benefit health pharmaceutical company participating pprs often concern profitability leading case must set price based statutory scheme however commercial distribution suspended germany however based health service medical supply cost act based arzneimittelversorgungsstärkungsgesetz april 2017 even company whose drug priced pharmaceutical care strengthening act amvsg enacted statutory scheme requested pay excess amount may 2017 flexible negotiation reimbursement department health pprs price allowed product 3 use pharmaceutical nh reference pricing pharmaceutical product divided reference price national institute health care excellence nice group maximum limit reimbursement price based factor efficacy mechanism action organization jurisdiction ministry health provides guideline diagnosis conduct technology appraisal specific medical technology including pharmaceutical 5 france provides recommendation pharmaceutical 1 characteristic healthcare system technology nh employ recommendation france citizen required enroll health insurance classified 5 category recommended optimized 90 citizen enrolled standard public health research recommended recommended use insurance program run caisse nationale de lassurance cancer drug fund cdf order pharmaceutical product maladie de travailleurs salariés french national health evaluated nice used nh appraisal insurance fund salaried worker also special recommended required nice appraisal system selfemployed civil servant national rail greatly impact number prescription product employee public corporation employee well however even pharmaceutical recommended agricultural benefit system agricultural worker patient nice still obtained patient access scheme freedom choice doctor medical institution negotiation additional commercial term private furthermore 92 insurees also enrolled contract setting upper limit sale discount supplementary medical insurance mutual aid association obtained used nh beneficial association voluntary insurance order receive cdf due complaint doctor patient use anticancer benefit outofpocket expense covered public drug limited nice appraisal new mechanism called cdf health insurance introduced 2011 till march 2016 helped improve access medicine recommended evaluated nice july 2016 2 mechanism pricing reimbursement pharmaceutical new anticancer drug evaluated nice nice requires additional reimbursement rate price determined based data reaching conclusion recommended recommended nice recommends product use cdf generally 2 year medical benefit assessment smr improvement nice reevaluates product medical benefit assessment asmr carried commision de la transparence ct haute autorité 4 germany de santé national authority health union nationale 1 characteristic healthcare system de caisses dassurance maladie national union health 2009 became compulsory citizen enroll insurance fund uncam set reimbursement rate either public private health insurance citizen whose gross 65 30 15 0 based ct smr assessment income certain amount retiree unemployed furthermore irreplaceable particularly expensive must enroll gesetzliche krankenversicherung statutory medication anticancer hematological drug health insurance gkv citizen may choose enroll medication certain chronic disease dementia privaten krankenversicherung private health insurance parkinson disease diabetes reimbursable 100 pkv instead approximately 90 population enrolled asmr assessment medication ranked scale public health insurance public health insurance system ⅰclear additional benefit ⅴ additional benefit based originally funded insurance premium due improvement symptom taking account asmr worsening insurance financing funding taxation level pharmaceutical company sale prediction added since 2004 price similar product comité economique de produits de 2 mechanism pricing reimbursement pharmaceutical santé economic committee health care product originally general rule pharmaceutical company ceps determines manufacturer price upper limit free set price however due increasing determining manufacturer price discount rate 91 eisai integrated report 2017 marketing decided based negotiation ceps actual price paid medical institution generally pharmaceutical company outpatient treatment determined two stage first provincial level bidding general rule insured pay full treatment price second direct negotiation medical medical organization sends doctor receipt organization pharmaceutical company including price prescription drug health insurance furthermore november 2015 price treatment fund reimbursed severe disease highly effective treatment high priced pharmaceutical determined via national price negotiation system discussion establish official 6 china transparency clinical pharmacology health insurance 1 characteristic healthcare system economics taxation law hospital administration etc based labor insurance regulation passed 1951 afterwards instead going provincial bidding medical benefit system based national financing drug directly sent hospital established however ever increasing medical cost 3 mechanism reimbursement pharmaceutical various reform made healthcare system order pharmaceutical reimbursed must first 1980 onwards currently employee civil servant listed provincial reimbursement drug list prdl required enroll basic medical insurance urban based national reimbursement drug list employee public health insurance program funded nrdl latest version nrdl published 2017 insurance premium paid employer employee reimbursement limitation based hospital class indication urban resident fall category etc added remark column many product voluntary insurance program basic medical insurance urban drug reimbursement differs province serious resident funded insurance premium supplemental illness relatively high reimbursement rate adopted payment government rural citizen another voluntary insurance program new rural cooperative medical insurance funded individual insurance premium reference material health labor welfare 2016 white paper contribution central regional government drug price calculation standard february 10 2016 announcement public health insurance coverage reached 95 0210 1st issue institute health economics policy research drug usage situation government wish establish new unified impartial etc report march 2017 basic insurance system minimize gap urban monthly social security study group china current social security situation future trend february 2016 rural citizen jpma international committee research material 426 china 2 mechanism pricing pharmaceutical pharmaceutical situation march 2015 jpma international committee research material 431 fy 2017 china june 2015 exception anesthetic status graph march 2017 category 1 psychoactive drug fixed price abolished maxinxin china public health insurance system reform 2015 flow rd drug creation research name literally suggests drug creation research research producing new drug broken three stage drug discovery research drug development research clinical research drug discovery research researcher employ stateof theart technology screen identify highly effective compound also conduct basic research using external resource identified drug candidate proceed drug development stage researcher lay groundwork filing approval around world evaluating compound physicochemical biological property assuring quality safety performing process chemistry research method largescale synthesis manufacturing drug candidate clear development research elevated clinical research stage three phase clinical trial phaseⅰ phase ⅱ phase ⅲ drug candidate approved regulatory authority launched market drug creation process research activity drug discovery research development drug fostering research evolution launch api supply investigational drug manufacturing drug use result survey synthesis drug discovery lead compound optimization process chemistry research clinical research clinical study formulation research approval physical property analysis screening review phase study phase ii study phase iii study research clinical new drug sub idea target candidate introduction mission approval safety research biological evaluation pharmacokineticspharmacodynamics drugdrug interaction vitro vivo drug development research efficacy study pharmacokineticspharmacodynamics general pharmacology compatibility testing physical property biomarker research general pharmacology build safety database safety nonclinical research biomarker research discovery research approval indication expansion new formulation development research postlaunch research carried pursue appropriate drug usage various improvement new drug development detail initiative pharmaceutical product safety side effect please refer page 81 92 company introduction management strategy value creation activity business base esg appendix drug discovery research phase ⅲ trial trial validate efficacy safety theory based drug creation idea research us cell obtained thus far via doubleblind test etc large based assay animal model identify compound number patient given permission required property generally compound library also postlaunch trial phase iv trial gather contain anywhere several hundred thousand longterm information efficacy safety since phase iv several million compound group searched compound trial carried approved indication dosage effect target protein related disease categorized therapeutic use trial compound chemically modified go biochemical pharmacological metabolic safety study application approval japan determine potential human use new drug gone efficacy safety trial pharmaceutical company applies ministry development research health labour welfare manufacturing marketing research implemented optimize drug candidate approval expert pharmaceutical medical identified drug discovery stage various test device agency pharmaceutical affair food including pharmacological pharmacokinetic study safety sanitation council review drug approval granted study toxicity study carried based glp pharmaceutical company may begin manufacturing standard process chemical research also performed marketing quality largescale synthesis formulization api active pharmaceutical ingredient human use synthesized based drug fostering evolution japan gmp standard even drug launched important glp good laboratory practice continually investigateevaluate patient background usage gmp good manufacturing practice method effect sideeffects etc collect information relating effective safe usage drug fostering clinical trial clinical study evolution based way thinking includes trial confirm effect pharmaceutical human various mechanism system activity carried goal trial evaluate factor efficacy respective standpoint doctor pharmacist pharmaceutical safety human order obtain regulatory approval company researcher patient improve drug based pharmaceutical affair law trial content term ease usage safety efficiency methodology report etc regulated pharmaceutical affair law gcp various governmental guideline postmarketing product surveillance japan gcp good clinical practice postmarketing product surveillance based gvp gpspstandards must implemented new drug released generally clinical trial divided following three market periodic safety report submitted phase certain period time drug reexamined following phaseⅰ trial trial investigate safety drug monitored within drug reevaluation system pharmacokinetics small number healthy people gvp good vigilance practice patient testing anticancer drug given gpsp good postmarketing study practice permission phase ⅱ trial trial confirm safe efficient dosage indication expansion amount administration method small number new indication added already approved patient given permission pharmaceutical patent new drug generic substance patent used lay claim chemical less 20 year field pharmaceutical compound patent term expires patent product must receive regulatory approval marketing owner licensee make sell import chemical due legal requirement reason possible use without infringing patent patent extend patent term five year country important pharmaceutical industry also additionally new drug company obligated patent protect discovery manufacturing method confirm efficacy safety certain period reexamination indication period data protection period launch many country including japan u europe examination period patent term expired patent term last 20 year starting filing date company manufacture sell generic application however effective patent term frequently active ingredient 93 eisai integrated report 2017 terminology alphabetical order aberrant splicing tissue measured assess normal abnormal majority eukaryotic gene area genome functionality presence state disease encodes protein information divided two part exon also used determine extent body reacting base sequence dna encode amino acid intron treatment process removing intron part immature rna transcript mrna precursor primary transcript conjugation technology combining exon part called splicing way antibodydrug conjugate adcs hybrid drug mainly mrna precursor becomes mature mrna aberrant splicing consist three element antibody linker payload abnormality splicing process aberrant small molecule drug conjugation technology technique splicing result loss lower functionality protein combining three element covalent bonding investigated relation various disease way antibody lose target recognition delivery function sometimes refers technique splicing adc break within cancer cell release dna exon intron exon intron exon payload transcription epigenetics precursor mrna study genetic mutation effect dna splicing sequence effect gene expression exon spliceosome consisted splicing factor rna exon part sequence base pair within mature mature mrna rna messenger contain information protein translation synthesis eukaryotic dna genetic information typically discontinuous stretch exon interspersed protein sequence contain information called intron angiogenesis firstline angiogenesis formation new blood vessel pre refers best drug firstly administered treat disease existing blood vessel angiogenesis normally tightly patient condition improve firstline controlled process occur except response treatment heavy side effect next drug estrus cycle wound healing tumor cancer remove known secondline used control tumor angiogenesis describes growth new blood vessel necessary tumor proliferation glial cell caused angiogenic factor released tumor nearby human brain made 100 billion neuron host cell 10 time number glial cell glial cell help maintain neuronal survival function regulating internal antibody drug environment brain providing metabolic support foreign substance antigen pathogen invades glial cell include microglia astrocyte oligodendrocyte human body body produce antibody bond schwann cell recent research reported relationship foreign substance detoxifying eliminating thus glial cell brain waste disposal system preventing disease antibody drug drug make use mechanism technique gene recombination hazard ratio cell cultivation used artificially produce antibody statistical terminology measure often particular event injected body treat illness happens one group compared often happens another group time clinical study hazard ratio used beta amyloid aβ compare effectiveness two treatment example also called amyloid beta aβ refers peptide approximately comparing new drug comparator b 40 amino acid also exist within healthy brain hazard ratio 1 difference b excessive number aβ deposit found within brain hazard ratio smaller 1 considered alzheimers disease patient aβ theory amyloid effective smaller number effective cascade hypothesis state aβ accumulates comparison b form senile plaque amyloid plaque within brain killing neuron thus causing alzheimers disease based human biology theory aβ drug target alzheimers disease human biology refers human target clinical epidemiological study drug discovery research new bioimaging technology treatment always tested animal model first technology used observing behavior molecule inside predicting efficacy safety human based animal testing living system using technique fluorescent imaging limited however thanks recent scientific advancement ct pet mri distribution localization protein particular spread new technology next etc cellular tissue individual organism level generation sequencer ip cell genome editing technique observed analyzed image identify optimal therapeutic target based human evidence genetic variation actual clinical data biomarker success rate drug discovery using therapeutic target based biomarkers biomolecules blood body fluid genetics estimated twice high eisai 94 company introduction management strategy value creation activity business base esg appendix sufficient confidence relevance safety screening target able leverage chemistry ability method searching group compound compound strength full effect even molecularlytargeted library find compound react drug target therapy highly challenging protein identified compound serve seed chemically modified analogue among compound median value demonstrate safety efficacy become statistical terminology arranging data set order size candidate clinical study median value data value middle position secondary endpoint messenger rna mrna clinical study confirming safety efficiency rna transcribes carry genetic information protein drug healthy people patient secondary endpoint biosynthesis messenger rna single stranded nucleotide supplementary indicator used evaluate effect drug formed complementary one strand dna mrna addition primary endpoint molecule carry information dna nucleus cell cytoplasm protein produced senile plaque abnormal deposit beta amyloid protein brain objective response rate orr characteristically present brain patient suffering ratio patient whose cancer regressed disappeared alzheimers disease treatment patient divided following four category based small molecule drug low molecularweight drug state cancer clinical trial chemically synthesized drug low molecular weight c r complete response complete disappearance tumor 1000 dalton less middlesize molecule defined p r partial response least 30 decrease tumor size 1000 10000 dalton macromolecule defined stable disease change tumor size meet neither 10000 dalton pr pd condition progressive disease least 20 relative increase p tau 5mm absolute increase tumor size appearance protein mainly found neuron central nervous system one new lesion glial cell type microtubuleassociated protein tau objective response rate calculated following equation regulates polymerization stability microtubule cr patient pr patient total number treated patient abnormal aggregation deposit tau thought 100 orr cause neurodegenerative disease alzheimers clinical study measuring objective response rate one disease method investigating efficiency new cancer treatment time progression ttp overall survival o time period start cancer treatment time period start cancer treatment death cancer becomes worse unlike progression free survival cause whether cause death cancer simply length time tumor becomes worse taken consideration variable clinical study include case death clinical study measuring measuring overall survival one method investigating time progression one method investigating efficiency efficiency new cancer treatment new cancer treatment placebo triplenegative breast cancer refers fake treatment contain active type breast cancer growth cancer medical ingredient placebo effect patient supported hormone estrogen progesterone improves due belief taking effective medicine presence many her2 receptor triple negative refers clinical study efficiency drug treatment method testing negative three breast cancer account 10 compared placebo treatment 15 cancer case primary endpoint tyrosine kinase result phenomenon used objectively measure enzyme capable phosphorylating tyrosine amino acid effectivity treatment tested clinical trial example include consists protein play important role transmitting measuring difference mortality rate treatment signal related proliferation division cell variation group control group tumor regression improvement gene cause tyrosine kinase become abnormally active quality life qol relief symptom etc primary leading abnormal proliferation cell disease endpoint decided study begin cancer progression free survival pfs time period start cancer treatment either cancer get worse patient dy reason whichever come first clinical study measuring progression free survival one method investigating efficiency new cancer treatment regimen treatment plan specifies type dosage schedule duration treatment 95 eisai integrated report 2017 status share march 31 2017 authorized common stock 1100000000 share issued 296566949 share including 10399676 share treasury stock number shareholder 62335 transfer agent mitsubishi ufj trust banking corporation principal shareholder percentage held note number share held 1numbers share rounded nearest thousand shareholder thousand share shareholder 2 indicates top 10 shareholder term percentage total voting right number outstanding share excluding treasury stock japan trustee service trust bank ltd trust account 31481 1101 3 10399000 share 351 treasury stock included table voting right 4 although following large shareholding report revised report master trust bank japan ltd trust account 25829 903 received end fiscal year case impossible make confirmation shareholder registry end jp morgan chase bank 385147 15038 526 fiscal year number share held ranked among top 10 included table holding nippon life insurance company 12281 429 percentage enclosed parenthesis percentage total number outstanding share rounded including treasury stock saitama resona bank limited 7300 255 1 including blackrock japan co ltd 7 company jointly held 15262000 share 515 november 28 2014 december 4 trust custody service bank ltd trustee mizuho 2014 large shareholding report bank ltd retirement benefit trust account reentrusted 5437 190 2 including mitsubishi ufj financial group inc 4 company mizuho trust banking co ltd jointly held 16113000 share 543 july 13 2015 july 21 2015 revised report naito foundation 4736 165 3 including wellington management company llp 2 company jointly held 27087000 share 913 july 31 2015 august 7 state street bank trust company 4207 147 2015 revised report 4 including sumitomo mitsui trust bank limited 3 company jointly state street bank west client treaty 505234 3936 137 held 14926000 share 503 april 15 2016 april 21 2016 large shareholding report trust custody service bank ltd 5 including mizuho bank ltd 2 company jointly held 18900000 security investment trust account 3796 132 share 637 october 14 2016 october 21 2016 large shareholding report total 114043 3990 6 vanguard health care fund held 14838000 share 500 november 24 2016 december 15 2016 large shareholding report trend ratio shareholder type 0 20 40 60 80 100 fy2015 426 289 147 71 36 31 fy2016 440 275 150 70 35 30 financial institution bank etc foreign entity etc individual company treasury stock financial instrument trader security company stock price trend 350 ー eisais stock price ー topix 300 250 200 150 100 50 0 fy2012 fy2013 fy2014 fy2015 fy2016 high 4405 yen high 4675 yen high 9756 yen high 9024 yen high 7338 yen low 3070 yen low 3600 yen low 3800 yen low 6633 yen low 5366 yen tsr 326 tsr 07 tsr 1178 tsr 190 tsr 128 note april 2 2012 closing price eisais stock price topix respectively represent 100 shown line graph total shareholder return please refer notice convocation 105th ordinary general meeting shareholder status share httpwwweisaicomirstockmeetinghtml 96 corporate information corporate data march 31 2017 corporate name eisai co ltd philosophy logomark combine spirit florence nightingale made enormous contribution development nursing profession public health human health care date founded philosophy logomark modeled signature prominent figure history modernday nursing december 6 1941 head office address 4610 koishikawa bunkyoku tokyo 1128088 japan paidin capital 44986 million number employee nonconsolidated basis10452consolidated basis 3246 stock exchange listing eisai common stock listed tokyo stock exchange security code number 4523 annual shareholder meeting public notice annual shareholder meeting held june available online httpwwweisaicom however circumstance dictate independent public accountant publication made nihon keizai shimbun deloitte touche tohmatsu llc social evaluation eisai selected following social responsibility index september 2017 dow jones robecosamswitzerland 2017 constituent msci japan esg sustainability asia pacific index sustainability award industry select leader index mover 2017 ftse4good ftse blossom japan investor relation eisai co ltd 4610 koishikawa bunkyoku tokyo 1128088 japan tel 81338173016 fax 81338116032 information httpwwweisaicom corporate website includes following information company information news release ir information patient 97 eisai integrated report 2017